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The pharmaceutical industry has traditionally implemented batch manufacturing for the 
production of a wide range of products due to its mature technological development and ability 
for recall of products where necessary. However, several demonstrations of Continuous 
Pharmaceutical Manufacturing (CPM) in the past two decades have drawn significant attention 
from academia, industry and regulatory bodies due to its potential for smaller equipment, enhanced 
efficiencies, access to difficult or hazardous process conditions with greater ease and safety and 
reduced costs and waste. While continuous processing is not new in other manufacturing sectors, 
its application to pharmaceutical production has only drawn significant attention in recent years 
due to the numerous demonstrations of continuous flow syntheses of complex molecules and 
functional groups inherent of Active Pharmaceutical Ingredients (APIs), which is the foundation 
of any end-to-end CPM plant. The literature to date has predominantly focussed on design and 
optimisation of flow synthesis routes; however, the development of efficient continuous 
separation processes is a major bottleneck to CPM and are often challenging and materially 
intensive unit operations. The design of effective continuous separation processes for societally 
important APIs amenable to continuous production is essential for CPM success. Mathematical 
modelling is a viable and useful tool in the elucidation of promising designs prior to pilot plant 
studies that can allow rapid screening of multiple candidate configurations and can circumvent 
expensive and laborious experimental campaigns. Moreover, they allow optimisation of process 
design configurations to maximise their operational and economic benefits. This PhD thesis aims 
to elucidate cost-optimal upstream CPM plant and continuous separation process designs for a 
range of APIs. Steady-state process models for upstream CPM plants for different APIs are 
constructed, using published data for reaction rate law elucidation and kinetic parameter 
estimation, activity coefficient and group contribution models for non-ideal multicomponent 
mixture phase equilibria prediction and pharmaceutical process costing methodologies. The 
constructed models are then used for process simulation, design and optimisation of CPM plants, 
using Nonlinear Programming (NLP) for individual case-based process optimisation and Mixed 
Integer Nonlinear Programming (MINLP) for CPM process synthesis to optimality. The 
systematic frameworks and methods used in this work can be expanded to other APIs amenable 
to CPM with similar processes. This work highlights the immense value in systematic and rigorous 







This PhD thesis involves modelling and optimisation for the design of Continuous Pharmaceutical 
Manufacturing (CPM) processes. The pharmaceutical industry has traditionally relied on batch 
processing methods; however, technical and economic drivers are pushing the industry towards 
implementing leaner methods, including continuous processing. The plethora of continuous flow 
chemistry demonstrations in the past two decades, including routes towards pharmaceutical and 
biopharmaceutically-active molecules, have sparked significant developments in CPM research, 
particularly in the demonstration of continuous flow syntheses of Active Pharmaceutical 
Ingredients (APIs). However, the number of demonstrated continuous synthetic routes is 
disproportionately larger than the number of suitable continuous separation processes, which are 
essential prior to downstream processing and formulation of the final Drug Product. Separations 
are often material- and energy-intensive and are thus challenging to implement in end-to-end CPM 
campaigns. Effective and efficient design of continuous separation processes is paramount for 
successful CPM implementation. Mathematical modelling and optimisation can be used to this end 
in order to screen for promising process designs while circumventing costly and laborious 
experimental studies. This PhD thesis implements mathematical modelling, simulation and 
optimisation for the design and process synthesis of economically viable upstream CPM plants, 
including continuous synthesis and separations, namely Liquid-Liquid Extraction (LLE) and 
crystallisation processes. The case studies considered in this thesis are based on published 
demonstrations of continuous flow syntheses for diphenhydramine, rufinamide, warfarin, 
nevirapine and atropine and continuous cooling crystallisation processes for cyclosporine, 
paracetamol, aliskiren and melitracen, all of which are societally important APIs with different 
pharmaceutical applications. Reaction rate law elucidation and kinetic parameter estimation from 
published reaction data for these APIs are implemented for flow reactor design. Process simulation 
and optimisation are implemented for various upstream CPM plants and crystallisation cascades 
to gain insight into the design and operation that yield promising economic outcomes. Following 
this, the formulation of Mixed Integer Nonlinear Programs for process synthesis is implemented 
for the first time for the design of a LLE cascade as part of an upstream CPM plant as well as a 
crystalliser cascade with solids recycle. Valuable insight into CPM separation design have been 
gained from this work and the described modelling and optimisation frameworks can be extended 
to other APIs amenable to CPM via similar processing routes and will be of paramount importance 
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PART I INTRODUCTION & MOTIVATION 
 
PART I 
















This chapter provides some background on the current state of the pharmaceutical industry as 
impetus for the motivation for this PhD thesis. Historical trends and the current state of Research 
and Development (R&D) in the pharmaceutical industry are first discussed, followed by the 
emergence of Continuous Pharmaceutical Manufacturing (CPM) over the past two decades as an 
alternative to the currently predominant batch processing paradigm and then Process Systems 
Engineering (PSE) applications related to CPM development. 
1.1 Pharmaceutical Industry Research and Development 
Batch processing has been the traditional manufacturing method used by the pharmaceutical 
industry due to established regulatory protocol for such a mature technology. Advantages offered 
by batch methods include high precision product quality control, specific batch recall and versatile 
equipment usage; thus, batch manufacturing methods currently dominate the pharmaceutical 
industry.1 However, batch processing has several drawbacks such as poor heat transfer and mixing 
efficiencies (potentially leading to unacceptable quality of product and difficulties in scaleup), large 
inventories of material (incurring large plant footprints and capital expenditures), high volumes of 
waste and intensive labour requirements.2 
 
Figure 1: European pharma R&D expenditures and total sales and UK pharmaceutical 
manufacturing R&D trends by sector.3–5 
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4 
In the past, production costs in the pharmaceutical industry have been considered low enough 
such that reductions have been unnecessary. However, Research and Development (R&D) costs 
for the pharmaceutical industry have been rapidly increasing over previous decades, with the 
pharmaceutical industry having the highest R&D expenditures of all industrial sectors6 (Figs. 1 and 
2). Capitalised costs of drug product commercialisation have also been historically increasing.7  
 
Figure 2: Historically increasing pharmaceutical R&D costs in the UK and US.4 
When the duration of clinical trials of potential drugs and product approval is accounted for, 
pharmaceutical products lose approximately half of their patent life by the time they have reached 
the market. This leads to significant profit losses for pharmaceutical firms and increasing 
competition from generics manufacturers (Fig. 3), presenting a threat to firm profitability. 
 







































Manufacturing contributes approximately 30% of overall costs for pharmaceutical enterprises.9 
The performance of pharmaceutical enterprises will be significantly improved by investigation and 
development of innovative manufacturing technologies in order to improve process efficiencies. 
These improvements can allow significant cost savings in order to maintain profitability and 
sustainability in pharmaceutical firms. 
The pharmaceutical industry produces a wide variety of products whose Active Pharmaceutical 
Ingredients (APIs) often have complex molecular structures, requiring multistep syntheses10 and 
whose products have stringent product purities set by regulatory bodies.11 Such requirements lead 
to materially-intensive manufacturing processes, which can be wasteful and have low operational 
asset efficiencies.12,13  
1.2 Continuous Pharmaceutical Manufacturing 
Continuous Pharmaceutical Manufacturing (CPM) has the potential to provide technological 
innovation, allowing several advantages over batch processing, including lower capital and 
operating costs,14 reduced solvent requirements and waste handling,15 increased process efficiency16 
and reduced plant footprints.17 The demonstration of a continuous flow synthetic route is the 
foundation of any CPM process; in the past decade, there have been many demonstrations of flow 
syntheses for various APIs and their intermediates, which have been summarised in recent 
literature reviews.10,18–21 Mixing patterns in flow reactors are much better understood than those in 
agitated batch vessels and the time for process development of flow reactors is significantly 
reduced in comparison. Implementing continuous flow synthesis often allows the application of 
microscale equipment (depending on the target plant capacity), featuring tubular flow reactors with 
inner diameters on the millimetre scale. Microreactors benefit from enhanced mixing, mass and 
heat transfer, safer operation, and reduced footprint.22  
Recent ventures highlight the beginning of the transition from batch to continuous manufacturing 
of pharmaceutical compounds. In the past two decades, there have been many demonstrations of 
API production processes which have benefited by changing to a continuous manufacturing 
paradigm. Table 1 provides a summary of certain APIs whose manufacturing processes have been 
converted from batch to continuous mode to various extents. Whilst Table 1 does not provide a 
comprehensive review of demonstrated CPM of APIs (detailed reviews are available in the 
literature10,23,24), it is clear that the transition of manufacturing paradigm from batch to continuous 
processing remains predominantly in the R&D stages (lab-scale and pilot plant capacity) with only 
two CPM processes at production level.  
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Table 1: API manufacturing processes converted from batch to continuous mode. 
API Application Level of Development Benefits of Converting to Continuous Mode API 
Capacity 
(kg yr-1) 






Ease / Safety of
Operation 




Aliskiren Hemifurate Hypertension ✓ ✓ ✓ Pilot ✓ ✓ — 360.00 Novartis-MIT CCM, USA (25) 
Amitriptyline Antidepressant ✓ ✓ X Lab — ✓ — 4.24 
University of Hanover, 
Germany 
(26) 
Amoxicillin Antibiotic ✓ ✓ ✓ Production ✓ — ✓ Unavailable GSK (27) 
Artemisinin Antimalarial ✓ X X Lab — ✓ ✓ 66.64 
MPI for Colloids and Interfaces, 
Germany 
(28) 
AZD6906 Reflux inhibitor ✓ X X Pilot — ✓ — Unavailable AstraZeneca (29) 
Darunavir HIV drug ✓ ✓ ✓ Production ✓ — ✓ Unavailable Janssen (30,31)
Diphenhydramine Antihistamine 
✓ ✓ X Lab — ✓ — 19.36 MIT (32) 
✓ ✓ ✓ Lab ✓ ✓ ✓ 18.72 MIT (33) 
Fanetizole Anti-inflammatory ✓ X X Lab — — — 79.68 University of Cambridge, UK (34) 
Fluoxetine Antidepressant 
✓ X X Lab ✓ ✓ — 11.84 Eli Lilly (35) 
✓ ✓ ✓ Lab ✓ ✓ ✓ 7.36 MIT (33) 
6-Hydroxybuspirone Psychotropic agent ✓ X X Lab — ✓ — 1,166.64 Bristol-Myers Squibb (36) 
Ibuprofen Anti-inflammatory 
✓ X X Lab — ✓ — 4.32 Florida State University, USA (37) 
✓ ✓ X Lab ✓ ✓ ✓ 64.72 MIT (38) 
Imatinib Leukaemia ✓ X X Lab ✓ — — 0.01 University of Cambridge, UK (39) 
Rufinamide Antiepileptic ✓ ✓ X Lab ✓ ✓ — 1.76 MIT (40) 
Tamoxifen Breast cancer ✓ X X Lab ✓ — — 432.00 University of Cambridge, UK (41) 
Telmisartan Hypertension ✓ X X Lab — — ✓ 0.48 
Virginia Commonwealth University, 
USA 
(42) 
Vitamin D3 Liver failure ✓ X X Lab ✓ ✓ ✓ Unavailable Tokyo Institute of Technology, Japan (43) 
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There is a stagnancy inhibiting wide-spread adoption of CPM due to investments in batchwise 
infrastructures and limited technological expertise in continuous pharmaceutical processes in 
comparison to current techniques.44 Significant financial investments in existing batch-operated 
plants make such a drastic change in production paradigm an unfavourable prospect.45 Process 
feasibility and viability studies must be conducted before significant time and financial investments 
for experimental and pilot plant studies are made.  
Ultimately, a process should only be implemented in continuous mode if it shows potential and 
benefits over existing processes. The numerous demonstrations of continuous flow syntheses of 
APIs19 and other pharmaceutically relevant compounds pave the way for the development of 
subsequent continuous unit operations, including recent demonstrations of end-to-end CPM 
campaigns.33 However, limited demonstrations of continuous separations in CPM plants impede 
its widespread adoption in industry, presenting a bottleneck to realising the full benefits of 
continuous mode. 
1.3 Process Systems Engineering in Pharmaceutical Manufacturing 
Recently, there has been significant interest in Process Systems Engineering (PSE)-driven efforts 
for pharmaceutical process design. The philosophy of PSE is a knowledge-based approach towards 
effective solutions for process design; the multipurpose, complex nature of pharmaceutical 
processes renders it suitable for such methods.2 A PSE approach to CPM process design has 
shown significant promise in recent research contributions. Data-driven methods may be 
appropriate to gain insight into correlations between in- and outputs of processes when time 
limitations are such that mechanistic model development is not possible.46 A 
knowledge/mechanistic approach is more appropriate for design and development, where models 
can be re-parameterisation for different systems.47 Theoretical modelling also allows rapid 
screening of novel CPM processes for the production of candidate APIs, whilst circumventing 
experimental costs and labour requirements.48 Process models have been implemented to 
demonstrate CPM technoeconomic feasibility and viability for various APIs.49–51  
Mathematical optimisation can be used to establish optimal design configurations.48,52 Theoretical 
methods have been previously implemented towards optimal pharmaceutical plantwide designs,53 
analysis of synthetic pathways54,55 and life-cycle assessments.56,57 Modelling and optimisation have 
also been implemented in the design of separation processes in pharmaceutical manufacturing, 
such as Liquid-Liquid Extraction (LLE),58–60 crystallisation61–67 and chromatographic methods.68 
Identification of optimal plantwide designs is essential,69 particularly end-to-end designs 






This chapter discusses the motivation for this PhD project. First, separation process design and 
its challenges for integration into upstream CPM plants is discussed with a focus on literature 
demonstrations of key separation unit operations in pharmaceutical processes, and modelling and 
optimisation demonstration in the literature implemented thus far. Identification of APIs which 
have been demonstrated as amenable to CPM in the literature, their societal importance and their 
market value are described as case studies for this work. The chapter is then concluded with the 
PhD thesis objectives and structure. 
2.1 Challenges of Continuous Separation Process Design 
Despite the numerous demonstrations of continuous flow syntheses21 towards APIs, including 
end-to-end production campaigns,33 only certain synthetic routes benefit from continuous 
operation71 and the lack of demonstrated continuous purification and separation methods 
integrated in CPM plants is an important obstacle to overcome.52 Establishing promising APIs for 
CPM application and screening for those with the highest likelihood of success is imperative for 
the elucidation of potential process configurations and successful CPM implementation.48 
Various efforts in modelling and simulation in pursuit of continuous pharmaceutical separation 
process development have been demonstrated in recent years. Mathematical optimisation can be 
used to identify optimal process designs for pharmaceutical manufacturing campaigns;72 plantwide 
modelling and optimisation with a focus on optimal continuous separation process design towards 
total cost minimisation have been previously implemented for various APIs.73–77 Elucidating 
optimal CPM designs will aid process development. 
A variety of different separation processes are implemented in pharmaceutical manufacturing 
processes, including (but not limited to) Liquid-Liquid Extraction (LLE), membrane 
purification/separation, distillation, crystallisation and chromatographic separations. Modelling 
and optimisation have been implemented in the design of continuous chromatographic methods68 
and membrane separations78 for pharmaceutical manufacturing.  
This PhD thesis focusses on the design of continuous LLE and crystallisation processes, both of 
which are very commonly implemented purification and separation processes essential to 
pharmaceutical production. 
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2.1.1 Continuous Liquid-Liquid Extraction 
The aim of Liquid-Liquid Extraction (LLE) is to purify a multicomponent mixture by addition of 
a solvent which induces the splitting of the mixture into multiple phases, between which solutes 
partition; the objective is to partition undesired solute components (e.g., impurities) into one phase 
while the desired solute (e.g., product API) preferentially partitions into the other. Purification via 
LLE is typically implemented in pharmaceutical processes prior to crystallisation to ensure as few 
undesirable impurities as possible are incorporated into crystalline products. The design of 
continuous LLE processes is an important aspect of end-to-end CPM plant development. 
The majority of LLE process demonstrations are still done in batch, even following a continuous 
flow synthesis precedent. That said, there have been a few experimental, as well as theoretical, 
studies on the design of continuous LLE processes for pharmaceutical manufacturing. Drageset 
and Bjørsvik (2016) performed an in-line continuous LLE for purification of a reactor product 
mixture prior to further downstream processing, allowing for input material reduction compared 
to the batch purification process.58 Monbaliu et al. (2016) also implemented a continuous LLE 
process as part of an end-to-end CPM process for lidocaine hydrochloride (a local anaesthetic) 
from synthesis to aqueous formulation.59 Jolliffe and Gerogiorgis (2017) performed a conceptual 
study for the technoeconomic optimisation for the purification of ibuprofen from the product 
stream of a demonstrated continuous flow synthesis, comparing hexane and toluene as LLE 
solvents.73 
Implementation of combined experimental and modelling approaches towards integrated LLE 
design in the literature for pharmaceutical purifications and separations demonstrate the utility of 
theoretical methods in establishing optimal design and operating parameters.58–60 
2.1.2 Continuous Crystallisation Processes 
A significant portion of pharmaceutical products are sold as solids (tablets, dispersions, gels or 
topical treatments), and thus crystallisation is an essential unit operation in drug product 
manufacturing. The aim of crystallisation is to form a solid product of the desired compound with 
minimal impurity and/or solvent incorporation into the crystal structure while also attaining the 
desired polymorph, suitable mean crystal size and size distribution properties, all of which affect 
subsequent downstream process unit operations and the bioavailability of the drug in the patient. 
The driving force for crystallisation is supersaturation, the condition in which the concentration 
of solute in the liquid phase (i.e., the mother liquor) is higher than its solubility concentration. 
Supersaturation can be generated by a number of different methods, depending on the 
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thermodynamics of the system, the most commonly implemented of which are: cooling (where 
solubility is strongly temperature-dependent), antisolvent addition (where addition of another 
solvent alters the solute solubility in the mixture) and evaporative crystallisation (where solvent 
removal increases the solute concentration in the mother liquor above its solubility). 
Traditional batch crystallisation techniques have been widely studied and are generally well-
understood, but batch variability leads to deviations from strict product specifications regarding 
crystal product quality attributes, which leads to significant quantities of waste.79 Continuous 
crystallisation has received attention for its potential to increase flexibility, efficiency and quality.80 
Continuous crystallisation operates under steady-state conditions, allowing higher reproducibility 
and better control of important crystal properties, such as the purity and the size distribution, 
which directly affect the bioavailability of the product; however, as continuous processes do not 
discharge at equilibrium, they tend to achieve lower yields than batch crystallisations.79 Systematic 
investigation of continuous crystallisation processes for pharmaceutical manufacturing is required 
for their implementation as part of integrated CPM plants. 
Continuous crystalliser designs applicable for the pharmaceutical industry are categorised as Plug 
Flow Crystallisers (PFCs), Continuous Oscillatory Baffled Crystallisers (COBCs) or Mixed 
Suspension-Mixed Product Removal (MSMPR) crystallisers. PFCs are suited to systems with fast 
crystal growth and short residence times and can attain narrow crystal size distributions,81 but 
fouling and clogging in narrow tube diameters is an important issue.82 COBCs are another 
emerging design, which enhance heat and mass transfer, but have issues handling high solid 
loadings.83 Various experimental and modelling studies have been conducted for estimation of 
crystallisation kinetics, proof-of-concept demonstrations, design and optimisation.65,84–88  
MSMPR crystallisers are idealised stirred tank designs better suited for systems with slower 
crystallisation kinetics and can easily be adapted from existing jacketed agitated vessels for 
continuous applications. The MSMPR crystalliser is a widely studied continuous crystalliser design 
due to its simple operation, low maintenance requirements, avoidance of rapid fouling typical of 
continuous solids processes and tubular crystalliser designs,89 and ease of adaptation from existing 
batch stirred tanks.80 Recent work using MSMPRs for crystallisation kinetic parameter 
estimation,90–93 comparison of operating strategies, process configurations and control,61,66,67,94–103 
novel crystallisation techniques,63,104–106 specialised separations107–113 and polymorph selectivity114,115 
have significantly developed their implementation, with some designs integrated into end-to-end 
CPM plants.25,116 However, continuous crystalliser designs operate at steady-state and thus do not 
reach equilibrium, leading to potentially lower yields compared to batch processes; establishing 
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technically feasible and economically viable operating parameters for continuous designs is 
essential for the successful transition from batch to continuous crystallisation methods. A variety 
of experimental and theoretical studies have already investigated the design, simulation and 
optimisation of steady-state and dynamic operations of MSMPR crystallisers for various 
pharmaceutically relevant compounds.117 Rapid screening of candidate flowsheet configurations of 
MSMPR cascades for different APIs can facilitate process development towards end-to-end 
CPM.118 Experimental studies are often coupled with process modelling and simulation 
methodologies to construct predictive models to screen various process conditions and 
configurations whilst circumventing excessive time requirements and costs.48 
The majority of continuous crystallisation studies in the literature to date have been focussed on 
design and optimisation for attainment of optimised process efficiency (i.e., high yield) and crystal 
product quality (purity, mean size, size distribution, target polymorph), which are very valuable 
regarding the importance of crystalline quality and purity in pharmaceutical products. This work 
approaches crystallisation process design and optimisation from a technoeconomic perspective. 
2.1.3 Nonlinear Programming for Process Optimisation 
A Nonlinear Programming (NLP) problem is defined as follows. For the objective function, f, of 
decision variables, x = x1, … , xn, with inequality constraints, g = g1, … , gm, equality constraints, h 
= h1, …, hp, the nonlinear minimisation problem is defined by Eqs. 1–4, where non-negativity 
constraints can be defined within g and the problem can be defined as a maximisation problem by 
minimising –f(x); x may also have lower (xLB) and upper (xUB) bounds, which may reflect feasibility 
constraints on an operating variable or limits of the range of applicability of a model to a range of 
variable values. 








(x1, … , xn) ≤ bm
 (2) 
h1(x1, …, xn) = c1
⋮ ⋮
hp(x1, … , xn) = cp
 (3) 
xLB ≤ x ≤ xUB (4) 
The formulation of NLP problems for pharmaceutical process optimisation is used in various 
instances in the literature. Jolliffe and Gerogiorgis (2017) performed technoeconomic optimisation 
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via NLP for the design of a continuous LLE vessel as part of an upstream CPM plant for 
ibuprofen, wherein plant total costs were minimised subject to limitations on LLE solvent usage 
(corresponding to the limits of biphasic mixture formation for different continuous separation 
operating temperatures and candidate LLE solvents, hexane and toluene) and feasible vessel 
volumes.73 The same authors also performed NLP optimisation for total cost minimisation of an 
upstream CPM plant for artemisinin with an antisolvent cooling crystallisation with constraints on 
antisolvent usage and crystallisation operating temperature, comparing different candidate 
antisolvents, numbers of implemented crystallisation vessels and assumption of fixed or variable 
crystalliser size.74 Li et al. (2017) used NLP optimisation for MSMPR cascade design for the 
continuous cooling crystallisation of cyclosporine, wherein they compared two different objective 
functions: (1) maximise yield subject to purity constraints, (2) maximise purity subject to yield 
constraints. Increasing the number of stages in the NLP problem instance allowed the yield to 
approach close to the attained batch crystallisation equilibrium value.63 Wang and Lakerveld (2017) 
used NLP to optimise a MSMPR cascade for the crystallisation of paracetamol from ethanol by 
cooling with membrane separations incorporated; the different problem instances considered were 
(1) maximise product crystal size subject to a fixed cascade residence time and impurity limit, (2) 
minimise the difference in temperature between different crystallisers to reduce cooling duty 
requirements of the cascade.78 
2.1.4 Mixed Integer Nonlinear Programming for Optimal Process Synthesis 
A Mixed Integer Nonlinear Programming (MINLP) problem is defined as follows. Similarly to the 
definition of a NLP problem (see Eqs. 1–4), the minimisation of an objective function is as follows, 
with decision variables, x, some of which may be integer (xi) and some binary (xj). 
min f(x) (5) 
s.t.  
 g(x) ≤ b (6) 
 h(x) = c (7) 
xLB ≤ x ≤ xUB (8) 
xi ∈ ℤ (9) 
xj ∈ {0,1} (10) 
MINLP has been implemented in a variety of applications including scheduling, asset management, 
power systems and process synthesis in engineering applications. Mixed integer problems are 
implemented for optimisation cases involving both continuous and discrete (binary or integer) 
decision variables, as opposed to pure NLP problems, which only have continuous decision 
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variables. MINLP optimisation is particularly useful for process synthesis because the number of 
individual problem instances that are required for comparison via simulation or NLP rapidly 
increases with increasing problem complexity (i.e., increasing number of unit operations, possible 
stream allocation etc.). Formulation and solution of MINLP optimisation problems for various 
separation processes have been demonstrated in the literature for reactor and synthesis network 
design as well as for separation process design;119 Table 2 lists a comprehensive review of 
demonstrated MINLP applications for non-pharmaceutical separation process design and 
synthesis, including numerous examples of traditional and hybrid distillation and membrane 
separation processes, adsorption design and scheduling, dynamic optimisation of Simulated 
Moving Bed  (SMB) chromatography processes. Despite the wide utility of MINLP for process 
synthesis, there are no applications of such methods for process synthesis and design of separation 
unit operations for pharmaceutical manufacturing. MINLP methods can be used for process 
synthesis of LLE and crystalliser cascade configurations to establish designs and flowsheet 
configurations that attain optimal process performances. 
2.2 Market Analysis and Process Flowsheets 
Identification of promising candidate APIs for CPM application as well as modelling and 
optimisation is essential. The experimental demonstration of a continuous flow synthetic route for 
upstream CPM plant design or a continuous separation cascade is required prior to model 
construction. Additionally, consideration of processes for APIs which are both societally 
important and are of economic impact in the pharmaceutical industry are key priorities in the 
identification of suitable APIs for CPM implementation. This sub-section discusses key APIs in 
the literature for which continuous manufacturing pathways have been demonstrated (on scales of 
lab-production or higher), their societal importance and economic impact. Continuous flow 
chemistry, process flowsheets and objectives from a process modelling and optimisation 
standpoint are discussed therein. 
2.2.1 Plantwide Upstream Continuous Manufacturing 
The following APIs have been identified for upstream CPM plant modelling and optimisation. 
2.2.1.1 Diphenhydramine 
A promising candidate API for CPM is diphenhydramine, an antihistamine with hypnotic and 
antidepressant applications.144 Diphenhydramine hydrochloride is the API in the popular brand 
formulations such as Benadryl® and Zzzquil®. Diphenhydramine is used in many non-prescription 
drugs with high revenues in both the UK and US (see Fig. 4). 
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Table 2: Review of demonstrated MINLP optimisation applications in separation process synthesis and design. 
No. Problem Objective Continuous Variables Integer Variables Literature Reference 
   Description No. Description No.  
1 Process synthesis of CSTR and 
distillation network 
Minimise cost / 
Maximise profit 
Reactor flowrates + product 
compositions + volumes, 
Operation time 
1,050 Existence of units + 
interconnections 
36 120 
(Kokossis and Floudas, 1991) 
2 Pressure Swing Adsorption (PSA) 
scheduling 
Minimise cost Bed cycle time 18 Existence of units + 
interconnections 
1–4 121 
(Smith and Westerberg, 1991) 
3 Multicomponent distillation 
design with multiple product 
streams and heat integration 
Minimise cost Column pressures, Component 
recoveries 
12–27 Column sequence + 
interconnection, Heat Exchange 
Network (HEN) design 
68–135 122 
(Aggarwal and Floudas, 1992) 
4 Distillation sequencing with heat 
integration 
Minimise cost / 
Maximise profit 
Column pressures + reflux ratio 
+ no. trays + diameter 
16 Column sequence + 
interconnection, HEN design 
19 123 
(Paules and Floudas, 1992 




Column pressures + reflux ratio 
+ no. trays  
588–1,621 Feedpoint locations 56–174 124 
(Viswanathan and Grossmann, 
1993) 
6 Distillation sequencing with heat 
integration 
Minimise cost No. trays 18 Column sequence + number 
 
1,093 125 
(Novak et al., 1996) 
7 Process synthesis of ethane 
extraction plant 
Maximise profit Compressors rotational speed, 
Cold tank pressure + 
temperature, Demethaniser 
pressure, Bottoms flowrate 
5 Existence of unit operations 5 126 
(Diaz et al., 1996) 




Column pressure + temperature, 
Solvent flowrate, Reflux ratio 
4 Existence of unit operations 4 127 
(Diaz, Gros and Brignole, 2000) 
10 Process synthesis of solvent 
extraction for chromium ion 
recovery from waste water 
Minimise cost Organic phase flowrate Product 
concentration 
2 No. compressors + 
interconnections 
15 128 
(Alonso, Lassahn and Gruhn, 
2001) 
11 Dynamic optimisation of 
chromatographic separation of 
molasses from water 
Maximise profit Feed flowrates 8 Recycle options 14 129,130 
(Emet and Westerlund, 2003, 
2004) 
12 Olefin separation process 
synthesis 
Minimise cost Various operating parameters 18,624 Existence of unit operations + 
interconnections 
5,851 131 
(Lee et al., 2003) 
13 Distillation + membrane hybrid 
separation process synthesis 




No. column trays ≤ 250 132 
(Kookos, 2003) 
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14 Brackish water electrodialysis 
process synthesis 
Minimise cost Stream flowrates + 
concentrations, Stack voltages, 
Pumping duties 
19 No. stages and cell pairs 2 133 
(Tsiakis and Papageorgiou, 
2005) 
15 Process synthesis for cryogenic 
air separation 
Minimise cost Stream flowrates + pressures, 
Product specifications 
11 Existence of unit operations + 
interconnection 
46 134 
(Sirdeshpande et al., 2005) 
16 Process synthesis for retrofitted 
mass exchange networks 
Minimise cost Stream flowrates + 
compositions 
203 Existence of unit operations and 
connections 
48 135 
(Chen and Hung, 2005) 
18 Bioethanol distillation process 
synthesis 
Minimise cost Feed flowrate, reflux ratio, 
boilup rate 
4,412 Feedpoint locations, ionic liquid 
feed flowrate, no. trays 
44 136 
(Chávez-Islas et al., 2011) 
19 Water regeneration network 
synthesis 
Minimise cost Stream flowrates + 
concentrations, Pressures 
926 Unit interconnections 432 137 
(Khor et al., 2011) 
20 Design of reverse osmosis 
systems 
Minimise cost Stream flowrates + 
concentrations, Pressures 
246 Unit interconnections 21 138 
(Lu, Liao and Hu, 2012) 
21 Reverse osmosis for dilute 
bioethanol purification 
Minimise cost Operating pressures 1,879 Existence of unit operation, 
Feedpoint location, Recycle 
options 
120 139 
(Kanchanalai et al., 2013) 
22 Process synthesis for gas drying 
via adsorption 
Minimise cost Bed length + diameter + 
regeneration temperature, Gas 
flowrate, Cycle times 
6 No. beds undergoing adsorption / 
regeneration 
2 140 
(Al Wahedi et al., 2016) 
23 Selection of zeolites for simulated 
moving bed (SMB) 
chromatography 
Maximise profit Stream velocities, Switching 
time, Column length 
45,788 Zeolite selection 96 141 
(Farque Hasan et al., 2017) 
24 Design of dividing wall column 
(DWC) for ethanol dehydration 
Minimise cost Reflux ratios and boilup rates 4 No. trays, Feed locations 5 142 
(Franke, 2017) 
25 Process synthesis of membrane 
cascade for gas mixture 
separation 
Minimise cost Operating pressures, Stream 
flowrates, Membrane areas 
703 Existence of unit operation 39 143 




The considered continuous flow synthesis of diphenhydramine has been demonstrated via two 
methods: in reaction solvent and as a neat mixture (without solvent).32 The CPM route features in-
line purification and crystallisation, full-atom economy and flow of molten ammonium salts. The 
benefits of using neat mixtures in microreactors are well documented in the literature.145–148  
 
Figure 4: Diphenhydramine brand sales in the US and non-prescription sales in the UK.149 
The considered continuous flow synthesis of diphenhydramine was described by Snead and 
Jamison (2013).32 The CPM route involves the etherification of chlorodiphenylmethane (CDPM) 
and dimethylaminoethanol (DMAE) to form the API hydrochloride salt. The synthesis reaction is 
carried out via two methods: (1) in carrier solvent, N-methyl-2-pyrrolidone (NMP), CPMa, and (2) 
as a neat mixture, CPMb (Fig. 5).  
 
Figure 5: Continuous flow synthesis of diphenhydramine hydrochloride.32 (a) Reaction in carrier 
solvent (NMP) at 180 °C, CPMa; (b) Reaction without carrier solvent (“neat”) at 175 °C, CPMb. 
The developed flowsheets for both syntheses are shown in Fig. 6. Reagents and carrier solvent 
flow into Plug Flow Reactor (PFR) R-101. Aqueous NaOH solution is then pumped into the 
reactor effluent to neutralise the API salt, after heating to the reaction temperature in heat 
exchanger (HX)-101. The neutralised effluent is then purified to obtain a product containing the 
API, following heating to the required separation temperature in HX-102. 
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Figure 6: Developed continuous flowsheet for synthesis of diphenhydramine. (a) Process using 
carrier solvent (CPMa), (b) Process without carrier solvent (CPMb). “F” denotes stream numbers. 
2.2.1.2 Rufinamide 
Active Pharmaceutical Ingredients (APIs) containing 1,2,3-triazole rings are known to have a wide 
range of applications including antifungal,150 anti-HIV,151 anti-cancer,152 antibacterial153 and 
tuberculosis treatments,154 amongst others. Synthetic routes towards molecules containing 1,2,3-
triazole cores require generation of organoazide intermediates which pose significant operational 
hazards due to their high propensity for detonation.155 Such reactions in flow can potentially be 
too hazardous in batch mode due to the accumulation and required isolation of organoazide 
intermediates between batch unit operations. Continuous operation of such reactions have the 
potential to circumvent these hazards by immediately reacting these intermediates in flow.156 
 


































































































An important advantage of continuous operation is the ability to access process conditions (e.g., 
high pressure and temperature) that would be otherwise too hazardous to operate in batch mode;158 
this is due to the improved heat and mass transfer characteristics inherent of the smaller equipment 
dimensions required for continuous operation compared to batch vessels.17,159 Operating 
hazardous reactions is also inherently safer in continuous mode due to the limitation of the hazard 
to a smaller footprint compared to equivalent setups in batch mode. 
Rufinamide is an anticonvulsant API developed for the treatment of Lennox-Gastaut syndrome 
(i.e., childhood onset epilepsy), present in formulations such as Banzel or Inovelon. Cases of death 
by epilepsy have been historically increasing (Fig. 7) and thus efficient manufacturing of 
antiepileptic APIs is important. Rufinamide contains a 1,2,3-triazole ring whose synthesis requires 
the generation of organoazide intermediates. Various synthetic routes towards rufinamide have 
been demonstrated in recent years40,160–163 with life cycle assessments also elucidating process 
benefits of various manufacturing routes.57 One of these demonstrations implements a continuous 
flow synthesis featuring three PFRs whilst avoiding the accumulation or holdup of hazardous 
organoazide intermediates.40 
 
Figure 8: Reaction scheme for the continuous flow synthesis of rufinamide.40 
The process model and flowsheet developed here is based on the continuous flow synthesis of 
rufinamide in a series of PFRs demonstrated by Zhang et al. (2014).40 The reaction scheme for the 
CPM of rufinamide is shown in Fig. 8 and the developed CPM flowsheet in Fig. 9. The first 
reaction is a SN2 substitution of 2,6-difluorobenzyl bromide (2) by sodium azide (NaN3) at 20 °C, 
forming the intermediate 2,6-difluorobenzyl azide (3) and sodium bromide (NaBr) as a by-product. 
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Both reagents use dimethyl sulfoxide (DMSO) as a carrier solvent. The second reaction features a 
mixture of neat methyl propiolate (4) and aqueous ammonium hydroxide reacting at 0 °C to form 
intermediate propiolamide (5), condensing methanol (MeOH) as a by-product. Intermediates 3 
and 5 mix at a T-junction and enter PFR-3 to synthesise the API.40  
 
Figure 9: Conceptual flowsheet for upstream CPM of rufinamide.40 
The original publication also reports the formation of an API regioisomer in PFR-3, which is not 
considered due to the lack of available kinetic data for this reaction.40 A back pressure of 100 psi 
is required to regulate NH3 gas generation.40 The effluent of PFR-3 then undergoes antisolvent 
crystallisation where rufinamide is crystallised and removed as a solid product. 
2.2.1.3 Warfarin 
(S)-Warfarin is an anticoagulant API commonly used for the treatment of deep vein thrombosis 
and pulmonary embolism.164 Prescription rates of cardiovascular treatments and global 
anticoagulant medications have both been historically increasing (see Fig.10).165 The continuous 
flow synthesis of (S)-warfarin features a single reaction and subsequent Liquid-Liquid Extraction 
(LLE) process.166 Comparison of different conceptual separation process alternatives is essential 
for establishing cost-effective, materially efficient designs for upstream CPM configurations. 
Screening of candidate continuous LLE configurations for this API has yet to be conducted; 
modelling, simulation and optimisation of continuous separation processes can be used for rapid 
design space investigation to elucidate technically feasible and economically viable processes.  
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Figure 10: Increasing prescriptions of cardiovascular treatments and global anticoagulant usage.165 
Here, steady-state process modelling and nonlinear optimisation (via NLP) is implemented for the 
upstream CPM of warfarin, including continuous flow synthesis and LLE. Flowsheet development 
based upon the published continuous synthetic route and a conceptual continuous LLE process 
are presented, comparing various separation solvents. Thermodynamic models for liquid-liquid 
phase composition and API solubility prediction in non-ideal, multicomponent mixtures for LLE 
design are described. Nonlinear optimisation problem formulation for total cost minimisation is 
subsequently presented. Minimum total costs, optimal API recoveries and material efficiencies for 
different process configurations are compared to establish promising LLE solvents. 
The flowsheet for the CPM of (S)-warfarin (API) is shown in Fig. 11. The continuous flow 
synthesis of the API features the nucleophilic addition of 4-hydroxy-coumarin with benzalacetone 
in the presence of trifluoroacetic acid (TFA) and a chiral amine catalyst at 75 °C in 1,4-dioxane, 
with a reported conversion of 61%. Aqueous HCl is added to the reactor effluent before entering 
the LLE unit. Upon addition of the candidate LLE solvent, the process forms an organic (product) 
phase containing recovered API and an aqueous (waste) phase, between which API partitions.  
 
Figure 11: Process flowsheet for the continuous flow synthesis of (S)-warfarin166 and subsequent 

















































































Affordability and accessibility of essential medicines remains a pressing issue for the treatment of 
diseases prevalent in developing countries. The treatment of the HIV continues to be one of the 
most prominent global health challenges; the prevalence of HIV has been historically increasing 
worldwide, with low- and middle-income countries being those most affected (Fig. 12). The 
development of efficient, cost-effective manufacturing routes towards drugs for HIV treatment is 
paramount to ensure global, affordable access to such medicines.167 
The utility of CPM platforms for the development of APIs for the treatment of HIV and other 
societally important diseases has been demonstrated in the literature;19,20 Table 3 lists various HIV 
APIs whose syntheses have benefited by implementing semi-continuous/continuous methods.  
The design of continuous separation processes for integration into upstream CPM is essential to 
realise the benefits of end-to-end continuous manufacturing for HIV API production. 
 
Figure 12: Increasing worldwide HIV prevalence168 + top 20 countries with the highest rates.169  
Nevirapine is a widely-prescribed API for HIV-1 treatment on the WHO List of Essential 
Medicines, whose continuous flow synthesis from two advanced starting materials was recently 
demonstrated with subsequent purification and batch crystallisation for final API separation.170 
The economic viability of different process alternatives for the API is yet to be systematically 
investigated and is essential to ensure cost optimal designs. Systematic comparison of process 
alternatives is essential to further aid the development of leaner manufacturing routes towards this 
societally important HIV API. 
Various commercial routes towards nevirapine have been demonstrated in the literature with 
varying complexities and material intensities.174 The recent demonstration of the continuous flow 
synthesis of nevirapine uses advanced starting materials (made prior to the flow synthesis in batch), 































































2-chloro-3-amino-4-picoline (CAPIC) and MeCAN (methyl-2-(cyclopropylamino)nicotinate).170 
The syntheses of CAPIC and MeCAN are summarised in Fig. 13. 
Table 3: Demonstrated continuous/semi-continuous flow syntheses of HIV APIs. 
API Year Continuous/Semi-Continuous Processing Benefits Ref. 
Efavirenz 2013 Semi-continuous 
Improved API yield 
171 
Reduced process time 
Reduced number of unit ops. 
Darunavir 2015 Continuous End-to-end continuous process at 
production scale 
30,31 
Lamivudine 2017 Semi-continuous Improved API yield 172 
Reduced process time 
Nevirapine 2017 Continuous Improved material efficiency 170 
Reduced number of unit ops. 
Dolutegravir 2018 Continuous Reduced process time 173 
Fig. 13a illustrates the published batchwise synthesis of CAPIC. Acetone and malononitrile react 
in toluene (PhMe) in the presence of basic Al2O3 to form ylidene, followed by filtration of Al2O3 
from the reaction mixture. Dimethyl formamide-dimethyl-sulfate (DMF-DMS) and acetic 
anhydride (Ac2O) and triethylamine (TEA) are then added to the filtrate under N2 to form enamine 
(5). Hydrogen chloride (HCl) gas is then bubbled into the reaction mixture and heated. The mixture 
is then concentrated by evaporating solvent and water followed by filtration of product 2-chloro-
4-methylnicotinonitrile (CYCIC). Sulfuric acid (H2SO4) is then added to the solid CYCIC and 
reacted at high temperature followed by the addition of water. Aqueous NaOH is added until pH 
= 11. The resulting suspension is then filtered for product 2-chloro-4-methylnicotinamide 
(COMAD). A mixture of COMAD, water and sodium hypobromite (NaOBr) is made at 0 °C. 
Water is then added and the mixture is heated to 80 °C and stirred. After cooling, PhMe is added 
to form a biphasic mixture; the organic layer is washed with water and concentrated under vacuum 
to remove solvent. Hexanes are then added to precipitate CAPIC. 
Fig. 13b illustrates the published batchwise synthesis of MeCAN. 2-chloronicotinonitrile, 
cyclopropylamine (CPA), TEA, water and isopropyl alcohol (IPA) are added at 140 °C and 
pressurised to 10 psi to form an intermediate. The mixture is stirred and then cooled to 60 °C. 
Potassium hydroxide (KOH) is then added to the reaction mixture and stirred. Concentrated HCl 
is added to change pH to 6 and cooled to 10 °C to precipitate 2-(cyclopropylamino)nicotinic acid 
(2-CAN), which is then vacuum filtered. 2-CAN is then dissolved in PhMe under N2, adding 
thionyl chloride (SOCl2). The reaction mixture is cooled to 0 °C followed by H2O addition and 
pH adjustment to 9 with NaOH (aq.), forming a biphasic mixture. The aqueous layer is washed 
with toluene (PhMe) and the combined organic layers washed with H2O and dried with Mg2SO4, 
followed by filtration and concentrated under vacuum to yield MeCAN. 
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Figure 13: Published batchwise syntheses of (a) CAPIC and (b) MeCAN.170 
The published continuous synthetic route for nevirapine from CAPIC and MeCAN is shown in 
Fig. 14. Starting materials CAPIC and MeCAN (in diglyme carrier solvent) are used to form 
intermediate N-(2-chloro-4-methylpyridin-3-yl)-2-(cyclopropylamino)nicotinamide (CYCLOR) in 
the presence of NaH, which then forms nevirapine (API). The CPM process in this work is based 
upon this demonstrated continuous flow synthesis, whose process modelling and simulation are 
further developed in later sub-sections. 
 
Figure 14: Nevirapine continuous synthesis from CAPIC and MeCAN.170 
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Fig. 15 shows the process flowsheet for nevirapine CPM based on the published continuous flow 
synthesis. The first reactor, R-101, is a thin-film reactor operated at 95 °C; reaction between 
CAPIC and NaH in diglyme at 95 °C forms the sodium salt of CAPIC (CAPIC-Na) with evolution 
of H2 gas and an estimated 100% conversion of CAPIC. The mixture containing CAPIC-Na is 
added to a continuous stirred tank (R-102, 65 °C) with neat MeCAN with 82.5% conversion of 
CAPIC-Na to CYCLOR (+ sodium methoxide, NaCH3O) reported. Finally, CYCLOR undergoes 
ring closure in the presence of a packed bed of NaH (R-103) to form nevirapine (API). The 
subsequent crystallisation can be performed in batch or continuous mode. 
 
Figure 15: Process flowsheet for the CPM of nevirapine. 
The flowsheet for the conceptual crystallisation process considered in this work following the 
continuous flow synthesis is shown in Fig. 16. The effluent of R-103 is fed to a stirred tank where 
aqueous HCl is added; the API is more soluble at lower pH in aqueous solutions. Activated carbon 
(AC) is then added to adsorb organic impurities prior to their subsequent removal via filtration.170 
Nevirapine is then crystallised from solution by decreasing the API solubility by increasing pH by 
addition of aqueous NaOH. The crystallisation following the continuous flow synthesis can be 
either implemented in batch or continuous mode. 
 
Figure 16: Crystallisation of nevirapine operated in batch (BX) or continuous (CPM) mode.  
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2.2.1.5 Atropine 
Atropine is a WHO essential medicine, primarily used for the treatment of the effects of nerve 
agents and poisons, often being the most readily available patient treatment in warzones where 
chemical warfare is used.175 Atropine is also used to induce cycloplegia and mydriasis for 
ophthalmic treatments, for the treatment of bradycardia and to inhibit salivary and mucus glands 
during medical procedures.176 The continuous flow synthesis of atropine was recently 
demonstrated, featuring two PFRs followed by a purification via LLE;177 the study showed an 
improved material efficiency over previous demonstrations.178 Systematic comparative evaluation 
of process alternatives for operational feasibility and economic viability for atropine CPM has yet 
to be conducted and can elucidate designs of improved economic viability. 
The reaction scheme for the continuous flow synthesis of atropine177 is shown in Fig. 17. Reaction 
1 features the esterification of tropine (in dimethylformamide, DMF) and neat phenylacetyl 
chloride at 100 °C to form tropine ester HCl, the free form of which is formed by the addition of 
sodium hydroxide (NaOH (aq.)). Reaction 1 attains a reported conversion of 99% of tropine to 
tropine ester HCl at 100 °C in a residence time of τPFR-1 = 3.5 min in the literature. Reaction 2a is 
the aldol addition of formaldehyde (CH2O) to tropine ester at 100 °C under basic conditions to 
form API (a mixture of the D- and L-isomers), attaining a reported conversion of 78%. An 
undesired elimination of API to apoatropine via condensation is also reported (reaction 2b).177 
 





























The process flowsheet for the CPM of atropine is shown in Fig. 18. Reaction 1 occurs in PFR-1 
while reactions 2a and b occur in PFR-2. Reaction conditions are as reported in the literature.7 The 
reaction mixture is neutralised with HCl (aq.).177 A subsequent API purification via LLE follows, 
discussed further in later sections.  
 
Figure 18: Process flowsheet for atropine CPM. 
2.2.2 Mixed Suspension, Mixed Product Removal Crystalliser Cascades 
The continuous cooling crystallisation of the following APIs has been considered in this work. 
2.2.2.1 Cyclosporine, Paracetamol and Aliskiren 
Several pharmaceutical compounds have been investigated for their MSMPR crystallisation in the 
literature, including cyclosporine, an immunosuppressant with applications for skin ailment 
treatment (namely psoriasis) and rheumatoid arthritis; paracetamol, the popular analgaesic + 
antipyretic; and aliskiren hemifumarate, a renin inhibitor for the treatment of primary 
hypertension. Historic and predicted revenues for prescription hypertensive179 and non-
prescription analgesics and skin treatment medicines149 (Fig. 19) and their multiple formulation 
types (Table 4) illustrate the societal and economic importance of these APIs in the pharmaceutical 
industry. The optimal design of continuous crystallisation processes for their integration into CPM 
campaigns is paramount. 
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Figure 19: Historic and predicted US revenues for prescription hypertension (aliskiren) and non-
prescription analgesic and skin treatment drug classes.149,179 
The process investigated here is the continuous MSMPR cooling crystallisations of cyclosporine, 
paracetamol and aliskiren (hemifumarate). The process flowsheet for a cascade of MSMPR 
crystallisers in series for continuous crystallisation based on experimental demonstrations63,91,92 is 
shown in Fig. 20. A mother liquor stream containing dissolved API enters the first crystalliser, 
whose product slurry is the feed stream to the subsequent crystalliser in the cascade. Crystallisation 
occurs by cooling only, without the need for an antisolvent to generate supersaturation. 
Experimental setups for the MSMPR crystallisation of cyclosporine, paracetamol and aliskiren 
have shown that configurations with no recycle are efficient in terms of both yield and purity.107 
For all three APIs, a series of MSMPR crystallisers without recycle are considered. 
Table 4: Brands and formulations of cyclosporine, paracetamol and aliskiren.  
API Application Brand Name Prescription? Patented? Formulation 
Cyclosporine 
Immunosuppressant 




Cicloral® ✓ X Oral capsule 
Deximune® ✓ X Oral capsule 
Psoriasis Neoral® ✓ ✓ Oral capsule 
Oral solution 
Rheumatoid arthritis Neoral® ✓ ✓ Oral capsule 
Oral solution 
Keratoconjunctivitis Restasis® ✓ ✓ Ophthalmic emulsion 
Paracetamola Analgaesic 
Tylenol® X X Oral tablet 
Calpol® X X Oral suspension 
Panadol® X X Oral tablet 
Aliskiren Hypertension Tekturna
® ✓ ✓ Oral tablet 
Rasilez® ✓ ✓ Oral tablet 
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Cyclosporine is crystallised by cooling from a mother liquor solvent of acetone;63 paracetamol is 
crystallised from a 4:1 mixture (volume basis) of isopropanol:water;91 aliskiren hemifumarate is 
crystallised from a 1:1 mixture of ethyl acetate:ethanol (mass basis).92 The experimental 
demonstration of aliskiren hemifumarate crystallisation describes a reactive crystallisation step 
performed at 20 °C prior to cooling crystallisation, which is assumed to have already been 
performed prior to the process considered here. 
 
Figure 20: Process flowsheet of a cascade of continuous MSMPR crystallisers. F = flowrate, C = 
solute concentration in liquid phase, M = slurry density, T = crystalliser operating temperature. 
2.2.2.2 Melitracen 
Melitracen is a tricyclic antidepressant API available as single drug preparations and also in 
combinative therapies.180 The number of US citizens affected by depression and of defined daily 
doses of antidepressants distributed in the UK have been historically increasing (Fig. 21). The 
continuous crystallisation of the API in MSMPR crystallisers was recently demonstrated,181 
facilitating its process modelling and optimisation. Existing work investigates the effects of 
different MSMPR design and operating parameters on crystal size for a maximum of two 
MSMPRs, showing significant variation in process performance and crystal product attributes 
when varying the number of implemented crystallisers. Investigating the effect of longer cascades 
and recycle options can further improve crystallisation yields in MSMPR design.99 Economic 
considerations are equally important as meeting specific product attribute targets when designing 
crystallisation processes, especially when the effect of production scale is considered.69,118,182 
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Figure 21: Historical trends in number of US citizens affected by depression (2016 US population 
= 323.4 million) and number of defined daily dosages administered per 1,000 UK inhabitants (2016 
UK population = 65.38 million).183,184 
2.3 Thesis Aims & Objectives 
It is clear from the literature review provided and by consideration of the different APIs, their 
processes and societal and economic impacts, that continuous separation design is fairly limited in 
comparison to the number of continuous flow synthesis demonstrations, presenting a significant 
bottleneck in the development of end-to-end CPM processes. Steady-state modelling and 
optimisation of candidate CPM processes for these APIs allows rapid screening for promising 
plant designs. From this discussion, the following objectives were pursued for this thesis. All 
calculations for the case studies presented are performed in MATLAB. 
2.3.1 Upstream Process Design and Simulation 
Diphenhydramine: The aim of this work is to produce a process model to simulate the upstream 
processing (synthesis and purification stages) for CPM of diphenhydramine based upon the 
published continuous flow synthesis. This will involve establishing kinetic expressions of the 
chemical reactions of API synthesis in solvent and in a neat mixture. Relevant physical property 
estimations are subsequently made where necessary for subsequent unit operation design. Plug 
Flow Reactor (PFR) design is next conducted with the calculation of required reactor lengths for 
appropriate inner diameters and their required heating duties. The design of a continuous 








































































contribution) methods, with a comparison of extraction performances and material efficiencies of 
different design options. An economic evaluation of the entire process shall then demonstrate the 
cost savings and improvements in material efficiency which can be realised by continuous 
separation train relative to the batch alternative, as well as the improvements realised by neat 
synthesis relative to the synthesis in carrier solvent. Finally, a critical discussion of the design 
methods will examine the technoeconomic viability of implementation of diphenhydramine CPM. 
Rufinamide: This work develops a steady-state process model for the simulation of the CPM of 
rufinamide based on the demonstrated continuous flow synthesis in the literature. Reaction kinetic 
parameter regression, mass balance calculation and reactor sizing are conducted for the upstream 
CPM of rufinamide. Batch and continuous crystallisation processes following the continuous flow 
synthetic route are also modelled, implementing API solubility modelling in multicomponent 
process mixtures to systematically compare different separation options. Subsequent economic 
analyses elucidate cost savings benefits when implementing continuous crystallisation of the API 
vs. the batch method. A critical discussion of the results, process modelling methodologies and 
design methods are then provided to examine the technoeconomic feasibility and viability of the 
CPM of rufinamide. 
2.3.2 Technoeconomic Optimisation for Reactors and Separators 
Warfarin: This work describes the steady-state process modelling and technoeconomic 
optimisation for the upstream CPM of (S)-warfarin, implementing reactor design and LLE solvent 
comparison for purification. Reported reaction conversions and computed LLE efficiencies allow 
mass balance calculation and total cost minimisation via NLP to establish promising LLE solvents. 
The nonlinear optimisation problem is formulated for total cost minimisation. Liquid-liquid phase 
equilibria, API phase compositions and solubilities for LLE design are implemented via surrogate 
polynomials based on extensive UNIFAC modelling; API recovery rates are calculated via detailed 
mass transfer correlations. The methodology used here screens optimum process configurations 
to inform the design of upstream CPM of (S)-warfarin. 
Nevirapine: This work conducts a systematic comparative evaluation of CPM process alternatives 
for nevirapine based upon the published synthetic routes via steady-state process modelling and 
optimisation. A conceptual continuous crystallisation process is considered for comparison to the 
demonstrated batch crystallisation process. Arrhenius parameter estimation from experimental 
kinetic data allows flow reactor design for the continuous synthesis of nevirapine. Crystallisation 
process design utilises an established API solubility model. A constrained NLP problem for total 
cost minimisation of different design alternatives is then formulated. Optimal total cost 
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components, plant material efficiencies and corresponding operating parameters are presented for 
different process configurations for comparative evaluation to establish promising designs. 
Cyclosporine, Paracetamol, Aliskiren: This work conducts total cost minimisation via NLP of 
different MSMPR cascades for cyclosporine, paracetamol and aliskiren hemifumarate. First, we 
describe the continuous crystallisation process implemented for all three APIs. Subsequently, we 
describe the process model, costing methodology and the constrained nonlinear optimisation 
problem formulation for total cost minimisation. We then present minimal total cost components 
for all APIs for varying numbers of crystallisers and different plant API capacities with 
corresponding optimal design parameters of the implemented crystallisers. 
2.3.3 Process Synthesis for Technoeconomic Optimisation 
Atropine: This work implements steady-state process modelling and MINLP optimisation for 
total cost minimisation of the upstream CPM of atropine, considering the possibility for multiple 
LLE stages and fresh solvent addition to intermediate tanks in the separation cascade. The 
considered superstructure for the conceptual continuous LLE process with varying solvent 
feedpoint locations is then presented along with the MINLP problem formulation for plant total 
cost minimisation. Optimisation solutions for candidate LLE solvents and varying numbers of 
LLE tanks are compared, considering cost optimal LLE design configurations, vessel volumes and 
solvent amounts, attained API recoveries, process material efficiencies and total cost components. 
Comparative evaluation of optimisation results establishes promising LLE solvent choices and 
design configurations for atropine CPM process development. 
Melitracen: This work implements MINLP optimisation of MSMPR cascades for continuous 
melitracen crystallisation to screen for cost optimal flowsheet configurations. The MINLP 
superstructure for MSMPR cascades considers varying crystalliser volumes, extent of recycle, 
concentration of recycle streams and their allocation to different MSMPR vessels. The MINLP 
optimisation problem is solved for different plant capacity assumptions and numbers of 
implemented crystallisers. Optimal total cost components (with sensitivity analysis on different 
economic parameters), flowsheet configurations and crystallisation yields and crystal product 
average sizes are compared for different problem instances. 
2.3.4 Thesis Structure 
This PhD thesis examines several different API case studies with different process flowsheets and 
different extents of modelling, simulation and optimisation methodological approach applied to 
each. The remainder of the main sections of this thesis will be structured as follows: Part II 
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presents process modelling and simulation for design of upstream CPM (reaction + separation) 
plants for diphenhydramine and rufinamide; Part III implements economic optimisation via 
Nonlinear Programming (NLP) for the upstream CPM of warfarin and nevirapine and for MSMPR 
cascade design for the continuous cooling crystallisation of cyclosporine, paracetamol and 
aliskiren. Part IV will describe process synthesis via MINLP optimisation for the upstream CPM 
of atropine and for the MSMPR cascade design for melitracen continuous cooling crystallisation. 
Part V will then summarise the original research contributions made in this work and the 
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This chapter describes the steady-state process modelling and simulation for technoeconomic 
evaluation and design for the CPM of diphenhydramine based on the published continuous flow 
synthesis, developing a conceptual continuous LLE process for reaction effluent purification, 
based upon the flowsheet presented in Chapter 2 (Fig. 6). 
The results presented in this chapter have also been published in the literature (Diab and 
Gerogiorgis, Org. Process Res. Dev. 2017, 21(7), 924–946); details can be found in Appendix B. 
3.1 Kinetic Parameter Estimation 
The original publication provides data for the CPMa synthesis (in NMP) at 180 °C for residence 
times of 5, 10 and 20 min. For the neat synthetic route (CPMb), data is provided at a reaction 
temperature of 175 °C for residence times of 16 and 32 min. In both routes, an equimolar mixture 
of CDPM and DMAE are used.32 By considering different functions of reactant concentrations 
(representing zero-, first- and second-order reactions) vs. residence time, coefficients of 
determination have been calculated to estimate reaction orders and rate constants for each 
reaction. The kinetic parameter estimations for both CPMa and b are shown in Fig. 22. 
 
Figure 22: Diphenhydramine flow synthesis kinetic parameter estimation from experimental 
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A first-order reaction in CDPM is found to be the most plausible case for CPMa (R2 = 0.972) 
compared to zero- (R2 = 0.438) and second- (R2 = 0.111) order reactions. It is possible that 
resonance stabilisation of the intermediate carbocation by the two phenyl groups on CDPM (see 
Fig. 5, Chapter 2.2.1.1) causes it to control the reaction rate more than CDPM. It is also possible 
that the steric hindrance of the aromatic groups on CDPM render it less mobile in solution than 
DMAE; thus, the concentration of CDPM affects the rate of reaction the most, hence it is first-
order in CDPM. It was estimated that the first-order rate constant for CPMa is k1 = 12.36 hr-1. 
For CPMb, a second-order reaction (first-order in CDPM, first-order in DMAE) is most plausible 
(R2 = 0.896) compared to zero- (R2 = 0.716) and first- (R2 = 0.778) order reactions. The second-
order rate constant has been estimated to be k2 = 46.44 L mol-1 hr-1 
3.2 Estimation of Thermophysical Properties 
Material properties of all components are required for process design. This section discusses 
estimation methods used where published pure component data has been unavailable. All 
published and estimated component properties, including candidate solvents for LLE are provided 
in Table 5. Note that although theoretical methods are employed for prediction of thermophysical 
properties of some species in Table 5, there are published experimental values available in the 
literature in some cases; the methods employed in Chapters 3.2.1–3.2.3 can have significant errors 
for less common compounds. 
3.2.1 Standard Enthalpy of Formation 
Enthalpies of formation (Δ0Hf) of components involved in solvent and neat syntheses (i.e., CDPM, 
DMAE and API) are required for calculation of the reactor heating duties. Where values have been 
unavailable in the literature, an estimation method has been used (Eq. 11).187 
Δ0Hf − hf0 =   Nih1i  +   Mjh2j
ji
 (11) 
Here, h1i refers to a contribution of primary functional groups on the molecule, whilst h2j refers to 
secondary functional group contributions, weighted by the number of occurrences of each 
functional group (Ni and Mj respectively); hf0 has a constant value of 10.835 kJ mol-1.187 Calculated 




Table 5: Diphenhydramine CPM component physical properties. 
















CDPM 90-99-3 202.68 1.14 16.0 140.0 1.111185 42.37186 88.37187 
DMAE 108-01-0 89.14 0.89 −59.0 134.1 1.090185 26.66186 −79.19187 
NMP 872-50-4 99.13 1.03 −24.0 203.0 0.838188 167.36189 n.r. 
API 58-73-1 5.36 1.20 162.0 343.7 1.111185 59.47186 −60.84187 
NaOH 1310-73-2 40.00 2.13 318.0 1,388.0 n.r. 59.45190 n.r. 
H2O 7732-18-5 18.02 1.00 0.0 100.0 n.r. 75.37 n.r. 
LLE 
Solvents 
nHex 110-54-3 86.18 0.65 −95.0 68.0 n.r. 194.77 n.r. 
nHep 142-82-5 100.21 0.68 −90.6 98.4 n.r. 226.64 n.r. 
CyHex 110-82-7 84.16 0.78 6.5 80.7 n.r. 156.00 n.r. 
MeCyHex 108-87-2 98.19 0.77 −126.3 101.0 n.r. 184.50 n.r. 
DCM 75-09-2 84.93 1.33 −96.7 39.6 n.r. 102.30 n.r. 
TCM 67-66-3 119.37 1.49 −63.5 61.2 n.r. 125.34 n.r. 
Et2O 60-29-7 74.12 1.11 −116.3 34.6 n.r. 172.50 n.r. 
nHex = n-Hexane; nHep = n-Heptane; CyHex = Cyclohexane; MeCyHex = Methylcyclohexane; DCM = 
Dichloromethane; TCM = Trichloromethane (Chloroform); Et2O = Diethyl ether. Values of CP and Δ0Hf for 
LLE solvent components taken from PubChem191 and NIST Webbook.192 
3.2.2 Constant Pressure Heat Capacity 
Specific heat capacities at constant pressure (CP) as a function of temperature (T) for relevant 
components are required for heat transfer design. Where published values are unavailable, the 
following group contribution method has been used (Eq. 12).186 Here, ak, bk, ck and dk are constants 
associated with functional group k, whilst nk is the occurrence of each group on the molecule. 
Calculated values of CP required for PFR duties are shown in Table 5. 
Cp =    nkak
k
 +   nkbkT
k
 +   nkckT
2
k






3.2.3 Enthalpy of Fusion 
The total phase change entropy is approximated as the entropy of fusion (Δ0
TfusSpc) and is estimated 
using Eqs. 13 and 14 for aliphatic and benzenoid aromatic hydrocarbons: 
Δ0
TfusSpc =   nkGk
k
 + nCH2CCH2GCH2 (13) 
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CCH2=  
1.31,  nCH2 ≥   nk
k




Gk represents the contribution of group k to the total phase change entropy. Group coefficients 
nk, Gk and Ck are used for multiple occurrences of group k on a molecule. The calculation requires 
tabulated values for Gk and Ck from the literature.193 
The enthalpy of fusion (ΔHfus) can then be calculated from the entropy of fusion and solute 
melting point (Tfus) as follows.  
ΔHfus ≅ Δ0
TfusSpsTfus (15) 
3.2.4 Reaction Enthalpy 
Isothermal operation is assumed for all unit operations, i.e., constant temperatures are maintained 
by provision of sufficient heat transfer requirements. Enthalpies of reaction (ΔHrxn) have been 
calculated using Hess’ Law (Eq. 16), considering the sum of enthalpy changes in cooling the 
reactants from the reactor temperature (T) to T0 = 298 K, the standard reaction enthalpy and the 
enthalpy associated with heating the products from standard to reaction temperature. 
ΔHrxn =   Cpreagents
(T0 − T) + ΔHrxn
0  +   Cpproducts
(T − T0) (16) 
The standard reaction enthalpy (Δ0Hrxn) is calculated as the difference between the sums of 
enthalpies of formation of products and reagents (Eq. 17). 
ΔHrxn







3.3 Reactor Design 
It has been assumed that reaction mixtures in the PFRs are homogeneous. In the PFRs, radial and 
axial concentration and temperature gradients have been assumed negligible, i.e., perfect mixing 
and sufficient heating is provided by appropriate reactor design and completely submerging the 
reactor in heat transfer media with adequate circulation. The required residence time required to 
produce QAPI = 100 kg API yr-1 has been calculated using the PFR design equation (Eq. 18). Here, 
τ = PFR residence time, CA,0, XA and rA = initial concentration, conversion and rate of reaction of 
limiting reagent A (in both cases, A = CDPM), respectively, and Xf is the final conversion. 
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The estimation of PFR residence times requires values of Xf. The published data indicates a 
maximum conversion of 98% is possible for CPMa, whilst 95% conversion is attainable for 
CPMb.32 A summary of the assumptions made for PFR design is provided in Table 6.  
Table 6: Diphenhydramine kinetic parameter estimation results as a basis for reactor design. 
Synthesis CPMa CPMb 
Reaction Order 1 2 
Rate Law −rCDPM = k1CCDPM −rCDPM = k2CCDPMCDMAE 
Reaction Temperature (°C) 180 175 
Conversion, XA (%) 98 95 
Rate Constant, ki (units) 12.36 (hr-1) 46.44 (L mol-1 hr-1) 
Coefficient of Determination (R2) 0.972 0.896 
Design of all unit operations requires a plantwide mass balance. The following assumptions have 
been made for mass balance calculations of all component streams: 
 The process’ production scale is QAPI = 100 kg API yr-1. The specified QAPI is met by altering 
a scaling factor such that the difference between the attained API production and QAPI is 
minimised; this is performed in MATLAB using the solver ‘fminsearch’. 
 Chemical reaction only occurs within the reactor, not in any previous or subsequent units or 
their connecting lines. 
 No reaction occurs between unreacted reagents and subsequent chemicals introduced in the 
process.  
 Reaction mixtures are modelled as homogeneous and ideal solutions. 
 Temperature changes throughout the process cause no phase transitions or precipitation of 
salts.  
Pure component densities (ρ) at elevated reaction temperatures are required for calculation of 
mixture densities and volumetric throughputs. Coefficients of isothermal expansion (β) have been 
found in the literature or estimated where unavailable in order to calculate component density as 
a function of temperature according to Eq. 19. Values of β are in Table 5. 
ρ(T) =
ρ(T0)
1 + β(T – T0)
 (19)













Here, Fij is the molar flowrate of component i exiting reactor j, FA,0j is the inlet molar flowrate of 
limiting reagent A in reactor j, Θij is the molar ratio of component i to limiting reagent A in reactor 
j and νij is the stoichiometric coefficient of component i in reactor j. Molar flowrates are converted 
to mass flowrates using the component Molecular Weights (MWs) listed in Table 5. 
Fig. 23 illustrates component mass flowrates of key streams from the process flowsheet (see Fig. 
6). It can be seen for both syntheses that the API formed constitutes a significant portion of the 
total stream; hence a large amount of neutralising agent (NaOH) is required for both syntheses to 
ensure the API is not present as a salt. Approximately the same amounts of NaOH (aq.) solution 
are added to both PFR effluents as the same amount of API salt is being neutralised in each case. 
The difference in extraction solvent added between CPMa & b are associated with differences in 
extraction efficiency of different LLE solvents, as well as the inefficiency of the Zefluor membrane 
required for CPMb (see Chapter 3.4). 
 
Figure 23: Component mass flowrates of key streams in the diphenhydramine CPM process (g 
hr-1) (a) with carrier solvent (NMP), CPMa (b) as a neat mixture, CPMb. 
Reactor volumes (Vj) are calculated from the required residence time and the volumetric 
throughput (Qj) required to attain the specified plant capacity (QAPI). 
Vj = τjQj (21) 
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Table 7 shows the computed PFR sizes for both CPMa and b. The reactor volumes obtained for 
both syntheses are small for the target capacity, which demonstrates the benefit of reduced 
equipment sizes offered by CPM. The significant difference in reactor volume between CPMa and 
b is due to differences in reaction mixture volumetric flowrate as the latter lacks carrier solvent.  
Reactor internal diameters, dPFR = {2.5, 5.0, 10.0, 15.0} mm have been considered to calculate 
resulting reactor lengths, LPFR, corresponding to the required volumes; these diameters are 
comparable with those in the literature, chosen to ensure radial temperature and concentration 
gradients are negligible.148 The inner diameter of the reactor is an important tuning parameter for 
the resulting reactor length and fouling and reactor clogging issues where solid handling is required. 
It is particularly important to maintain a constant reactor temperature in the neat synthesis to 
ensure clogging does not occur. Such issues require the need for rigorous process control to ensure 
high reactor performance.  
Table 7: PFR design results for diphenhydramine CPM. 




























The original paper describing the continuous flow synthesis of diphenhydramine also describes 
two side reactions: the formation of benzhydrol by nucleophilic substitution of CDPM, and the 
self-etherification of benzhydrol to form dibenzhydryl ether.32 The work did not provide enough 
information to estimate kinetic parameters of these side reactions, so the model described here 
only accounts for the synthesis reaction. In order to obtain more accurate reactor sizes, data on 
these side reactions must be found in order to obtain accurate reaction kinetics. 
Calculated reaction enthalpies at the reaction temperature for both CPM routes are shown in Table 
8. The heating requirement of each reactor is considered as the sum of feed heating from standard 
to reaction temperature and heating of the endothermic reaction. The duty for CPMb is 
significantly lower than for CPMa due to the lower throughput, however both are of the same 
order of magnitude. As a result of the significantly lower reactor volume, the specific duties for 
the PFR for CPMb are higher than for CPMa. The magnitudes of both duties are considerable for 
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the reactor size and plant capacity; this is due to the elevated reaction temperatures of both 
synthesis routes. In the original CPM publication, there is not enough data available to determine 
the temperature dependence of the reaction rate constants, so analysis into the effect of 
temperature on conversion and heat transfer design could not be evaluated. It is also assumed that 
these temperatures are sufficient to keep the reaction mixtures fluid enough such that reactor 
clogging does not occur.32 These calculations consider the power requirements of the reactors only, 
and do not include pumping, losses, LLE solvent and crystallisation heating/cooling requirements, 
or power for analysis and control. It is important to consider heat integration of the full process 
for the detailed design of CPM plants. 
Table 8: Heat transfer requirements of PFRs for diphenhydramine CPM. 














CPMa Endothermic 32.02 180 0.42 
2.5 3759 0.021 
7.934 
5.0 940 0.084 
10.0 235 0.338 
15.0 104 0.763 
CPMb Endothermic 32.07 175 0.13 
2.5 656 0.023 
1.530 
5.0 164 0.093 
10.0 41 0.373 
15.0 18 0.850 
3.4 Phase Equilibria Prediction 
3.4.1 Solid-Liquid Equilibrium 
Estimation of API solubility in carrier and extraction solvents is required where published data is 
unavailable for accurate design of API purification. The UNIFAC method has been used.194,195 
This model assumes negligible difference in heat capacity between API at T and Tfus, which is 
commonly done in the chemical engineering literature.196,197 The solid solubility of component i in 















The activity coefficient (γi) at saturation is calculated by Eqs. 23–34. Iteration is required to 
calculate the solubility of solute i, as the activity coefficient is a function of composition. The 
UNIFAC activity coefficient is the sum of a combinatorial (describing shape and volume effects 
of functional groups) and residual component (describing their energetic interactions). The 
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combinatorial component (γic) is calculated via the UNIQUAC model. i and i are molar weighted 
segment and area fractional components respectively. Li is a compound parameter defined by 
parameters ri, qi and z (= 10). ri and qi are calculated from contributions of volume and surface area 
parameters for each functional group (Rk and Qk, respectively) weighted by their occurrence on 
each a molecule (vki). 
ln γ
i
 = ln γ
i








































 ri − qi  − (ri − 1) 
(27) 











The residual component (γir) of the activity coefficient is calculated by Eq. 30. k and ki are 
residual group activity coefficients of group k in the multicomponent mixture and in a reference 
solution of pure substance i, respectively. m is the summation of the area fraction of group m over 
all different groups. xm is the mole fraction of group m. mn represents the interaction between 
different functional groups in solution, and is calculated using an Arrhenius-type expression. 
Tabulated values of R and Q are required for calculation of the UNIFAC activity coefficient of 
molecule i, and are available in the literature.198,199 
ln γ
i
r  =   vk


























  (33) 
3.4.2 Liquid-Liquid Equilibrium 
Ternary mixture phase composition prediction is required for LLE modelling. The condition for 
liquid-liquid phase equilibria for phases 1 and 2 and solvent mixture component i is described by 
Eq. 35.199 
xi,1γi,1 = xi,2γi,2 (35) 
Activity coefficients can be estimated via the UNIFAC or NRTL models; estimation via the 
UNIFAC model are as per Eqs. 23–34.  
The NRTL activity coefficient model for a multicomponent system is described by Eq. 36.200 Here, 
αij is the non-randomness parameter between components i and j. The dimensionless interaction 
parameter, τij, gives the temperature dependence of the model. aij is the interaction between 








































Table 9: Initial list of candidate solvents for diphenhydramine CPM LLE application. 




UNIFAC NRTL Exp. data UNIFAC Exp. Data FDA203 Pfizer202 
Alkanes nHex ✓ ✓ 205 ✓ ✕ 2 Undesirable NRTL ✓ 
nHep ✓ ✕ ✕ ✓ ✕ 3 Preferred UNIFAC ✓ 
CyHex ✓ ✓ ✕ ✓ ✕ 2 Useable NRTL ✓ 
MeCyHex ✓ ✕ ✕ ✓ ✕ 2 Useable UNIFAC ✓ 
Chloroalkanes DCM ✕ ✕ 205 ✓ ✕ 2 Undesirable Experimental data ✓ 
TCM ✕ ✕ 205 ✓ ✕ 2 Undesirable Experimental data ✓ 
Alcohols MeOH ✕ ✕ ✕ ✓ 205 2 Preferred Lack of data X 
EtOH ✕ ✕ ✕ ✓ 205 3 Preferred Lack of data X 
1-PrOH ✕ ✕ ✕ ✓ ✕ 3 Preferred Lack of data X 
1-BuOH ✕ ✕ ✕ ✓ ✕ 3 Preferred Lack of data X 
iBuOH ✕ ✕ 205 ✓ ✕ – Preferred Single phase X 
1-PnOH ✕ ✕ 206 ✓ ✕ 3 Useable Single phase X 
1-HxOH ✕ ✕ 206 ✓ ✕ – – Single phase X 
Carboxylic acids AcOH ✕ ✕ ✕ ✓ ✕ 3 Useable Lack of data X 
Ketones DMK ✕ ✕ ✕ ✓ 205 3 Preferred Lack of data X 
MEK ✕ ✕ ✕ ✓ ✕ 3 Preferred Lack of data X 
Esters EtOAc ✕ ✕ ✕ ✓ 205 3 Preferred Lack of data X 
iPrOAc ✕ ✕ ✕ ✓ ✕ 3 Preferred Lack of data X 
nHex = n-Hexane; nHep = n-Heptane; CyHex = Cyclohexane; MeCyHex = Methylcyclohexane; DCM = Dichloromethane; TCM = Chloroform; MeOH = Methanol; EtOH = 
Ethanol; 1-PrOH = 1-propanol; 1-BuOH = 1-butanol; iBuOH = Isobutanol; 1-PnOH = 1-pentanol; 1-HxOH = 1-hexanol; AcOH = Acetic Acid; DMK = Acetone; MEK = Methyl 
ethyl ketone; EtOAc = Ethyl acetate; iPrOAc = Isopropyl acetate. 
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3.5 Continuous Liquid-Liquid Extraction Process Design 
The product stream of both PFRs contains API in an aqueous solution after addition of NaOH 
(aq.). In CPMa, the PFR outlet is a binary mixture of NMP + H2O, whilst in CPMb the solution 
is predominantly aqueous. In both CPMa & b, the aqueous mixture exiting R-101 is assumed to 
contain several dissolved solutes (unreacted CDPM and DMAE, API and NaOH). API must be 
extracted from this stream in order to obtain a purified product. For CPMa, this can be done by 
continuous Liquid-Liquid Extraction (LLE). For CPMb, addition of n-hexane to the aqueous 
stream yields a binary phase mixture which can be separated by a Zefluor membrane, as in the 
original CPM publication.32 The performance of the membrane with other solvents is unknown, 
and thus other LLE solvent options for CPMb cannot be explored here. The emphasis in this 
process design case study is on technoeconomic evaluation of the impact of selection of different 
LLE solvent choices and less on LLE vessel design (regarding residence time + vessel volume). 
3.5.1 Candidate Separation Solvent Selection 
For design of LLE, equilibrium data is required for ternary systems containing NMP, water and 
LLE solvent (CPMa) and for the binary system of n-hexane and water (CPMb). An industrial 
solvent selection guide, classifying solvents as “preferred”, “useable” or “undesirable”, has been 
consulted for solvent selection.202 A wide range of candidate solvents has been considered for the 
design of the API purification stage (Table 9). In order for a solvent to be considered suitable for 
application, three criteria had to be fulfilled:  
 The API must exhibit preferential solubility in the candidate solvent vs. NMP + H2O. 
 The candidate solvent must form a two-phase mixture with a wide region of immiscibility. 
Experimental liquid-liquid equilibrium data is used where possible, with theoretical modelling 
employed (via UNIFAC/NRTL) where experimental data was unavailable. If there was no 
experimental data or required interaction parameters for the models used, the solvent could 
not be considered. 
 The toxicity of the solvent is considered unacceptable if it is both “undesirable” in the 
industrial solvent selection guide202 and a Class 1 solvent according to FDA guidelines.203  
3.5.2 Solute Partitioning 
Theoretical modelling of liquid-liquid equilibria of different ternary systems than those available 
in the literature has been implemented using the popular UNIFAC and NRTL models, depending 
on which has been able to converge for different systems. Organic and aqueous phase composition 
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Figure 24: Liquid-liquid equilibrium phase diagrams for different candidate LLE solvents for 
diphenhydramine CPM. (a) – (f): Ternary systems of NMP-H2O-Solvent, (g) Binary system of n-
C6H14 and H2O for the neat process (using experimental data). S:F = LLE solvent-to-feed ratio. 
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are estimated via the UNIFAC/NRTL model to conduct a mass balance around the LLE process. 
The partition coefficient of API between the phases is assumed to be equal to the ratio of API 
solubilities in each phase. 
Fig. 24 shows the various ternary phase diagrams obtained for the NMP-water-solvent system 
using theoretical methods or experimental data where appropriate (Table 9). The binary phase 
diagram for the n-hexane-water system required for CPMb has been obtained from experimental 
data.204 Temperatures of 20, 30 and 40 °C have been considered for LLE design. Liquid-liquid 
equilibria for systems containing dichloromethane and chloroform could only be assessed at 20 °C 
as experimental data at other temperatures were unavailable, and these systems could not be 
modelled with UNIFAC or NRTL models due to the lack of required interaction parameters and 
non-convergence of Eqs. 23–38. For CPMb, the performance could only be examined at 20 °C as 
the behaviour of the membrane at higher temperatures is unknown. 
3.5.3 Plantwide Recoveries and Material Efficiencies 
An important design parameter in Liquid-Liquid Extraction performance is the solvent-to-feed 
(S:F) ratio, as it directly affects the extraction performance, the material efficiency and the 
operating costs associated with material usage and waste disposal. There are a wide variety of green 
chemistry metrics which can be used for quantitative comparison of processes.207 The simplest, yet 
most intuitive of these metrics, is the Environmental (E)-factor, defined as the mass of waste 
generated per unit mass of product obtained.208 In Eq. 39, mwaste = mass of waste, mAPI = mass of 
recovered API, mbpd = mass of byproducts, mur = mass of unreacted reagents, mus = mass of 





mbpd + mur + mus + muAPI
mAPI
 (39) 
Values of E-factor for different industrial sectors vary, with typical ranges for oil refining < 0.1, 
bulk chemicals manufacturing = 1–5, fine chemicals manufacturing = 5–50; in pharmaceutical 
manufacturing, the E-factor is typically in the range 25–200.209,210 This is due to the complexity of 
typical product molecules which require multistep syntheses and intermediate separations, 
incurring greater volumes of waste than other processes.211 
Another useful green chemistry metric is the Mass Productivity (MP), which expresses how 
efficiently a process uses material, including reagents as well as required neutralisation agents and 






API extraction, E-factors and mass productivities have been evaluated for varying operating 
temperatures and LLE solvent-to-feed ratios, S:F (mass basis) for the solvents listed in Table 10. 
API recoveries, E-factors and Mass Productivities have been calculated for various S:F = {0.25, 
0.50, 1, 2, 3, 4, 5} on a mass basis for all candidate solvents to evaluate performance on the basis 
of API extraction and material efficiency. Extraction performance results for both CPMa/b are 
shown in Fig. 25. It can be seen that the extraction performance of all candidate solvents decreases 
as temperature increases. The best extractions for all solvents occur at TLLE = 20 °C. It can also be 
seen that as S:F increases, the API extraction performance of all solvents increases, accompanied 
by an increase in E-factor. The increase in E-factor indicates a decrease in material efficiency of 
the extraction process as more solvent becomes present in the aqueous waste stream. In CPMa, 
both nHex and nHep achieve unacceptably low API extractions of 60.6% and 53.1%, respectively, 
even at T = 20 °C and a S:F = 5. These poor extraction performances are also accompanied by 
high E-factors of 40.31 and 48.15, respectively. CyHex and MeCyHex achieve acceptable 
extraction performances of 88.3% and 81.1%, respectively, both at S:F = 5, accompanied by 
adequate E-factors of 27.18 and 31.06, respectively. DCM and TCM both achieve very high 
extraction performances of 98.5 % and 98.7 %, respectively, at a low S:F = 0.5. Expectedly, the 
resulting E-factors attained are very good, at 3.59 and 3.43 respectively. The overall extraction 
performance in CPMb, which includes the inefficiency of the membrane, is unacceptably low, even 
at S:F = 5. This is partly due to the poor extraction performance of n-hexane, as described above.  
Fig. 26 compares the E-factors and Mass Productivities obtained for the operating conditions 
considered here. Expectedly, as S:F increases, MP decreases due to increasing amounts of waste 
incurred by additional use of extraction solvent. MP is directly related to the E-factor, and thus the 
highest MP corresponds to using chloroform as an extraction solvent at T = 20 °C and S:F = 5. 
The best performances of all candidate solvents for CPMa/b are summarised in Table 10. From 
this analysis, chloroform is the best candidate LLE solvent for CPMa due to its high extraction 
performance and material efficiency; however, its inherent toxicity and EHS characteristics render 
it unsuitable for CPM application. All of the other non-chlorinated candidate LLE solvents attain 
good E-factors for pharmaceutical manufacturing.210 In order to gain a full understanding of the 
performance of each separation option, cost estimates as well as assessment of extraction 
performance and material efficiencies are required. 
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Figure 25: Performances of different diphenhydramine CPM LLE solvents and varying solvent-
to-feed ratios and temperatures. CPMa (a) nHex (b) nHep (c) CyHex (d) MeCyHex (e) DCM (f) 
TCM; CPMb (g) nHex + membrane. 
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CPMa nHex 20 5 60.6 39.4 40.31 2.42 
nHep 20 5 53.1 46.9 48.15 2.03 
CyHex 20 5 88.3 11.7 27.18 15.91 
MeCyHex 20 5 81.1 18.9 31.06 9.44 
DCM 20 0.5 98.5 1.5 3.59 21.79 
TCM 20 0.5 98.7 1.3 3.43 48.73 
CPMb nHex 20 5 51.9 49.1 31.55 6.71 
 
 
Figure 26: E-factors and mass productivities for all candidate LLE solvents at various operating 
conditions for diphenhydramine CPM. 
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3.6 Pharmaceutical Process Economic Evaluation 
An approximate costing of the process is required to demonstrate the economic benefits and 
viability of CPM. It has been assumed that the design is constructed at an existing pharmaceutical 
manufacturing site with essential infrastructure already in place, operating for 8,040 hours per year. 
In order to demonstrate the cost savings benefits of CPM separations relative to the batch 
alternative (BX), an economic comparison of the two processes is made.  
3.6.1 Methodology 
3.6.1.1 Capital Expenditure 
Where possible, vendor prices have been found for equipment of the same or similar capacity. A 
cost-capacity correlation has been used.212  






In Eq. 41, Pj and Sj are the purchase costs and capacities, respectively, of equipment at capacity j. 
The exponent, n, is particular to specific equipment and ranges between 0.0–1.0. The correction 
factor, f, accounts for differences in equipment operation compared to the reference equipment. 
Where the applicable capacity range of the reference equipment has been much greater than 
required, the correction factor is not required (i.e., f =1).212 The cost of batch equipment of the 
same capacity as the continuous equipment is accounted for by applying a factor of 0.9 to the cost 
of the reference continuous equipment. This is due to the established status of most batch-mode 
technologies. Inflation of equipment prices taken from the past has been accounted for by applying 
Chemical Engineering Plant Cost Indices (CEPCIs). The inflation adjusted total equipment costs 
provides the Free-on-Board (FOB) cost.  
To calculate the Battery Limits Installed Cost (BLIC), the Chilton Method213 has been employed 
as follows. The cost of equipment installation is equal to 0.43 times the FOB cost. Additional costs 
incurred by process piping and instrumentation are taken as 0.3 and 0.12 times the installed 
equipment costs, respectively. The sum of installed, process piping and instrumentation costs gives 
the total physical plant cost, to which a construction factor of 0.3 is added (accounting for 
electricity installations, required buildings, site preparation etc.) to give the BLIC. The Working 
Capital cost is calculated as 35% and 3.5% of annual material costs for batch and continuous 
processes, respectively.49 Contingency costs are taken as 20% of BLIC. The final CapEx value is 
taken as the sum of BLIC and Working Capital and Contingency (WCC).  
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The equipment requirements (reactors, heating/cooling and auxiliaries) for API synthesis for 
CPMa/b are the same but with different capacities. A modular plug-flow microreactor system with 
integrated heating is used for both reactors (R-101a/b).214 An exponent of 1.0 is used, as suggested 
in the literature for PFRs.212 The cost of heaters and coolers (HX-101a/b, HX-102) are based upon 
data from an appropriate vendor.215 Solenoid metering pumps are used for pumping of reagents 
and solvents; costing data is taken from vendor sources of such pumps with appropriate 
capacities.216 
The batch separation train (BX) for the synthesis with carrier solvent is shown in Fig. 27a. The 
original CPM synthesis of diphenhydramine described a threefold batchwise extraction of API 
with diethyl ether (Et2O) for the synthesis with carrier solvent.32 Thus, three LLE tanks are required 
(BX-T101/2/3) with intermediate pumps (BX-P101/2/3) for the batchwise extraction. Pumps are 
costed using the same source as those used in the API synthesis; LLE tanks are costed as closed, 
agitated vessels.212 
 
Figure 27: Different separation trains considered for diphenhydramine CPM economic analysis. 
(a) Batch separation train, (b) CPM separation trains for process with carrier solvent (CPMa) and 
without carrier solvent (CPMb). 
The CPMa separation train is shown in Fig. 27b. In this work, a continuous LLE process is 
designed, with various solvents compared for performance in terms of API recovery and mass 
efficiency (E-factor). The continuous extraction unit (CPMa-T101) is costed as a mixing tank with 
a gravity phase separator including the required drives and pumps.212 
The CPMb separation train is shown in Fig. 27c. The original CPM synthesis of diphenhydramine 
describes extraction of API from the aqueous PFR effluent with hexanes followed by membrane 
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separation of the biphasic mixture (CPMb-M101). Costing of the Zefluor membrane used data for 
a similar membrane.217 
Table 11: Material requirements (kg yr-1) for diphenhydramine CPM with different separation options. 
Material BX CPMa CPMb 
nHex nHep CyHex MeCyHex DCM TCM 
CDPM 128 169 194 116 126 104 103 203 
DMAE 56 74 85 51 55 46 45 89 
NMP 288 380 437 261 284 234 233 0 
NaOH 252 333 383 228 249 205 204 400 
H2O 117 154 177 106 115 95 95 185 
Solvent 1,181 5,479 6,381 3,804 4,144 341 340 439 
3.6.1.2 Operating Expenditure 
Specific material prices have been sourced to estimate the costs associated with reagents and 
solvent requirements, which constitutes a significant portion of Operating Expenditure (OpEx) 
costs; material requirements for the process with different separation options are provided in Table 
11; material prices are provided in Table 12. Costs of utility requirements are taken as 0.96 GBP 
kg-1 of material input. Costs of waste disposal are taken as 0.35 GBP L-1 solvent, which are a 
significant portion of the waste. These costings are taken from an economic analysis of an 
integrated CPM process.49 Labour costs for CPM separations have been not included due to the 
small scale of this design, as well as the automated nature of CPM processes. 
Table 12: Prices of materials used in diphenhydramine CPM with different separation options. 
Synthesis LLE 
Material Price (GBP kg-1) Material Price (GBP kg-1) 
CDPM 0.18 nHex 0.49 
DMAE 0.45 nHep 0.13 
NMP 1.98 CyHex 1.07 
NaOH 0.25 MeCyHex 0.12 
H2O 0.60 DCM 0.12 
    TCM 0.11 




3.6.1.3 Plantwide Total Costs 
The total cost has been estimated assuming a 20-year plant lifetime and discount rate (taken as the 
annual discount rate, t) of 5%. This is a rather conservative estimate for the current economic 
climate. The total cost is calculated as the sum of CapEx and time-discounted OpEx. 






3.6.2 Comparative Economic Analysis 
Material requirements have been increased to account for the calculated inefficiencies of different 
unit operation designs. A comparison of different separation scenarios for both CPMa and b is 
shown in Fig. 28. Total cost savings are achieved for all continuous separations (CPMa/b) relative 
to the process with a batch separation (BX). This is due to the significant CapEx savings available 
by significant reductions in separation equipment requirements relative to the batch separation. 
The greatest total cost savings are attainable by implementing CPMb; this is due to the reduced 
material requirements which give CapEx savings from the reduction in equipment size in the 
absence of carrier solvent. In CPMa, the greatest CapEx savings are available with chloroform as 
LLE solvent. This is also due to the reduced material requirements compared to separations 
implementing other LLE solvents, accessible by the high extraction efficiency of both 
dichloromethane and chloroform. However, neither chlorinated solvent options can be considered 
acceptable due to their EHS characteristics. 
 
Figure 28: Diphenhydramine CPM cost savings elements of different separation options relative 
to the batch separation. (a) Total cost savings, (b) CapEx savings, and (c) OpEx savings. 
The greatest OpEx savings are available by using chloroform as LLE solvent in CPMa. This is due 
to the high extraction performance (i.e., material efficiency) and the low material cost compared 
to other solvents. Indeed, the OpEx savings available with chloroform in CPMa are even greater 
than for CPMb due to its low cost compared to nHex as well as the poor extraction performance 
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of CPMb. OpEx savings are unavailable with nHex and CyHex in CPMa, due to the higher material 
costs of these solvents. 
3.7 Discussion 
By determination of kinetic parameters from published experimental data, reactor volumes of 
18.45 mL and 3.22 mL have been calculated for CPMa and b, respectively. The obtained reactor 
volumes demonstrate the benefit of small equipment requirements available via CPM. Group 
contribution methods have been used for material property estimation. Such estimations have 
been required in order to calculate of reactor heating duties, which showed that considerable 
heating is required for both CPMa and b due to the elevated reactor operating temperatures.  
Activity coefficient models have been required for calculation of API solubility in different 
solvents and for calculation of liquid-liquid equilibria. Original thermodynamic studies are 
necessary for the provision of experimental ternary equilibrium data which would enable 
comparisons, corroboration and further validation of the model-based process simulation results 
and the technoeconomic conclusions presented. Several candidate solvents for continuous Liquid-
Liquid Extraction of API from the aqueous PFR effluent into an organic product phase have been 
considered based upon their propensity to form a multiphase mixture, favourable solubility of API 
in the candidate LLE solvent compared to the carrier solvent, and their inherent toxicity according 
to an industrial solvent selection guide and FDA guidelines. From an initial list of solvents (limited 
by available experimental data, convergence of UNIFAC/NRTL models and EHS criteria), n-
hexane, n-heptane, cyclohexane, methylcyclohexane, dichloromethane and chloroform have been 
compared as promising candidates for application. The evaluated solvents cover a wide range of 
toxicities and extraction performances. From a solely technical viewpoint, the best LLE solvent in 
terms of process performance and material efficiency (E-factor) is chloroform, demonstrating an 
impressively high API extraction of 98.7%, which secures a low E-factor of 3.43; this material 
efficiency is very good for pharmaceutical processes, which are typically very wasteful. This solvent 
also promises the greatest total cost savings (49.5%) and reduction in E-factor relative to the batch 
separation (E = 3.43 compared to E = 10.21 for batch) of all separation cases for CPMa. 
Nevertheless, the known and extremely high toxicity of this solvent prohibits any recommendation 
for CPM consideration, because the subsequent solvent exchange (required for downstream 
processing and final product formulation) would be extremely costly, and any remnant traces 
would be catastrophic to product as well as patients. 
Prediction of phase equilibria of non-ideal multicomponent mixtures for which experimental data 
is not available for corroboration, necessitating methods such as UNIFAC + NRTL models. The 
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accuracy of these models for less common mixtures can be poor, which must be considered when 
interpreting the presented results. Activity coefficient models are best used for highlighting 
promising process options, but not for high accuracy design. 
Methylcyclohexane is the next strongest performer among all candidate LLE solvents considered; 
it also presents remarkably advantageous characteristics (E = 31.06, which is low for 
pharmaceutical manufacturing; total cost savings of 37.3%) and its lower toxicity renders it 
significantly more acceptable for CPM implementation. Indeed, the most environmentally friendly 
solvent analysed, n-heptane, shows the worst extraction performance and highest E-factor of all 
candidates considered. If greater amounts of solvent are acceptable for production-scale CPM use 
(i.e., S:F > 5), then greener solvents are an even more attractive option, which would though incur 
greater OpEx. This trade-off between high-performance (yet toxic) solvents and less advantageous 
LLE candidates (which are inherently safer due to significantly lower toxicity) is an undeniable 
reality underlining the importance and potential of model-based plantwide design, simulation and 
optimisation of CPM processes. 
3.8 Chapter Conclusions 
Diphenhydramine is a promising candidate for Continuous Pharmaceutical Manufacturing. Its 
high global demand necessitates materially and economically efficient manufacturing techniques 
which have been explored via process modelling in this work. By illustrating the small reactor 
volumes typical of the CPM process, the material efficiencies available through continuous 
separation trains, and the associated financial benefits, a strong case can be made for the 
advantages of this emerging technology.  
Despite the small scale of production considered in this study, the viability of CPM of 
diphenhydramine is evident. The benefits of small equipment and material efficiency compared to 
batch processes are apparent for specific separation options. Further experimental investigation of 
neat CPM processes at pilot plant and production scale should be conducted (with perhaps even 
more efficient separations than those explored here), in order to gain further understanding of 
these desirable operating conditions. It is also important that downstream processing options be 










This chapter describes the steady-state process modelling and simulation for technoeconomic 
evaluation and design for the CPM of rufinamide based on the published continuous flow 
synthesis, developing a conceptual continuous antisolvent crystallisation process for API 
separation from the reactor effluent, based upon the flowsheet presented in Chapter 2 (Fig. 9). 
The results presented in this chapter have also been published in the literature (Diab and 
Gerogiorgis, Comput. Chem. Eng. 2018, 111, 102–114); details can be found in Appendix B. 
4.1 Reactor Design and Comparison of Rate Law Assumptions 
Steady-state process modelling and simulation for the CPM of rufinamide assumes a plant capacity 
of QAPI = 100 kg API yr-1; this is ensured via the same method as in Chapter 3. PFR design requires 
reaction kinetic parameter regression and mass balance calculations. The following general 
assumptions are made in the process modelling methodology: 
1. Reactions occur in the PFRs only and not in any associated connecting lines or units. 
2. The only reactions occurring in PFRs-1–3 are those shown in Fig. 9. 
3. Isothermal operation of all PFRs is ensured by providing suitable heat transfer media and 
the selection of appropriate PFR dimensions. 
4. Temperature changes and reaction/formation of components in the process cause no 
phase changes or affect the flow – no phase changes during the synthesis stages were 
observed by the authors of the experimental demonstration.40 
5. All process mixtures prior to crystallisation are homogenous and considered ideal 
solutions. 
Molecular weights and densities of process components are required for the conversion of stream 
flowrates for the purposes of reactor design, calculation of API mixture solubilities and economic 
analyses. Physical properties and details of all process components described above for the 
continuous flow synthesis of rufinamide are listed in Table 13. 
Kinetic parameters are required for the design of PFRs. Reaction rate constants are calculated 
from experimental data and assumptions made are described in this section. The results and 
assumptions for kinetic parameter estimation are summarised in Tables 14 and 15. 
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Table 13: Rufinamide CPM process component physical properties. 
Component CAS # MW (g mol-1) ρ (g mL-1) M.P. (°C) B.P. (°C) 
2 85118-00-9 207.02 1.63 53.50 184.90 
DMSO 67-68-5 78.13 1.10 19.00 189.00 
NaN3 26628-22-8 65.01 1.85 275.00 300.00 
3 106308-60-5 133.15 1.07 unavailable unavailable 
NaBr 7647-15-6 102.89 3.21 747.00 1390.00 
4 922-67-8 84.07 0.95 unavailable 104.05 
NH3 7664-41-7 17.03 0.77 -77.73 -33.34 
H2O 7732-18-5 18.02 1.00 0.00 100.00 
5 7341-96-0 69.06 1.10 59.50 134.60 
MeOH 67-56-1 32.04 0.79 -97.60 64.70 
API 106308-44-5 240.21 1.52 198.23 431.97 
Reactions 1 and 2 (Fig. 8) are assumed to be pseudo-first-order, as they involve large organic 
molecules (2 and 4 in Reactions 1 and 2, respectively) reacting with an excess of a smaller molecules 
(NaN3 and NH3 in reactions 1 and 2, respectively). Reaction 3 involves two large organic 
molecules, for which results considering reaction 3 as either first-order in 3, or overall second-
order (first-order in both 3 and 5) are compared. Here, kinetic parameter estimation methods for 
all three reactions are described. Given a target/known conversion (see Tables 14 and 15), the 














ki,j is the ith order rate constant of the reaction occurring in PFR j, ΘB is the molar ratio of excess 
reagent to the limiting reagent and νB is the stoichiometric coefficient of excess reagent. The 
integral in Eq. 44 is calculated for reported attainable conversions.  
In reaction 1, 1.3 equivalents of NaN3 react with 2 to form 3, with a reported conversion of 2 of 
100% at room temperature for a residence time of 1 min.40The first-order rate constant of reaction 
1 is estimated as k1,1 = 9.21 min-1. Reaction 2 involves 4 equivalents of NH3 reacting with 1 
equivalent of 4; the reported conversion of 4 is 95% at 0 °C for a residence time of 5 min.40 The 
first-order rate constant of reaction 2 was estimated to be k1,2 = 0.60 min-1. 
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Table 14: Rufinamide CPM kinetic parameter estimation results for reactions in PFRs 1 and 2. 
 PFR j 
 1 2 
Reaction 2 + NaN3  3 4 + NH3  5 + MeOH 
Reaction Order, i 1 1 
Rate Law –rA = k1,1CA –rA = k1,2CA 
Reactor temperature, Tj (°C) 20 0 
Final conversion, Xf (%) 99.99 95 
First-order rate constant, k1,j (min-1) 9.21 0.60 
Fig. 29 summarises attainable API yields at varying temperatures for reaction 3 (T3) reported for 
the continuous flow synthesis of rufinamide.40 Attainable API yield decreases beyond a certain 
temperature due to the reported formation of an API regioisomer. A third-order polynomial has 
been fit to the experimental API yield-temperature data, from which the temperature 
corresponding to the maximum API yield is estimated; this temperature is 117 °C with a maximum 
API yield of 99.56%. Below T3 = 117 °C, it is assumed that only the desired reaction occurs. First- 
and second-order rate constants for reaction 3 at temperatures of 90, 110 (both considered in the 
literature40) and 117 °C, are considered for which we assume that the only reaction occurring in 
PFR-3 is reaction 3. 
In reaction 3, 1 equiv. of 3 reacts with 1.42 equiv. of 5 to form rufinamide (API). First- and second-
order reaction rate constants were estimated using Eqs. 43 and 44 from attainable conversions of 
83%, 98% and 99.56% at operating temperatures (T3) of 90, 110 and 117 °C, respectively, all for 
residence times of 6.47 min.40 First- and second-order reaction rate constants for reaction 3 are 
listed in Table 15. 
The Arrhenius law (Eq. 45) describes the temperature-dependency of reaction rate constants. 





where A is the pre-exponential factor and Ea is the reaction activation energy. Values of A and Ea 
can be estimated from calculated first- and second-order rate constants at different temperatures 
in PFR-3; these values are provided in Table 15. The estimated Arrhenius parameter values are A 
= 1.06×106 and Ea = 4.58×106 J mol-1. The operating temperature of PFR-3 (T3) affects the 
reaction conversion, which alters the process mass balances and total costs of different process 
designs. We compare the effect of the operating temperature (T3 = 90, 110 and 117 °C) and the 
assumed order of reaction 3 (first- and second-order) on process modelling results. 
Figure 29: Rufinamide yield in PFR-3 reported by Zhang et al. (2014)40 as a function of reaction 
temperature, T3. 
Reactor volumes are calculated as in Chapter 3.3. The calculated mass balances are based on the 
process for the continuous flow synthesis of rufinamide (API) described by Zhang et al. (2014).40 
Component mass flowrates of key flowsheet streams (see Fig. 9) for all considered operating 
temperatures of PFR-3 (T3 = 90, 110 and 117 °C) are shown in Fig. 30; these streams are the feed 
to PFR-1 (F8), PFR-2 (F14) and PFR-3 (F16) and the effluent of PFR-3 (F17) prior to crystallisation.  
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For all CPM process variations (different considerations of the operating temperature of PFR-3), 
DMSO (the carrier solvent in PFR-1) contributes a significant portion of the total mass balance 
throughout the whole process. Reagents for reaction 1 in PFR-1 (2 and NaN3) are nearly negligible 
in streams following PFR-1 (F16 and F17 in Fig. 9) due to the high attainable conversion (99.99% 
assumed here). Similarly, the reagents for reaction 2 and PFR-2 (4 and NH3) are in trace quantities 
following PFR-2 due to the high conversion attained in the reactor. Due to these high conversions, 
there are significant quantities of desired intermediates (3 and propiolamide) and by-products 
(NaBr and MeOH) in the feed to PFR-3 (F16 in Fig. 9). Rufinamide (API) is present in significant 
quantities due to the high conversions attained at all PFR-3 operating temperatures (T3) considered 
and to account for subsequent crystallisation inefficiencies. 
Table 15: Rufinamide reaction kinetics and Arrhenius parameter estimation results for the reaction in PFR 3. 
Reaction 3 + 5  API 
PFR 3: T3 (°C) 90 110 117 
XA (%) 83 98 99.56 
Reaction Order 1 2 1 2 1 2 
Rate Law –rA = k1,3CA –rA = k2,3CACB –rA = k1,3CA –rA = k2,3CACB –rA = k1,3CA –rA = k2,3CACB 
CA,0 (M) n.r. 0.248 n.r. 0.248 n.r. 0.248 
ki,j (units) 0.27 (min-1) 1.34 (M-1 min-1) 0.60 (min-1) 3.51 (M-1 min-1) 0.79 (min-1) 4.85 (M-1min-1) 
PFR volumes are calculated (Fig. 31) from required reaction residence times to meet reported 
attainable conversions and material throughputs calculated from process mass balances. Small 
reactor volumes are calculated for PFRs-1 and 2 for all PFR-3 operating temperatures (T3) 
considered; this is due to the high attainable conversions (= 99.99% and 95% in PFRs-1 and 2, 
respectively) short residence times (= 1 and 5 min for PFRs-1 and 2, respectively) and low material 
throughputs required to meet the desired plant capacity. Computed volumes for PFR-3 for all 
considered operating temperatures (T3) and both reaction order assumptions are higher due to the 
higher material throughput and longer residence time (= 6.47 min) required to reach the target 




Figure 30: Process mass balances of key flowsheet streams for the CPM of rufinamide under 
different considerations of the operating temperature of PFR 3 (T3). 
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Figure 31: Rufinamide CPM PFR volumes for different assumptions of temperature and reaction 
order in PFR-3. 
Appropriate choice of the internal diameter of PFRs (dPFR) is an important design parameter for 
the resulting PFR length as well as ensuring negligible axial temperature and concentration 
gradients.219 Here, we consider PFR inner diameters of 2.5–15.0 mm, in accordance with reported 
microreactor applications;25 the flow regime corresponding to these reactor diameters was not 
considered as part of reactor design and analysis here, but is later integrated as part of the 
methodology in Chapter 8. Resulting reactor lengths for different inner diameters are shown in 
Fig. 32 for all PFR-3 design variations. Reactor lengths vary from very small (< 10 cm) to 
considerable sizes (< 750 cm). Reactors of significant length can be coiled in order to reduce the 
overall equipment size and maintain the benefit of small plant footprint available via continuous 
operation.17,25,28 
 
Figure 32: Rufinamide CPM PFR lengths for varying inner diameters for different assumptions 
of the temperature and reaction order in PFR 3. 
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Figs. 31 and 32 show only a small difference in PFR volumes and lengths between different 
considerations of first- and second-order assumptions for reaction 3. It is important to note that 
these results neglect the undesired side reaction forming a regioisomer of rufinamide in PFR-3, 
which will affect the results presented here. It has been assumed that only the desired reaction 
occurs in PFR-3 for the operating temperatures considered in this work. Kinetic data for this side 
reaction is required. 
4.2 Rufinamide Aqueous Solubility Estimation 
The modelling of crystallisation processes requires API solubility data in multicomponent 
mixtures. Very limited data for rufinamide solubilities in pure components or mixtures exist in the 
literature; experimental solubilities of rufinamide in pure DMSO and water at 25 °C (mole fraction 
solubility = 0.014) are available. Theoretical methods for drug solubility estimation in pure solvents 
and multicomponent mixtures can be implemented;220 however, essential interaction parameters 
for rufinamide (corresponding to the triazole functionality) for even the most rigorous and 
established activity coefficient models are unavailable. A correlation between the octanol-water 
partition coefficient (ln Kow = –0.12) and the API molar volume (Vm = 212.47 cm3 mol-1) can be 
used to estimate the API solubility in water221 
ln CAPI
sat  = χ −  ωVm − ln KOW + ln η (46) 









 ≈ 6.8 (48) 
where CAPIsat is the solute solubility in water (mol m-3), η is the fugacity ratio, ΔS is the entropy of 
fusion, χ and ω are model parameters (χ = 3.9 ± 0.2, ω = 0.005 ± 0.001).221 Kow is a function of 
temperature; a correlation between Kow and temperature is unavailable, so all crystallisation 
processes are modelled at Tcryst = 25 °C. The API solubility in the mixture is calculated as the sum 
of mole fraction weighted API solubilities in DMSO (carrier solvent) and water (antisolvent). 
4.3 Continuous Crystallisation Design 
The crystallisation yield of API is calculated from the feed API mole fraction and the API mole 
fraction solubility at saturation 
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 Y = 100  1 −
CAPIsat
CAPI
feed   (49) 
where Y is the API crystallisation yield and CAPIfeed is the API concentration in the effluent of PFR-
3 fed to the crystalliser. The method was validated by reproducing the experimental batch 
crystallisation yield of rufinamide within 1%. 
In all cases, the effluent of PFR-3 is considered a binary mixture of DMSO and water (single phase) 
in which all stream components (API, unreacted reagents, by-products) are considered dissolved 
solutes. The original continuous flow synthesis publication for rufinamide reports direct batchwise 
antisolvent crystallisation from the effluent of PFR-3 using water as an antisolvent at an 
antisolvent-to-feed ratio (AS:F, by mass) of 1.83, with a total crystallisation residence time of 75 
min.40  
Here, we compare the continuous flow synthesis of rufinamide with the demonstrated batch 
crystallisation route (BX) to that with a conceptual continuous crystallisation method also using 
water as an antisolvent (CPM). Both BX and CPM crystallisation processes are considered single-
stage. For the modelling of continuous crystallisation, we consider antisolvent-to-feed ratios of 
0.25–5 to investigate the effect of varying antisolvent usage. A crystalliser residence time (τcryst) = 
60 min is assumed for all CPM processes and a factor of 90% is applied to consider the non-
attainment of thermodynamic equilibrium in steady-state (continuous) processes. Assumptions 
about the continuous crystalliser residence time were made due to the lack of crystallisation kinetic 
parameters for higher-fidelity population balance modelling. Continuous crystalliser residence 
times range from the scale of minutes222 to as long as 20 hr.63 The considered continuous crystalliser 
residence time considered here for rufinamide production is optimistic; longer residence times will 
incur greater CapEx contributions and lead to lower CPM cost savings vs. the process with a batch 
crystallisation. It should also be noted that possible polymorphism is not considered here, which 
may impose further limitations of feasible regions of operation for rufinamide CPM. 
Crystalliser volumes (Vcryst) for CPM processes are calculated from the crystalliser residence time 
and the total volumetric flowrate through the crystalliser (Qcryst). 





4.4 Technoeconomic Analysis 
4.4.1 Plantwide Yields 
Calculated API mixture solubilities and attainable crystallisation yields for continuous 
crystallisation of rufinamide from the effluent of PFR-3 using water as an antisolvent are shown 
in Fig. 33. In all cases, increasing AS:F decreases the API mixture solubility and thus increases the 
attainable crystallisation yield. Beyond AS:F = 2, the crystallisation yield only increases 
incrementally, and thus the increased antisolvent usage and resulting crystalliser volumes will lead 
to unnecessary increases in CapEx, OpEx and poorer material efficiencies (implying greater 
quantities of waste). For this reason, AS:F = 2 is chosen for all  subsequent economic analyses. 
 
Figure 33: Rufinamide mixture solubility and attainable crystallisation yield. 
4.4.2 Material Efficiencies 
Process Mass Intensities (PMI = E + 1) and Mass Productivities (MPs) (see Chapter 3.5.4) for the 
batch process and varying CPM process considerations (different PFR-3 operating temperatures, 
T3) are shown in Fig. 34. CPM process options consider 70% recovery of carrier- and anti-solvent 
following continuous crystallisation; AS:F = 1.83 for batch crystallisation40 and AS:F = 2 for all 
considered continuous crystallisations. As the operating temperature in PFR-3 (T3) increases, PMIs 
decrease and, correspondingly, MPs increase due to the increased plantwide API recoveries 
attainable as the conversion in PFR-3 increases. The PMIs attained for CPM processes are good 
for typical attainable values for pharmaceutical processing (see Chapter 3.5.3).209 These results 
show the significant improvements in material efficiency and reduction in environmental impact 
available via CPM implementation from the improved green chemistry metrics shown in Fig. 34. 
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Figure 34: Process Mass Intensities (PMIs) and Mass Productivities (MPs) of the process with 
batch and continuous crystallisation options for different assumptions of the operating 
temperature of PFR 3. 
4.4.3 Plantwide Total Cost Components 
Total cost components are calculated as per Chapter 3.6.1. Unit capacities and material 
requirements are scaled to account for reaction and crystallisation inefficiencies to meet the 
specified plant capacity. A comparison between different total cost components for processes with 
a batch crystallisation process and a continuous crystallisation from the effluent of PFR-3, 
considering different operating temperatures of PFR-3 (T3). Table 16 shows the calculated cost 
components and differences between batch and CPM process variations. 
BLIC savings are only attainable for T3 = 110 and 117 °C when a first-order reaction in PFR-3 is 
considered, and only for T3 = 117 °C when a second-order reaction in PFR-3 is considered. This 
is due to the higher plantwide API recoveries attainable when implementing a batch crystallisation 
compared to the continuous crystallisation when PFR-3 is operated at lower temperatures; lower 
recoveries require increased material throughputs to meet the plant capacity and thus larger 
equipment. WCC costs are significantly lower for all continuous options considered due to the 
significantly lower solvent requirements due to the solvent recovery option considered for CPM 
as well as the additional labour and handling requirements of the batch process. Correspondingly, 
both material and Utilities and Waste (U&W) costs are significantly lower for all CPM options 
compared to the process implementing a batch crystallisation. 
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Table 16: Cost components (103 GBP) and differences between rufinamide batch and CPM processes for different 
operating temperatures in PFR 3 (T3). 
PFR 3 = 1st order 
 Batch CPM (AS:F = 2; SR = 70%) 
T3 (°C) 110 90 110 117 
 Cost Cost Difference Cost Difference Cost Difference 
BLIC 156 174 +11.5% 150 –4.0% 148 –5.3% 
WCC 396 60 –84.8% 51 –87.1% 50 –87.3% 
CapEx 552 234 –57.5% 201 –63.6% 198 –64.1% 
10-1 · Materials 1,298 909 –30.0% 909 –30.0% 909 –30.0% 
10-1 · U&W 1,249 874 –30.1% 874 –30.1% 874 –30.1% 
10-1 · OpEx 2,547 1,783 –30.0% 1,783 –30.0% 1,783 –30.0% 
Total 26,020 18,060 –30.6% 18,027 –30.7% 18,024 –30.7% 
PFR 3 = 2nd order 
 Batch CPM (AS:F = 2; SR = 70%) 
T3 (°C) 110 90 110 117 
 Cost Cost Difference Cost Difference Cost Difference 
BLIC 163 182 +16.6% 156 +0.3% 154 –1.1% 
WCC 397 62 –84.4% 53 –86.7% 52 –86.9% 
CapEx 560 244 –55.8% 209 –62.1% 206 –62.7% 
10-1 · Materials 1,298 909 –30.0% 909 –30.0% 909 –30.0% 
10-1 · U&W 1,249 874 –30.1% 874 –30.1% 874 –30.1% 
10-1 · OpEx 2,547 1,783 –30.0% 1,783 –30.0% 1,783 –30.0% 
Total 26,028 18,069 –30.6% 18,035 –30.7% 18,032 –30.7% 
CapEx, OpEx and total cost savings of CPM options relative to the process implementing batch 
crystallisation for varying PFR-3 design assumptions are shown in Fig. 35. It is shown that varying 
the operating temperature in PFR-3 (T3) and different assumptions of reaction order (first- or 
second-order) have only a small effect on the calculated total cost components. CapEx savings 
variations across different design options are observed due to the effect of PFR-3 operating 
temperature (T3) on conversion, and thus plantwide API yield, which directly affects the required 
material throughput and unit sizes. OpEx costs show little variation for each PFR-3 operating 
temperature (T3) chosen for first- and second-order reaction assumptions (in PFR-3) due to similar 
mass balances. Thus, there is little variation in total cost savings for different design assumptions 
for PFR-3. Thus, the reaction order in PFR-3 has only a slight effect on the CPM process.  
Nevertheless, it is imperative to make informed decisions from detailed kinetic data to present 
accurate cost components for different process options. 
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Figure 35: Rufinamide CPM cost savings of implementing a continuous crystallisation process 
relative to implementing a batchwise crystallisation. 
4.5 Chapter Conclusions 
Rufinamide is an anticonvulsant API that requires materially efficient and economically viable 
manufacturing methods. This study has developed a steady-state process model for the CPM of 
rufinamide for a plant capacity of QAPI = 100 kg API yr-1. The model is based upon a published 
continuous flow synthetic route featuring three PFRs for the API synthesis which circumvents the 
accumulation or isolation of hazardous intermediate organoazides required for the generation of 
molecules containing 1,2,3-triazole rings. The demonstrated route features short residence times 
and high conversions towards rufinamide. 
The technoeconomic evaluation conducted features kinetic parameter estimation for different 
assumptions of the reaction order in the final PFR, reactor sizing based on steady-state mass 
balance calculations and the desired API plant capacity for different operating temperatures of the 
final PFR, comparison of batch and continuous crystallisation routes via API solubility modelling 
in multicomponent mixtures and economic analyses to establish cost savings attainable when 
implementing a continuous crystallisation with respect to the batch crystallisation. 
Small PFR volumes and lengths for the specified plant capacity are computed for all process design 
variations (different assumptions on the reaction order in the final PFR and its operating 
temperature), demonstrating a clear CPM advantage. Calculated crystallisation yields for varying 
extents of antisolvent usage account for non-attainment of thermodynamic equilibria typical of 
steady-state (continuous) operation. Environmental impacts of different process options are 
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compared via the PMI and MP which quantify the material efficiency of manufacturing processes; 
results show a significant reduction in environmental impact when implementing a continuous 
crystallisation method compared to the batch crystallisation (lower PMIs and higher MPs). Cost 
estimations follow an established methodology for batch and continuous pharmaceutical processes 
and show significant total cost savings when implementing a continuous crystallisation process 
with respect to the batch crystallisation route.  
The process modelling and simulation for the CPM of rufinamide demonstrated in this work 
shows the importance of conducting such conceptual studies for pharmaceutical processes prior 
to further development and scale-up. The results demonstrate the environmental and economic 
benefits of continuous operation for the manufacturing of this societally important API. The 
potential for a scaled-up application of this process must be further developed by considering its 
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This chapter describes the steady-state process modelling and technoeconomic optimisation (via 
NLP) for design of CPM of warfarin based on the published continuous flow synthesis, developing 
a conceptual continuous LLE process for reaction effluent purification, based upon the flowsheet 
presented in Chapter 2 (Fig. 11). 
The results presented in this chapter have also been published in the literature (Diab and 
Gerogiorgis, Comput. Aided Chem. Eng. 2018, 43, 1643–1648); details can be found in Appendix B. 
5.1 Optimisation Problem Formulation and Constraints 
The aim of the optimisation is to minimise the total cost (calculated as per Chapter 3.6) objective 
function. 
min Total Cost  (51)
s.t. 
0 < τLLE (52)
1 < rLLE < 4 (53)
The discount rate (t = 5%) accounts for inflation and the plant lifetime = 20 years. Annual 
operation of 8,040 hours is considered. Optimisation decision variables are the LLE residence time 
(τLLE) and relative solvent feed rate (rLLE). Total cost components are calculated as described in 
Chapter 3.6. Solvent recovery following LLE is arbitrarily chosen as 70% in accordance with 
similar CPM studies;73 all material requirements are scaled to account for reaction and separation 
inefficiencies. The plant capacity (QAPI = 100 kg API yr-1) is met by specifying a NLP constraint. 
5.2 Reactor Design 
The literature demonstration of the continuous flow synthesis of warfarin166 describes the attained 
conversion of XA = 61% for a residence time of 10 min; due to the lack of kinetic data (as a 
function of reaction/residence time), it is assumed that designed PFRs have this residence time 
and attainable conversion. Reactor (PFR) volumes and component stream flowrates are calculated 




5.3 Continuous Liquid-Liquid Extraction Design 
5.3.1 Candidate Liquid-Liquid Extraction Process Solvents 
The considered continuous LLE process for optimisation via NLP is a single stage mixer-settler. 
Upon addition of the candidate LLE solvent, the process forms an organic (product) phase 
containing recovered API and an aqueous (waste) phase, between which API partitions. Several 
candidate separation solvents are compared for continuous LLE: ethyl acetate (EtOAc), isopropyl 
acetate (iPrOAc), isobutyl acetate (iBuOAc), 1-heptanol (HepOH), 1-octanol (OcOH) and n-
heptane (nHep). These solvents allow a wide envelope of immiscibility and are considered 
acceptable by an industrial solvent selection guide.223 Ternary phase equilibria for phase 
composition prediction uses the UNIFAC model and API partitioning estimation are calculated 
as per Chapter 3.5. 
5.3.2 Mass Transfer Correlations 
The solute extraction factor (Ef), which is calculated from the solute molar partition coefficient 
(m) between the LLE solvent (S) and the feed (F). The continuous LLE efficiency, ELLE, is 













Here, K is the overall mass transfer coefficient, QLLE is the LLE volumetric throughput, a is the 
interfacial area between phases, and VLLE is the LLE tank volume. K is calculated from continuous 
and dispersed phase mass transfer coefficients, kc and kd, respectively, which are calculated by 
phase Sherwood numbers, Shp (p = c and d denote continuous and dispersed phases, respectively) 












 ≈ 6.6 (57) 
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  (58) 
Here, d32 is the Sauter mean droplet diameter, DAPI,p is the API molecular diffusivity in phase p, Scc 
is the continuous phase Schmidt number, Frc is the continuous phase Froude number, Eo is the 
Eotvos number, ϕ is the continuous phase volume fraction, Reimp is the LLE tank impeller 
Reynolds’ number and dimp and dt are the impeller and tank inner diameters, respectively, assuming 



































Here, TLLE is the LLE operating temperature (25 °C), μp and ρp are the phase viscosity and density, 
respectively, rAPI is the API molecular radius, Nimp is the LLE tank impeller speed (= 6 r.p.s. in this 
work), g is the acceleration due to gravity, σ is the interphase surface tension, and ρm and μm are the 
mixture density and viscosity, respectively. Estimation of mixture densities and viscosities assume 
perfect mixing. The Sauter mean droplet diameter, d32, depends on the Weber number, We.  
d32 =  
0.052dimpWe
-0.6e4ϕ , We < 103
0.390dimpWe
















5.4 Plantwide Recoveries and E-Factors 
Attainable E-factors (calculated as per Chapter 3.5.3) for all processes vary between 57–127; whilst 
these values are high in comparison to other manufacturing sectors, they are between modest and 
poor for pharmaceutical manufacturing processes (see Chapter 3.5.3).225 The E-factor variations 
are directly related to corresponding API recoveries; as API recovery increases, material 
requirements and waste (and thus the E-factor) decrease. Implementing the process configuration 
with the lowest total costs (iBuOAc, 60 °C) attains E = 58.4, which is low in comparison to other 
options in this work. 
 
Figure 36: Warfarin CPM recoveries and E-factors corresponding to total cost minima. 
5.5 Plant Total Cost Components 
Minimum total costs for each LLE solvent and operating temperature are shown in Fig. 37. The 
LLE solvent with the lowest minimum total costs is iBuOAc (293.87×106 GBP, 60 °C), followed 
by EtOAc (299.91×106 GBP, 20 °C) and iPrOAc (299.93×106 GBP, 60 °C). These solvents 
perform comparably due to their similar molecular structures and polarities, inducing similar phase 
compositions and thus comparable API recoveries. This effect is also observed for HepOH and 
OcOH, which attain the next lowest total costs (339.43×106 GBP and 324.54×106 GBP, 
respectively) both operating at TLLE = 60 °C. The poorest performance is attained using nHep 
(lowest cost = 350.52×106 GBP at TLLE = 60 °C). 
For most cases, increasing operating temperature leads to lower total costs due to the enhanced 
mass transfer (recovery) rates of API into the product phase, which requires shorter LLE tank 
residence times (lower CapEx) and material requirements (lower OpEx) to meet the plant capacity 
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of QAPI = 100 kg API yr-1. When nHep is implemented as a separation solvent, OpEx is significantly 
higher for all LLE operating temperatures (TLLE = 20, 40, 60 °C) considered, due to the low API 
recoveries attainable in comparison to other separation solvents considered in this work (Fig. 36). 
In all process configurations, the solvent feed rate (rLLE) is pushed to its lower bound (= 1). The 
solvent feed rate and its assumed recovery following LLE directly affects materials and waste 
treatment costs (key OpEx components). The sensitivity of total cost minima to varying solvent 
recovery can be readily compared using the framework described here. 
 
Figure 37: Minimum total costs attainable for different warfarin CPM LLE configurations. 
The described framework can be used to perform sensitivity analyses with respect to economic 
data (e.g., varying material prices, rates of interest) and other operational assumptions (e.g., 
achieved solvent recovery). It also allows the investigation of the effect of plant capacity on total 
cost components and E-factors, an essential consideration during process development. Candidate 
separation solvents investigated for application here have been selected based upon their suitability 
for LLE (i.e., exhibit rapid phase splitting with the process mixture and are considered suitable 
with respect to detailed EHS criteria). Warfarin is available in both liquid (dispersion) and solid 
(tablet) formulations, and thus consideration of crystallisation and downstream processing 
following the upstream CPM considered in this work is important. Consideration of the effects of 
LLE solvent choices and resulting API recoveries and purities in the organic product phase on the 
requirement for additional purification prior to further processing will aid LLE solvent selection. 
The methodology described in this work can be implemented for other APIs requiring continuous 
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LLE, provided essential mass balance and thermodynamic data are available for modelling and 
total cost minimisation. 
5.6 Chapter Conclusions 
This study presents the systematic evaluation of six candidate separation solvents for the 
continuous Liquid-Liquid Extraction (LLE) of (S)-warfarin following the experimentally 
demonstrated continuous flow synthesis. Comparison of minimum total costs via nonlinear 
optimisation with LLE solvent feed rate and tank residence time as decision variables establish 
promising candidate LLE solvents for the CPM of (S)-warfarin. Isobutyl acetate (iBuOAc) 
emerges as a promising candidate LLE solvent, attaining the lowest minimum total costs of 
293.87×106 GBP and a reasonable E-factor of 58.4, followed by ethyl acetate and isobutyl acetate. 
The considered alcohols (1-heptanol and 1-octanol) and n-heptane attain inferior performance 
(higher total costs) due to their lower maximum (theoretical) API recoveries. 
The technoeconomic and environmental impact analyses presented in this work can inform the 
future design of CPM processes for this societally important API. Consideration of wider 
operating parameter sets and additional LLE solvents can be performed by adapting the existing 
framework, given the availability of required thermodynamic data and physical properties. 
Sensitivity analyses with respect to varying performance assumptions (e.g., varied attainable 
reaction and separation efficiencies upon scale up) and economic considerations (available solvent 
recovery, interest rates etc.) can be implemented within the framework and will add robustness to 
the presented results. Consideration of the effects of carrier and separation solvent combinations 
on subsequent upstream (e.g. crystallisation) and downstream (product formulation) unit 





This chapter describes the steady-state process modelling and technoeconomic optimisation (via 
NLP) for design of CPM of nevirapine based on the published continuous flow synthesis, 
developing a conceptual continuous pH crystallisation process for reaction effluent purification, 
based upon the flowsheet presented in Chapter 2 (Fig. 15). 
The results presented in this chapter have also been published in the literature (Diab et al., Org. 
Process Res. Dev. 2019, 23(3), 320–333); details can be found in Appendix B.  
6.1 Arrhenius Parameter Estimation for Reactor Design 
Modelling and design of each reactor in the process flowsheet (Fig. 15) is discussed. Fixed process 
conditions for each reactor are summarised in Table 17. 
Table 17: Summary of continuous flow reactor conditions used in nevirapine CPM. 
Reactor Reaction Temperature, T (°C) τ (units) XA (%) 
R-101 CAPIC + NaH → CAPIC-Na 95 8.56 (s) 100 
R-102 CAPIC-Na + MeCAN → CYCLOR 65 2 (hr) 82.5 
R-103 CYCLOR → API TR103 21 (min) XAR103 = f (TR103) 
Full conversion of CAPIC to CAPIC-Na (XAR101 = 100%) is reported for a R-101 operating 
temperature of 95 °C and an estimated residence time of 8.56 s; this stoichiometric conversion in 
a short residence time is attained by implementing a thin-film reactor to enhance and heat and 
mass transfer to expedite the reaction.170 The operating temperature of R-101 is chosen to be the 
same as in the published experimental demonstration; thus, the same reaction performance  is 
assumed for modelling CAPIC-Na formation in R-101. The operating temperature, residence time 
and attained conversion of CAPIC-Na in R-102 are also assumed as per the published 
experimental demonstration. 
Temperature-dependent kinetic data for API formation in R-103 is available in the literature;170 at 
temperatures of 120, 140 and 165 °C, CYCLOR conversions to API of 10, 60 and 96% are 
attainable, respectively, each for an estimated residence time of 21 min.10 The reactor volume is 
calculated as in Chapter 3.3. The limiting reagent is CYCLOR as NaH in the packed bed is in 
significant excess and so it is assumed that the reaction is first-order in CYCLOR. Following this 
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assumption, the first-order rate constant, k, at different temperatures can be estimated. This allows 
the regression of Arrhenius law (see Chapter 4.1) parameters for API formation in R-103, allowing 
the explicit modelling of CYCLOR conversion to API as a function of temperature, T. The 
Arrhenius plot from the available kinetic data is shown in Fig. 38 with good fit (R2 > 0.96); 
regressed parameters are Ea = 1.565 kJ mol-1 and A = 8.49×1013, assuming the reaction is first-
order in CYCLOR. Availability of a wider kinetic dataset will allow further validation of Arrhenius 
parameter estimation results and investigation of more complex candidate rate law expressions. 
Reactor volumes and process flowrates are calculated as in Chapter 3.3. 
 
Figure 38: Arrhenius plot for ring closure in nevirapine continuous flow synthesis from CYCLOR. 
6.2 Continuous Crystallisation Design 
The batch crystallisation yield has a reported yield of 96% in a residence time of 1 hr operating at 
25 °C and pHCRYST = 7.170 Here, we compare the conceptual steady-state continuous crystallisation  
to the demonstrated batch process by varying the pH of the continuous crystallisation. Table 18 
summarises fixed processing conditions for both batch and continuous crystallisation process 
designs. The pH of the stream fed to the crystallisation process for both batch and continuous 
crystallisation processes is approximately 0.5 following reactor effluent purification with HCl and 





















Table 18: Summary of process conditions for nevirapine batch + continuous crystallisation process models.
 Batch (BX) Continuous (CPM) 
Temperature (°C) 25 25 
Thermodynamic efficiency (%) 100 70 
τ (hr) 1 0.5 
Feed pH ≈ 0.5 ≈ 0.5 
Operating pH, pHCRYST 7 Variable 
Yield, Y (%) 96 Y = f (pHCRYST) 
6.2.1 Nevirapine Aqueous Solubility Estimation 
Crystallisation process design requires modelling of API solubility in process mixtures. The 
mixture prior to pH increase for API crystallisation is predominantly aqueous (solvent content 
>96 mol% H2O), thus the mixture is assumed to be purely aqueous for crystallisation modelling 
purposes. The aqueous solubility, Saq, of nevirapine in the crystallisation stage (see Fig. 38) as a 
function of pH is modelled by226 
Saq = S0(1 + 10pKa–pH) (67)
where S0 = 4.58×10-2 g L-1 (solubility under non-ionising conditions) and pKa = 2.8 at 25 °C; 
correlation parameter values (S0 and pKa) are only available at 25 °C, thus additional temperatures 
for pH crystallisation modelling cannot be considered. The modelled aqueous API solubility as a 
function of pH is shown with experimental values as reported by various literature references in 
Fig. 39, showing good agreement with experimental values.226–228  
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6.2.2 Crystallisation Yield Estimation 
The crystallisation yield (Eq. 67) is estimated from the API concentration in the mother liquor, Ci, 
and the aqueous API solubility.  





Both batch and continuous crystallisation processes’ feed streams enter at pH ≈ 0.5. A residence 
time of 0.5 hr is assumed for the continuous crystallisation. The residence time for the considered 
continuous crystallisation of nevirapine was arbitrarily chosen due to the lack of crystallisation 
kinetic parameters require to enable higher-fidelity population balance modelling. The chosen 
value for the continuous crystallisation residence time is on the lower end of the range of typical 
values;63,222 longer residence times will lead to larger crystalliser vessels which imply greater CapEx. 
This will affect the total cost component results, cost differences vs. the process with a batch 
crystallisation. It is assumed that the batch crystallisation attains full (100%) thermodynamic 
equilibrium. A conservative thermodynamic efficiency of 70% is assumed for the continuous 
crystallisation to account for uncertainty in the non-attainment of equilibrium and assumed 
residence time and the calculated yield. This will likely result in an under-prediction of continuous 
crystallisation yield and thus an over-estimation of total costs, which should be considered when 
interpreting the optimisation results presented here.  
6.3 Effect of Unit Operation on Plant Efficiency 
Total cost components are calculated as per Chapter 3.6. Cost response surfaces under different 
design assumptions were generated (presented in Fig. 40) to investigate the design space and to 
ensure that multiple cost minima are not present. Cost response surfaces for all design cases show 
a sharp peak (i.e. very high total costs) at low R-103 operating temperature TR103 and low 
crystallisation pH (pHCRYST). Under these conditions, very low API recovery is attained and thus 
higher material requirements and unit operation capacities are required to meet the desired plant 
capacity (QAPI), resulting in high CapEx and OpEx. At higher capacity (QAPI), response surfaces 
take a similar shape but present higher total cost values due to the increased material throughput 
and correspondingly larger unit operation scales. Varying Solvent Recovery, SR = {0, 40, 80}% 
(reflecting worst-case, intermediate and lab-reported values170). is also shown to significantly affect 
the cost response surfaces due to its effect on solvent requirements, which is a major contributor 
to the mixture composition and thus on OpEx components, as well as waste. 
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The effect of R-103 operating temperature (TR103) on total costs is significant; total costs decrease 
rapidly as TR103 increases from 120 to 165 °C. Operating temperature in R-103 significantly affects 
the conversion of CYCLOR to API, thus plantwide API yield is very sensitive to TR103; expensive 
reagents, especially starting materials CAPIC (= 5 GBP kg-1) and MeCAN (= 10 GBP kg-1), make 
materials costs a major contributor to total costs and so a high API yield in R-103 (i.e., high TR103) 
is preferred. The effect of each decision variable (TR103 and pHCRYST) on plantwide API yield is 
shown in Fig. 41 to illustrate this point. The optimisation problem formulation in this work could 
alternatively be defined to maximise Net Present Value (NPV), which may yield different results. 
Comparison of results for a different objective function formulation could be useful, given the 
availability of reliable projected API and brand sales prices. 
 
Figure 40: Total cost response surfaces for nevirapine CPM under different design assumption of 
plant capacity (QAPI) and solvent recovery (SR). 
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The effect of operating crystallisation pH (pHCRYST) on total costs is also similar across different 
design assumptions. At the lower bound of R-103 operating temperature (TR103 = 120 °C), low pH 
(e.g., at the lower bound of pHCRYST = 1) results in high total costs. At low TR103, the low conversion 
of CYCLOR to API in R-103 means plantwide yield is already poor prior to crystallisation; low 
pHCRYST implies lower crystallisation yield and thus higher total costs are incurred due to increased 
material requirements and unit operation scales needed to meet the desired plant capacity (QAPI). 
The implemented model of aqueous API solubility vs. pH shows a plateau in solubility beyond 
some pH value below 7. Increasing the crystallisation pH too high will result in incremental 
increases in API yield only which will unnecessarily increase material usage and crystallisation 
volumes, and thus total costs (as observed in the cost response surfaces in Fig. 40). At the upper 
bound of R-103 operating temperature (TR103 = 165 °C), the effect of crystallisation pH is not so 
significant. The yield of API is already high when TR103 is higher (due to increased conversion of 
CYCLOR to API in R-103) and thus the effect of higher pH in the crystallisation is not as 
important. This is further illustrated by the plantwide API yield response surface in Fig. 41. 
 
Figure 41: Response surface of plantwide nevirapine yield vs. R-103 operating temperature (TR103) 
and crystallisation pH (pHCRYST). 
6.4 Optimisation for Plant Total Cost Minimisation 
The objective of the NLP problem is to minimise plantwide total costs, calculated as per Chapter 
3.6. The continuous decision variables are the operating temperature of R-103, TR103, and 
crystallisation pH, pHCRYST, both of which influence the final API yield by influencing R-103 
conversion to API and crystallisation yield, respectively. While increasing TR103 enhances the 
conversion of CYCLOR to API, there are associated utilities costs with heating R-103, which 

















































increases, but also incurs higher material costs as well as larger crystallisation capacities, which 
contribute to total costs.  
min Total Cost (68) 
s.t.  
120 °C ≤ TR103 ≤ 165 °C (69) 
1 ≤ pHCRYST ≤ 7 (70) 
Constraints on R-103 operating temperature are chosen to be the lower and upper bounds of 
available temperature data for Arrhenius parameter estimation (120 and 165 °C, respectively) to 
ensure validity of the regressed parameters for subsequent modelling and optimisation (Eq. 69). 
Constraints on crystallisation pH (Eq. 70) were chosen to be from pHCRYST = 1 (close to feed 
mixture point, pH ≈ 0.5) and pH = 7 (the BX crystallisation pH). 
The optimisation problem is solved in MATLAB using the interior-point algorithm with tolerances 
of 10-6. Plant capacities of QAPI = {102, 103} kg API yr-1 are investigated to represent small-/pilot-
scale designs. As in Chapter 5, the plant capacity is met by specifying it as a NLP constraint. The 
effect of solvent recovery, SR, is also considered, as this has a significant effect on material 
consumption, and thus OpEx. A reported SR = 80% is reported in the literature;170 the attainable 
SR may be lower and so SR = {0, 40}% are also considered.  
The NLP problem was solved for all individual combinations of plant capacity, QAPI = {102, 103} 
kg API yr-1 and assumed Solvent Recovery, SR = {0, 40, 80}%, i.e., six problem instances. Multiple 
initial values for decision variables are tested to ensure a unique optimal solution for each problem 
instance. Initial values of decision variable for each problem instance are R-103 temperature, TR103,0 
= {130, 145, 160} °C and crystallisation pH, pHCRYST,0 = {2, 4, 6}, i.e., a total of nine initial points 
per problem instance. Unique solutions were attained for all problem instances for different 
decision variable initial values. Solution times were short for all problem instances (Table 19). 
Table 19: Nevirapine CPM NLP solution time for different problem instances. 










The optimal values of the decision variables (TR103 and pHCRYST) corresponding to minimum total 
costs under different design assumptions are shown in Fig. 42. These optima are compared to the 
process implementing a batch crystallisation, where TR103 = 165 °C and pHCRYST = 7. In all of the 
batch and continuous crystallization design cases, the optimum TR103 is the upper bound (165 °C). 
The optimum crystallization pH varies across different SR assumptions. At lower SR (= 0%), an 
optimum pH of ∼4 is observed for both considered capacities; OpEx components are significant 
contributors to cost, and thus, higher crystallisation yields are preferred to minimise the objective 
function. For higher SR (= 40, 80%), pHCRYST is driven to the lower bound (= 1); the effect of 
enhancing the crystallisation yield by increasing pHCRYST is not as important when a significant 
percentage of the solvent is recovered and TR103 is high. At higher capacity (QAPI = 103 kg API yr–
1), higher SR is required to allow a lower pH for minimum total cost. In industrial practice, for 
safety purposes it may be necessary to neutralise the mixture following crystallization and API 
crystal removal, but this was not considered as part of the presented analysis. 
 
Figure 42: Optimal reactor operating temperature (TR103) and crystallisation pH (pHCRYST) 
corresponding to the total cost minima under different design assumptions for nevirapine CPM. 
Material efficiencies of different design assumptions quantified by the E-factor (see Chapter 3.5.4) 
are shown in Fig. 43. For all batch designs, E-factor values are very high, even for pharmaceutical 
processing which is renowned for having highly materially intensive manufacturing routes;12 this 
is due to all batch crystallisation processes being operating at pHCRYST = 7, requiring significant 
quantities of base to neutralise the feed mixture. In all cases, increasing solvent recovery 
significantly reduces E-factor due to the large contribution of solvent to process mixture and waste 
compositions. All CPM designs achieve values lower than this, but only higher solvent recoveries 
allow this for the process with a batch crystallisation; even so, the attained E-factors are mid-range 
with respect to typical pharmaceutical manufacturing processes (see Chapter 3.5.3). Elucidation of 
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attainable solvent recoveries at different production scales will further clarify the likely material 
efficiencies of different design assumptions to elucidate materially efficient CPM plant designs. 
 
Figure 43: Environmental (E)-factors at cost optima for different nevirapine CPM design 
assumptions. 
It should be noted that the wide range of conditions considered here (reactor temperature and 
crystallisation pH) will possibly lead to different polymorphs forming in the purification + 
crystallisation processes. Although the literature study upon which the considered process is based 
did not contain sufficient data to perform population balance modelling, nor did it investigate the 
attained polymorphs of the obtained nevirapine crystals,170 the possibility of polymorphism under 
different process conditions should be considered in future work. 
6.5 Economic Analysis 
6.5.1 Plant Total Costs 
Minimum total cost components for CPM compared the process with the BX crystallisation are 
compared in Fig. 44. Total costs at QAPI = 103 kg API yr-1 are higher, reflecting the increased 
material requirements and unit operation scales. OpEx components are more significant than 
CapEx in all design cases due to the expensive reagents required for the API synthesis. As solvent 
recovery increases, OpEx components decrease significantly and substantially lower total costs. 
Utilities and waste components are the most significantly affected by varying solvent recovery due 
to the large quantity of solvent in the process mixture; materials costs are less affected by varying 
solvent recovery as the reagents used are much more expensive than solvent components in the 
considered process. In all cases, CPM designs have significantly lower OpEx components than for 
BX designs due to the reduced material requirements of the crystallisation process when operating 
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For varying solvent recovery assumptions, CapEx components remain roughly the same, as 
internal process stream flowrates through each unit operation remain fairly consistent. In all cases, 
CPM designs have lower CapEx components than their BX counterparts due to the lower material 
throughputs of these processes. The availability of detailed crystallisation kinetic models with 
experimental data and model parameters can help to elucidate crystallisation process performance 
and unit operation design, which will likely have a significant effect on CapEx. The equipment cost 
correlation used is the most widely implemented and reliable available in the peer-reviewed 
literature; design capacities required for the considered plant capacities (QAPI) are at the lower end 
of the cost correlation application range, and thus purchase cost overestimation may be present. 
Additional uncertainty in calculated unit purchase costs is present due to the lack of cost estimation 
methods for specific equipment, e.g., thin film reactors; however, the cost correlation used here is 
the best available. Some specialised unit operations have specific cost correlations established, 
which may be more accurate than the general correlation used in this work. Cost correlations 
specific to particular unit operations should be used where possible to allow accurate prediction 
of CapEx component contributions to total costs. Furthermore, the considered processes (both 
BX and CPM) are considered to take advantage of being constructed at an existing pharmaceutical 
manufacturing site; additional costs may also be incurred if green-field construction is required. 
 
Figure 44: Total cost components for different nevirapine CPM design assumptions. 
6.5.2 Nevirapine Cost of Goods: Batch vs. Continuous Manufacturing 
In all cases, CPM designs are more economically viable than those implementing a BX 
crystallisation. The most significant savings are realised in OpEx components (materials, utilities 
and waste components, as described in the costing methodology), which allow significant total 
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medicines is essential; HIV drug unit prices have varied widely in previous years, so quantifying 
attainable price per unit mass is an important consideration for HIV drug manufacturing.229 The 
API Cost of Goods (CoG) is calculated to quantitatively compare differences in affordability of 
nevirapine under different design assumptions. The CoG is calculated as the mass of API produced 
during the plant lifetime (= 20 yr) divided by the total cost of constructing and operating the plant.  






The resulting API CoG values under different design assumptions are presented in Fig. 45. For all 
cases, CPM designs allow lower API CoG than their batch (BX) alternatives due to the significant 
total cost savings allowed by continuous operation. Solvent recovery has a significant effect on the 
resulting CoG due to the large contribution of solvent to OpEx components, which dominate total 
costs of all design cases. While this analysis does not clarify exactly what price the API will be sold 
at, the estimated CoG values indicate that CPM implementation can allow for lower API sales 
prices to expand global access to this HIV drug. 
 
Figure 45: Estimated nevirapine cost of goods from total costs of different plant design. 
6.5.3 Sensitivity Analysis: Effects of Starting Material Prices 
The starting materials (CAPIC and MeCAN) for the continuous synthesis of nevirapine considered 
in this work are advanced compounds synthesised from multistep batch processes (see Fig. 13).170 
Consideration of key material price fluctuations is an important form of sensitivity analysis that 
should be implemented in modelling and economic evaluation during candidate process screening 
and development stages. Here, we consider the effect of increasing CAPIC and MeCAN material 
prices by 50% from the base case values on plant total costs, i.e. CAPIC price = [5,10] GBP kg-1, 
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°C and pHCRYST = {2, 4, 6} for QAPI = 102 kg API yr-1 and SR = 40%; observed trends are expected 
to be the same for alternative values of QAPI and SR. The effects of varying material prices for 
these discrete decision variable values are shown in Fig. 46. Although starting material prices do 
affect total plant costs in all design cases, the effect of TR103 is still the most sensitive parameter 
affecting total costs. Further process intensification for the batchwise syntheses of CAPIC and 
MeCAN will ensure reasonable starting material prices to ensure the economic viability of the 
process designs investigated here. 
 
Figure 46: Effect of starting material prices and TR103 and pHCRYST on nevirapine CPM plant total 
costs (QAPI = 102 kg API yr-1, SR = 40%). 
6.6 Chapter Conclusions 
This work has formulated and solved a NLP problem for the total cost minimisation of the 
plantwide upstream CPM of nevirapine, a societally important API for HIV-1 treatment. 
Optimisation of a conceptual continuous crystallisation for the purification of the API synthesis 
effluent following the continuous flow synthesis under various design assumptions (plant capacity 
and solvent recovery) are used to quantitatively evaluate different designs for nevirapine CPM. 
The operating temperature of the final reactor R-103 (TR103) is driven to the upper bound in all 
design cases to maximise API synthesis yield while crystallisation pH (pHCRYST) is always lower than 
that of the batch crystallisation (pH = 7) for CPM designs to minimise major OpEx contributions 
to plant total costs. In all design cases, CPM designs achieve lower total cost components, 
improved material efficiencies and lower API CoG values, demonstrating the promise of CPM 
over batch for nevirapine production and improving global, affordable access to HIV APIs. This 
work also demonstrates the value of conducting technoeconomic optimisation studies towards the 
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Chapter 7 
Cyclosporine, Paracetamol and Aliskiren 
This chapter considers MSMPR cascades without recycle for continuous cooling crystallisation of 
cyclosporine, paracetamol and aliskiren, based upon the flowsheet in Chapter 2 (Fig. 20). 
The results presented in this chapter have also been published in the literature (Diab and 
Gerogiorgis, Ind. Eng. Chem. Res. 2018, 57(29), 9489–9499); details can be found in Appendix B. 
7.1 MSMPR Crystalliser Design 
The considered cooling crystallisation MSMPR cascades have no antisolvent usage, recycle 
implementation or up-/downstream requirements as part of the study. We assume that fresh 
mother liquor feed streams contain negligible amounts of impurity that will affect the attained 
crystal product in these processes. Knowledge of typical crystallisation feed stream compositions 
in integrated CPM processes will greatly enhance the understanding of impurity distributions on 
optimal continuous crystallisation process designs for the APIs studied here. 
The cascade consists of N = 1–3 crystallisers. We consider plant API capacities (QAPI = {102, 103, 
104} kg API yr-1) to investigate the effects of production scale, which can significantly affect the 
economic viability of CPM designs.69 Varying design capacities considered here do not signify a 
range of capacities implemented for a single plant; they are considered for separate plant designs 
to comparatively illustrate the effect of capacity on relevant cost components and their relative 
contribution to total plant costs. As in Chapters 4 and 5, the plant capacity is met by specifying it 
as a NLP constraint. The considered plant capacities are low in comparison to typical market sizes 
of such societally important APIs. Continuous technologies are not yet widely implemented in 
pharmaceutical manufacturing, and so it is likely that a CPM process would first be implemented 
on smaller scales, as have been most demonstrations in the literature. Three different capacities 
have been compared for each API to illustrate the effect of capacity on relative cost component 
contributions to total costs and on cost optimal design and operating parameters. One to three 
implementable MSMPRs is a reasonable number of vessels and is consistent with other literature 
studies. Crystalliser operating temperatures are between –10 and 20 °C, and the maximum total 
cascade residence is 15 hr. Concentrations of dissolved API in mother liquor feed streams (C0) 
vary according to experimental procedures;63,91,92 cyclosporine, paracetamol and aliskiren feed 
concentrations of 25, 8.86 and 6% w/w, respectively, are assumed. 
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7.1.1 Solubility Estimation 
Solubilities of APIs (i.e., API saturation concentrations, Cisat) as a function of temperature are 
required for description of crystallisation kinetics. Saturation concentrations as a function of 
temperature are described as temperature-dependent polynomials regressed from experimental 
solubility data for cyclosporine,103,230 paracetamol,91 and aliskiren.92 
Cisat = (1.17×10-4)Ti2 + (2.00×10-4)Ti + 0.05                                         for cyclosporine (72) 
Cisat = (3.79×10-2)Ti2 + (3.77×10-1)Ti + 0.21                                         for paracetamol (73) 
Cisat = (7.60×10-7)Ti3 – (3.20×10-5)Ti2 + (5.20×10-4)Ti + (4.50×10-3)      for aliskiren (74) 
7.1.2 Nucleation and Growth Kinetics 
Crystal growth and nucleation kinetics are described by Arrhenius-type power law expressions.231 
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Here, Gi and Bi are the crystal growth and nucleation rates in MSMPR i operating at temperature 
Ti, respectively. Ci and Cisat are the MSMPR outlet and saturation (solubility) concentrations at Ti, 
respectively. Mi is the slurry density in MSMPR i. Growth kinetic parameters are kg0, the growth 
pre-exponential factor, Eag, the growth energy barrier, and gMSMPR, the growth exponent. Nucleation 
parameters are kb0, the nucleation pre-exponential factor, Eab, the nucleation energy barrier, bMSMPR, 
the nucleation exponent, and mMSMPR, the slurry density exponent. The crystallisation studies from 
which parameters were taken did not distinguish between primary and secondary nucleation effects 
and thus it is assumed that both are lumped into Eq. 76; for this reason, consideration of specific 
agglomeration and breakage effects could not be considered here. Temperature-dependency of 
crystal nucleation for paracetamol and aliskiren has not been considered in the literature.91,92 
Similarly, m for aliskiren is considered equal to zero.92 No effects of polymorphism were observed 
in the experimental studies from which crystallisation kinetic parameters were taken and so it is 
also assumed that no polymorphs are observed in this work. Crystallisation kinetic parameters 
from the literature for all APIs are summarised in Table 20. 
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7.1.3 Population Balance Equations 
The general one-dimensional (i.e., linear growth is assumed) steady-state population balance model 
is described by a system of Ordinary Differential Equations (ODEs). For a MSMPR cascade with 
slurry recycle, the population balance equations are described by Eqs. 78–80. Here, ni is the 
population density function of crystals between size L and L+dL. In Eq. 79, the first term 
represents the stream entering from the previous stage (i–1), the second term represents the recycle 
stream entering stage i and the last term represents the product stream leaving stage i. Eqs. 78–80 
form a system of ODEs that are satisfied by the boundary conditions, ni0 (Eq. 80), representing 




 = R1nN+1 − F1n1 









= ni (L = 0) ∀i = 1,…,N  (80) 
The suspension density, Mi, is also calculated from the population balance via Eq. 81. Here, kv and 
ρAPI are the volume shape factor and crystal density of API solute. 
Mi = kv ρAPI   niL
3dL (81) 
Table 20: Steady-state process model parameters for continuous MSMPR crystallisation of cyclosporine, 
paracetamol and aliskiren. 
API Cyclosporine63 Paracetamol91 Aliskiren92 
 Value Units Value Units Value Units 
kg0 1.13×107 m min-1 2.00×10-2 m min-1 2.9×10-4 m min-1 
Eag/R 9.06×103 K 1.73×103 K 3.5×102 K 
gMSMPR 1.33 (–) 1.08 (–) 1.08 (–) 
kb0 4.80×1020 # crystals m-3 min-1 295 # crystals kg-1 s-1 3.2×107 # crystals m-3 min-1 
Eab/R 7.03×103 K (–) K (–) K 
bMSMPR 1.50 (–) 2.14 (–) 1.95 (–) 
mMSMPR 2/3 (–) 1.62 (–) 0 (–) 
kv π/6 (–) 0.61 (–) 0.04 (–) 
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7.1.4 Mass Balances 
The steady-state mass balances for each process assume no material accumulation and account for 
volumetric changes due to API crystallisation. The general mass balance equations are as follows. 









− F1M1 = 0 














  Ci − FiMi = 0       ∀i = 2,…,N (83)
Eq. 82 describes stage 1 in the MSMPR cascade. The first term in Eq. 82 is the dissolved API in 
the feed mother liquor stream to the cascade, the second and third terms are the API dissolved in 
the mother liquor and crystallised API in the recycle stream fed to stage 1, respectively, and the 
third and fourth terms are the API dissolved in the mother liquor and crystallised API leaving 
stage 1, respectively. For processes with no recycle (as is the case here), Ri = 0. Eq. 83 describes 
MSMPR stages i = 2,...,N, whose terms are similar to Eq. 82 but without the fresh feed mother 
liquor term (F0C0). In both Eqs. 82 and 83, the bracketed terms describe the volume fraction of 
the suspension not occupied by crystallised API. 
7.1.5 MSMPR Model Solution 
Simultaneous solution of the MSMPR model requires iteration on the vector of Ci values, where 
C0 > Ci > Cisat holds for all crystallisers. Fig. 47 illustrates the workflow for the solution of the 
MSMPR model.93,230 First, an initial guess is made for Ci values. The suspension densities are then 
estimated by solution of the mass balance equations, Mimb. Crystallisation kinetics are then 
computed, allowing solution of the system of ODEs describing population balances. Suspension 
densities calculated from the population balance equations, Mipbe, are then calculated. If the 
difference between Mimb and Mipbe is greater than the set tolerance (= 10-6), another guess of Ci 





7.2 Technoeconomic Optimisation of MSMPR Cascades 
7.2.1 Optimisation Problem Definition 
The objective function (Eq. 84) of the nonlinear optimisation problem is the total cost, calculated 
as in Chapter 3.6. The decision variables are the residence time and temperature of each crystalliser 
in the cascade, both of which affect the final attainable crystallisation yield, process mass balances 
and total costs of the cascade design. Crystallisation temperatures are constrained between –10 
and 20 °C and the temperature of each crystalliser must be lower than or equal to the previous. 
Crystallisers of equal residence times are assumed for the problem formulation. Implementing 
crystallisers of equal volumes makes their purchase and acquirement from equipment 
suppliers/manufacturers simpler and less expensive. Additionally, the total cascade residence time 
is allowed a maximum of 15 hr in accordance with previous work.230 
min Total Cost (84) 
–10 °C ≤ TN ≤ … ≤ T1 ≤ 20 °C (85) 
τ1 = … = τN  (86) 





The NLP formulation here is described to minimise total costs; if the formulations were to 
maximise profits or Net Present Value (NPV), it is possible that different residence times would 
be preferred. Formulating the objective function as NPV (for maximisation) requires the 
estimation of product sales revenues. While API class sales trends have been historically increasing 
(Fig. 19), future market sales variations of individual APIs and brands are unknown and cannot be 
accurately accounted for. For this reason, the objective is instead to minimise the plant total costs. 
Incorporation of crystal quality constraints (size properties, purity, desired polymorph) in the NLP 
objective function definition is not considered here, but is important for downstream production 
and Drug Product efficacy. Varying the objective function definition of an optimisation problem 
can give differing optimal design and operating parameters; comparison of optimisation results for 
a different objective function formulation here could be useful, given the availability of reliable 
projected API and brand sales prices. 
The optimisation problem is solved in MATLAB using the interior-point algorithm with tolerances 
of 10-6. The problem was solved separately for all combinations of API = {cyclosporine, 
100 
paracetamol, aliskiren}, number of implemented crystallisers, N = {1, 2, 3}, and plant capacity, 
QAPI = {102, 103, 104} kg API yr-1, i.e., 9 problem instances in total. 
 
Figure 47: Solution algorithm for the MSMPR crystallisation model. 
Multiple initial values for decision variables have been used to ensure a unique optimal solution 
for each problem instance. Different combinations of initial temperature of each crystalliser were 
selected based upon values evenly distributed between lower and upper permissible temperature 
bounds (Eq. 85). Different combinations of initial residence times were chosen such that their sum 
was less than the maximum allowable value (Eq. 87). The temperature and residence time of each 
crystalliser in series are the decision variables of the nonlinear optimisation problem; thus, the 
number of decision variables for configurations consisting of N crystallisers = 2N. Table 21 shows 
the combinations of starting points used for varying numbers of crystallisers for each API and 
considered plant capacity. Each problem instance resulted in a unique solution, independent of 
the starting point. 
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Table 21: Decision variable initial values for and plant capacities for different numbers of crystallisers. 
N Decision Variable Initial Value No. points, 
 T0 × τ0 
1 
T0 = T1,0 (°C) { -5 , 0 , 5 } 
9 
τ0 = τ1,0 (hr) { 3 , 8 , 13 } 
2 
T0 = [T1, T2]0 (°C) { [-5,-5] , [0,-5] , [10,5] , [15,15] } 
20 
τ0 = [τ1, τ2]0 (hr) { [3,3] , [3,6] , [3,9] , [6,3] , [9,3] } 
3 
T0 = [T1, T2, T3]0 (°C) { [-5,-5,-5] , [0,-5,-5] , [5,0,0] , [10,5,5] , [15,10,10] , [15,15,15] 
24 
τ0 = [τ1, τ2, τ3]0 (hr) { [3,3,3] , [3,3,6] , [3,6,3] , [6,3,3] } 
7.2.2 Total Cost Components 
Total cost minimisation via NLP optimisation was implemented for each API (cyclosporine, 
paracetamol and aliskiren), for a varying number of crystallisers and plant capacity. Fig. 48 shows 
total cost components, which illustrates the decreasing contribution of CapEx components to total 
costs. Total CapEx increases with plant API capacity due to the need for larger crystalliser volumes 
to contain higher throughputs of crystallisation magma. Total CapEx values are dominated by 
BLIC contributions due to the high cost of crystallisation equipment, and WCC contributions 
increase with plant capacity as it is a linear function of material requirements. Both BLIC and WCC 
contributions increase with the number of implemented crystallisers, despite decreasing total 
crystallisation volumes and material requirements. This is due to the cost of additional pumps and 
cooling equipment accompanying the crystalliser cascade for continuous operation. 
Fig. 49 illustrates optimal process configurations (i.e., crystalliser operating temperatures and 
residence times corresponding to total cost minima) for each API with different numbers of 
crystallisers and API capacities considered. Crystalliser volumes increase with plant capacity to 
accommodate increased material throughputs. Increasing the number of implemented crystallisers 
decreases the total crystallisation volume required. MSMPR operation assumes perfectly mixed, 
homogeneous crystalliser magmas discharging at equilibrium, and thus the crystalliser operates at 
the exit concentration; implementing multiple crystallisers increases product concentrations and 
thus increases yields, which thus requires smaller crystallisers for a given capacity. Total residence 
times for aliskiren are long due to the slow crystallisation kinetics of the API (and hence its good 




Figure 48: Minimum total cost components for cyclosporine, paracetamol and aliskiren at 
different plant capacities. 
Crystalliser design capacities (i.e., volumes) required for the considered plant capacities are at the 
lower end of the cost correlation application range, and thus purchase cost overestimation may be 
present. Additional uncertainty in calculated crystalliser purchase costs is present due to the lack 
of cost estimation methods for smaller crystalliser volumes associated with lower plant capacities, 
e.g., cyclosporine at QAPI = 102 kg API yr-1; however, the cost correlation used here is the best 
available in the literature. 
Total OpEx increases with plant API capacity due to the higher required material throughputs and 
associated utilities and waste handling costs. Fig. 50 shows the fractional relative minimum total 
cost component contributions for each API at varying plant capacities for one crystalliser. At lower 
API capacities, CapEx contributions are more significant; as plant capacity increases, OpEx 
component contributions become more significant, which is further illustrated by their continuing 
dominance over normalised CapEx components as plant API capacities increase. Utilities costs 
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dominate OpEx contributions, however materials and waste handling costs become more 
significant with increasing plant capacity. 
 
Figure 49: Crystalliser operating temperatures and residence times corresponding to total cost 
minima for cyclosporine, paracetamol and aliskiren; bubble diameters are proportional to 
crystalliser volumes. For N > 1, different bubbles correspond to different crystallisers at different 
operating temperatures (T1 ≥ … ≥ TN). 
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Cyclosporine operating temperatures are above zero and decrease along the crystalliser cascade 
(Fig. 49), as described in the NLP constraints. Crystallisers for paracetamol and aliskiren also 
decrease in temperature along cascades, however, operate at lower temperatures. In both cases, as 
the number of implemented crystallisers is increased, operating temperatures increase and 
residence times decrease; additional costs associated with increased cooling duties and larger 
crystallisers are not considered beneficial with respect to total costs. Rigorous temperature control 
via high-fidelity instrumentation can ensure designs remain at their optimal design parameters. The 
implementation of Process Analytical Technology (PAT) is essential for the success of CPM 
technologies, with recent studies illustrating its importance in crystallisation applications.232 
Optimal crystalliser operating temperatures correspond to those required to attain minimum total 
costs of a design option; deviations from optimum design and operating parameters will lead to 
sub-optimal designs (i.e., higher total costs). 
 
Figure 50: Component contributions towards total costs when implementing one crystalliser for 
cyclosporine, paracetamol and aliskiren. 
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Minimum total costs for cyclosporine crystallisation are attained when implementing one 
crystalliser only for API capacities of 102 and 103 kg API yr-1 (see Fig. 48). Yield improvements 
associated with multiple crystalliser usage are only incremental; thus, the associated additional 
BLIC costs are not beneficial. However, when the plant capacity is increased to 104 kg API yr-1, 
cyclosporine crystallisation has lower total costs when two crystallisers are implemented. At higher 
capacities, OpEx components dominate total costs, and so even incremental increases in 
crystallisation yield and distributed cooling loads across crystallisers can bring cost savings benefits. 
For plant capacities of 102 and 103 kg API yr-1, paracetamol crystallisation is cost optimal when 
implementing one crystalliser due to incremental yield improvements attainable with multiple 
crystalliser implementation at these capacities. Implementing two crystallisers is optimal at a plant 
capacity of 104 kg API yr-1; this is due to the greater contribution of OpEx towards total costs at 
increased capacities as well as the reduced total crystalliser volume required. 
Continuous crystallisation of aliskiren at a plant capacity of 102 kg API yr-1 is cost optimal when 
implementing one crystalliser only; implementing two crystallisers at a capacity of 103 kg API yr-1 
and three crystallisers at 104 kg API yr-1 is more cost effective. The mother liquor solvent 
considered here (ethyl acetate:ethanol mixture) is more expensive than solvents for cyclosporine 
and paracetamol, thus material costs contribute more towards the dominant OpEx components. 
For the considered APIs and number of implementable crystallisers (N = {1, 2, 3}), multiple 
crystalliser usage is favoured as capacity increases. It is likely that there is some maximum number 
of crystallisers that allow minimum total costs for capacities beyond a certain value, however this 
cannot be stated with certainty from the results presented here; this can be clarified in future work. 
Total cost minimisation at higher capacities can be investigated in the described modelling 
framework and methodology. 
The relative effect of varying crystallisation kinetics between the considered APIs varies with the 
plant capacity. For QAPI = 102 kg API yr-1, cyclosporine CapEx components are significantly more 
dominant than at higher capacities for this API; material costs (OpEx) are less significant at lower 
capacities and thus the effect of cyclosporine’s slow crystallisation kinetics on CapEx (requiring 
longer residence times and crystalliser volumes) become more significant. CapEx component 
contributions for aliskiren are greater than those for paracetamol due to its slower crystallisation 
kinetics. For both aliskiren and paracetamol, OpEx components are more significant even at QAPI 
= 102 kg API yr-1 as these APIs both require more expensive solvent components than 
cyclosporine. The current modelling methodology and framework allows different APIs, capacities 
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and numbers of implemented MSMPR crystallisers to be considered easily, given the availability 
of crystallisation kinetic parameters and API temperature-dependent solubility data. 
7.3 Chapter Conclusions 
This work has conducted total cost minimisation of continuous MSMPR crystalliser cascades for 
three societally and economically important APIs widely produced by the pharmaceutical industry: 
cyclosporine, paracetamol and aliskiren. Nonlinear optimisation results show that the optimal 
number of crystallisers attaining minimal total costs is dependent on plant capacity. For the 
considered APIs, implementing one crystalliser is preferred at lower capacities, whilst multiple 
crystalliser usage is preferred at higher plant capacities. This result is observed due to the increasing 
dominance of operating expenditure contributions towards total costs at increased capacities, 
making the benefits of implementing more crystallisers (enhanced yields, reduced utility loads) 
worth the increased capital expenditure of purchasing multiple crystallisation units. This work has 
illustrated the value of conducting technoeconomic optimisation studies such as this towards the 


















PART IV PROCESS SYNTHESIS VIA MIXED 






















This chapter describes the steady-state modelling and MINLP optimisation for process synthesis 
for CPM of atropine based on the published continuous flow synthesis, developing a conceptual 
continuous LLE process for reaction effluent purification, based upon the flowsheet in Chapter 2 
(Fig. 18). All relevant material properties are listed in Table 22. 
The results presented in this chapter have also been published in the literature (Diab et al., Comput. 
Chem. Eng. 2019, 124, 28–42; Diab et al., Comput. Aided Chem. Eng. 2019, 46, 211–216; Diab and 
Gerogiorgis, AIChE J. 2019, 65(11), e16738); details can be found in Appendix B. 
Table 22: Atropine CPM component physical properties.191,192 











Tropine 120-29-6 C8H15NO 141.21 64.0 233.0 1.02 – 
DMF 68-12-2 C3H7NO 73.09 –60.5 153.0 0.95 0.92 
Phenylacetyl chloride 103-80-0 C8H7ClO 154.59 – 94.5 1.17 – 
Sodium hydroxide 1310-73-2 NaOH 40.00 318.0 1,388.0 2.13 – 
Water 7732-18-5 H2O 18.02 100.0 0.0 1.00 1.00 
Formaldehyde 50-00-0 CH2O 30.03 –92.0 –19.0 0.82 – 
API 51-55-8 C17H23NO 289.37 118.5 – 1.21 – 
Apoatropine 207-906-7 C17H21NO 271.36 62.0 – – – 
Hydrogen chloride 7647-01-0 HCl 36.46 –114.2 –85.1 1.49 – 
LLE  
Ammonium chloride 12125-02- NH4Cl 53.94 338.0 520 1.52 – 
Dichloromethane, DCM 75-09-2 CH2Cl2 84.93 –96.7 39.6 1.33 0.43 
Diethyl ether, Et2O 60-29-7 C4H10O 74.12 –116.3 34.6 0.71 0.22 
Butyl acetate, BuOAc 123-86-4 C6H12O 116.16 –78.0 126.1 0.88 0.69 
Toluene 108-88-3 C7H8 92.14 –95.0 111.0 0.87 0.59 
8.1 Reaction Kinetic Parameter Estimation 
Kinetic parameter estimation from available experimental reaction performance data should be 
implemented where possible to gain an understanding of kinetic behaviour and for PFR sizing. 
For the esterification reaction, the published continuous flow synthesis reports 99% conversion 
to tropine ester at 100 °C in a residence time of 3.5 min.177 As time-dependent kinetic data is not 
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available for this reaction, this work assumes the same reported performance; given the availability 
of a wider dataset for this reaction, kinetic parameter estimation can be performed, which will 
deepen insight into its kinetic behaviour. 
For the aldol addition, conversions of 5 of 67% and 78% are attained after 8 min and 24 min, 
respectively, at 100 °C, using 6.0. equiv. formaldehyde with 1.2 equiv. NaOH (aq.) added to the 
effluent of PFR-1 prior to entering PFR-2.177 This data is used to compare candidate rate law 
expressions for PFR-2; by plotting different functions of reagent (tropine ester and formaldehyde) 
concentrations vs. time, coefficients of determination (R2) are estimated to determine the goodness 
of fit of candidate rate law expressions. Zero-order, first-order in limiting reagent tropine ester and 
overall second-order (first-order in both tropine ester and formaldehyde) rate law expressions are 
considered. The integral forms of the zero-, first- and second-order rate laws are written as Eqs. 
88–90, respectively; these give linear functions of reagent concentration vs. time from which 
reaction rate constants can be estimated.  









   = k2 CCH2O,0–C5,0 τPFR 
(90)
Functions of reagent concentrations vs. time representing candidate rate law expressions 
considered here are plotted in Fig. 51. An overall second-order (first in 5, first in formaldehyde) 
rate law is the most plausible case (R2 = 0.890), followed by a first-order rate law (R2 = 0.670), 
followed by a zero-order rate law (R2 = 0.512) of the candidate rate law expressions considered 
here. The second-order rate law constant for the aldol addition reaction is estimated as k2 = 1.68 
L mol-1 hr-1. Greater availability of kinetic data for the reaction set will allow further validation of 
kinetic parameter estimation results, allow investigation of more complex candidate rate law 
expressions and allow explicit consideration of the elimination of API to apoatropine. The dataset 
size per regression should be as large as reasonably possible, i.e., enough to establish whether a 
linear relationship is present whilst considering the effects of noise. However, the required 
experimental effort in terms of time and labour to generate sufficiently large datasets for multiple 
reactions is an important consideration in kinetic data acquisition, warranting the consideration of 
simulation and model optimisation to aid such efforts.54,233 From the limited published data, 
approximately 39.2% of API formed converts to apoatropine;177 this is considered in mass balance 
and equipment sizing calculations. 
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Figure 51: Comparison of goodness of fit of candidate rate law expressions for the aldol addition 
from experimental kinetic data for atropine CPM. 
8.2 Dimensionless Number Analysis for Reactor Diameter Selection 
Selecting an appropriate PFR inner diameter (dPFR) is an important consideration in reactor design 
for continuous flow synthesis to ensure the benefits of enhanced heat and mass transfer 
demonstrated on lab-scale are realised at larger production scales, as well as considerations of 
process safety and operability of inherently hazardous reactions. Here, we calculate the required 
PFR diameters and the corresponding reactor lengths for different designs to ensure the 
assumption of homogeneity is valid and to maximise the benefits of synthesising atropine in 
continuous flow. Turbulent flow conditions (i.e., homogeneous velocity profile) are ensured by 
designing PFRs such that their diameter allows for a Reynolds number (Re, Eq. 91) > 4,000. The 
Péclet number (Pe, Eq. 82) describes the ratio of convective to conductive heat transfer; it is desired 












Here, uPFR is the average fluid mixture velocity in the PFR (calculated from the volumetric flowrate, 
QPFR, and the cylindrical cross section), LPFR is the PFR length and Cp,m and λm are the mixture 
specific heat capacity at constant pressure and thermal conductivity, respectively. Mixture 
viscosities (m) and densities (m) are calculated from solvent components (DMF + H2O) at the 
reactor temperatures (both T = 100 °C) as solvent content is ≥ 90 mol% in both PFRs. 
The Damköhler number, Da, describes the ratio of reaction to mixing time-scales: it is desired that 


















































































































































concentration gradients at any axial position in the PFR. Here, Di is the reagent diffusivity (Eq. 
93), kb is the Boltzmann constant, µm is the mixture viscosity and ri is the component molecular 
radius. First-order kinetics are assumed for reaction 1 in PFR-1 and overall second-order (first-
order in both limiting reagent A and excess reagent B with stoichiometric feed quantities) are 
considered for reaction 2a in PFR-2. The expression for Da depends on the rate law expression of 
the reaction.71,234,235 First-order kinetics in limiting reagent A describe Da via Eq. 94; overall second-
order (first-order in both limiting and excess reagent A and B, respectively) kinetics for 




  (93) 





for first-order kinetics in A (94) 
 DaA = 
ΘB









for first-order in both A and B  
(non-stoichiometric) 
(95) 
 DaB = 
DaA
ΘB
  (96) 
To ensure homogeneity in the reaction mixture for both PFRs, the critical diameters allowing 
homogeneous velocity (Re ≥ 4,000), temperature (Pe ≥ 1) and concentration (Da ≤ 1) are 
calculated. The following analysis compares the critical diameters corresponding to these 
dimensionless number values; the smallest diameter allowing for all conditions simultaneously for 
each reactor is found to establish design values. Values of Re and Pe are dependent on plant 
volumetric throughputs, which vary between LLE design cases. Each LLE design case considered 
for MINLP optimisation vary the LLE solvent implemented and number of implemented LLE 
tanks (N). The screening of candidate LLE solvents for consideration and MINLP problem 
formulation are described further in later sections. 
The Reynolds number as a function of PFR diameters is plotted for different design cases in Fig. 
52. Critical PFR diameters corresponding to Re = 4,000 vary between design cases, as Re is a 
function of PFR volumetric throughput (QPFR), which varies between design cases (LLE solvent 
choice and number of implemented tanks, N), as well as the chosen diameter. A similar analysis 
of Péclet numbers as a function of diameter between different designs is shown in Fig. 53. Critical 
diameter values corresponding to Pe = 1 are significantly higher than for Re = 4,000. 
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Figure 52: Reynolds number as a function of PFR-diameter for different atropine CPM design 
cases. LLE solvents: Et2O = diethyl ether, BuOAc = butyl acetate. N = no. LLE vessels. 
The Damköhler number is a function of conversion, reactor diameter and residence time. 
Damköhler numbers for each PFR are the same for different design cases (LLE solvent choice, 
number of implemented LLE vessels, N), as they are independent of volumetric throughput. The 
Damköhler number of limiting tropine in PFR-1 as well as for limiting tropine ester and excess 
CH2O in PFR-2 as a function of PFR diameter is plotted in Fig. 54. The maximum allowable 
diameters corresponding to Da = 1 are much lower than for the critical Re and Pe values. Ensuring 
the reaction mixture is sufficiently mixed before reaction occurs is essential to maximise reaction 
efficiency, which is ensured by keeping Da ≤ 1. The Damköhler number of limiting tropine ester 








































4 5 6 7 8 9 10 11 12 13


















































4 5 6 7 8 9 10 11 12 13












4 5 6 7 8 9 10 11 12 13
PFR-2 Diameter, dPFR-2 (mm)
114 
 
Figure 53: Péclet numbers as a function of PFR diameters for different atropine CPM design 
cases. LLE solvents: Et2O = diethyl ether, BuOAc = butyl acetate. N = no. LLE tanks. 
Critical diameters corresponding to different dimensionless number analyses and design cases are 
summarised in Table 23. In all design cases, the Damköhler number gives the lowest critical 
diameter, i.e. the maximum design value for each PFR diameter, to ensure the assumption of 
homogeneous reaction mixtures is valid and to maximise the benefits of continuous API synthesis. 
The maximum allowable PFR diameters are dPFR-1 ≤ 4.03 mm and dPFR-2 ≤ 3.63 mm. Design PFR 
diameters of dPFR = {1, 2, 3} mm are chosen to ensure all design values are below the critical values 
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Figure 54: Damköhler number vs. PFR diameter for different atropine CPM design cases. 
Table 23: Atropine CPM critical PFR diameters for dimensionless numbers corresponding to homogeneity 
conditions. LLE solvents: Et2O = diethyl ether, BuOAc = butyl acetate. N = no. LLE tanks. 
Et2O PFR-1 PFR-2 
N Re = 4,000 Pe = 1 Da = 1 dPFR,MAX (mm) Re = 4,000 Pe = 1 Da = 1 dPFR,MAX (mm) 
1 7.87 252.41 4.03 
4.03 
12.06 288.59 3.63 
3.63 2 5.79 216.50 4.03 8.87 247.53 3.63 
3 5.12 203.52 4.03 7.84 232.68 3.63 
4 4.78 196.77 4.03 7.33 224.97 3.63 
BuOAc PFR-1 PFR-2 
N Re = 4,000 Pe = 1 Da = 1 dPFR,MAX (mm) Re = 4,000 Pe = 1 Da = 1 dPFR,MAX (mm) 
1 8.12 256.34 4.03 
4.03 
12.44 293.08 3.63 
3.63 2 5.95 219.44 4.03 9.12 250.90 3.63 
3 5.24 205.89 4.03 8.02 235.40 3.63 
4 4.88 198.76 4.03 7.48 227.25 3.63 
PhMe PFR-1 PFR-2 
N Re = 4,000 Pe = 1 Da = 1 dPFR,MAX (mm) Re = 4,000 Pe = 1 Da = 1 dPFR,MAX (mm) 
1 7.50 246.39 4.03 
4.03 
11.49 281.70 3.63 
3.63 2 5.61 212.98 4.03 8.59 243.50 3.63 
3 4.99 200.93 4.03 7.64 229.72 3.63 










































Figure 55: Computed PFR volumes and lengths for different diameters for atropine CPM. 
Process flowrates and required PFR volumes are calculated as in Chapter 3.3. Fig. 55 shows 
computed reactor volumes for PFR-1 and 2 for different optimised MINLP problem instances of 
different LLE solvent and numbers of tanks (N). For all LLE solvent choices, VPFR-2 > VPFR-1 due 
to the larger volumetric flowrate through PFR-2 due to the greater number of reagents (reactants 
+ solvents + other) at this point in the process flowsheet (Fig. 18) as well as τPFR-2 being slightly 
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dPFR-2,MAX = 3.63 mm 
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total reaction volume required for atropine continuous flow synthesis due to the corresponding 
increasing LLE efficiency, which in turn increases plantwide efficiency and reduces the total 
material throughput required to meet the desired plant API capacity (QAPI) and thus the PFR 
volumes. The current modelling framework can easily consider alternate values of QAPI to 
investigate the effect of varying plant capacity on all MINLP optimisation results.  
Fig. 55 also shows resulting PFR lengths for various diameter values. Design reactor diameter 
values of dPFR = {1, 2, 3} mm are considered, as these are safely below the critical diameter values 
for homogeneous reaction mixtures (Table 23). In all cases (cost optima for different problem 
instances), resulting reactor lengths are feasible and appropriate for the given plant capacity (QAPI) 
and for the assumption of homogeneous reaction mixture implemented in this work. Although 
smaller diameters are preferable, the resulting PFR length is an important consideration for the 
equipment footprint and implemented heating media in which PFRs will be immersed. Coiling 
reactors can also allow for easier heat exchange and immersion in necessary heat transfer media. 
Table 24: Initial list of candidate LLE solvents for atropine CPM. 
Class LLE Solvent Notation L-L Equilibria Partition 
Coefficient 
Classification Consider
   Exptl. UNIFAC?  FDA
203 GSK223 
 








































8.3 Candidate Separation Solvent Screening 
Appropriate solvent selection for LLE design is imperative due to its significant effect on material 
usage and impact on process performance. Table 24 provides an initial list of LLE solvents based 
on the attainability of immiscible mixtures, API partition coefficient data in the ternary system 
DMF + H2O + LLE solvent and EHS classification by the FDA and a GSK solvent classification 
guide.223 The FDA classes solvents as class 1 (should be avoided), 2 (should be limited) and 3 
(lower risk), while the GSK guide classifies solvents as “red” (major issues), “amber” and “green” 
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(few issues). The chosen LLE solvent must be able to form an immiscible mixture with the 
incoming binary DMF + H2O solvent mixture (all those listed in Table 24), have API partition 
coefficient data available and be suitable based on EHS criteria, i.e., FDA classification > 1 and 
“green” or “amber” based on the GSK guide. The considered LLE solvents in this work are diethyl 
ether (Et2O), butyl acetate (BuOAc) and toluene (PhMe). 
8.3.1 Ternary Phase Diagrams 
Modelling of candidate continuous LLE designs requires liquid-liquid equilibria data for the ternary 
solvent system DMF + H2O + LLE solvent. The ternary diagrams of the considered LLE solvents 
are shown in Fig. 56, estimated by solution of the UNIFAC model for liquid-liquid equilibria (see 
Chapter 3.4);236 all options have a high propensity to form multiphase mixtures, i.e., exhibit rapid 
phase splitting in a wide operating region.  
 
Figure 56: Ternary phase diagrams for the system DMF + H2O + LLE solvent (Et2O, BuOAc, 
PhMe) computed via the UNIFAC model (TLLE = 25 °C) for atropine CPM. 
Fig. 56 also shows the LLE feed point (DMF + H2O mixture) compositions before LLE solvent 
(Et2O, BuOAc, PhMe) addition and minimum r required to form an immiscible mixture = rMIN, 
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and the pure LLE solvent corner on the ternary phase diagrams) intersects the binodal 
curve/separatrix (the boundary of compositions separating miscible and immiscible regions, 
estimated via UNIFAC). Values of rMIN vary between different ternary systems due to the differing 
thermodynamic behaviour between them, e.g., the rMIN value for the ternary system containing 
Et2O is higher than for BuOAc and PhMe systems due to the smaller envelope of immiscibility. 
To remain safely within the immiscible region in the design of different LLE processes, a minimum 
value of r ≥ 0.20 is chosen. 
8.3.2 Modelling of Phase Compositions 
Estimation of LLE phase compositions are required for calculation of phase properties (densities, 
viscosities, surface tensions) for continuous LLE efficiency estimation. Varying the LLE solvent-
to-feed ratio (r) affects resulting phase compositions, quantities and physical properties that 
consequently affect LLE efficiency. Modelling of phase compositions is implemented via surrogate 
polynomials, expressing solvent component compositions in organic and aqueous phases as 
functions of r via Eq. 97, where xi,p,S is the mole fraction of component i in phase p for the solvent 
system DMF + H2O + S and α, β and γ are the quadratic polynomial coefficients. Partition 
coefficients of API between organic and aqueous phases for different solvent systems at TLLE = 
25 °C are taken from the literature.177 Table 25 provides coefficient values for Eq. 97 for each 
solvent system, solvent component and phase. 
xi,p
S  = αi,p
S r2 + β
i,p
S  r + γ
i,p
S  (97)
Table 25: Coefficients for Eq. 97 estimating ternary phase compositions of the system DMF + H2O + LLE solvent
(S) for atropine CPM based upon extensive UNIFAC modelling. 
LLE Solvent (S) Et2O  BuOAc  PhMe 
Phase Component α β γ  α β γ  α β γ 
Org. 
DMF 5.50∙10-3 -4.66∙10-2 1.11∙10-1  -9.00∙10-4 -5.10∙10-4 7.78∙10-2  2.90∙10-3 -2.37∙10-2 8.57∙10-2 
H2O 1.80∙10-3 -1.70∙10-2 9.05∙10-2  4.40∙10-3 -3.44∙10-2 1.76∙10-1  3.00∙10-5 -2.00∙10-4 6.00∙10-4 
S -7.20∙10-3 6.36∙10-2 7.98∙10-1  -3.60∙10-3 3.96∙10-2 7.46∙10-1  -2.90∙10-3 2.39∙10-2 9.14∙10-2 
Aq. 
DMF 3.50∙10-3 -3.20∙10-3 -3.00∙10-4  1.40∙10-3 -1.35∙10-2 5.14∙10-2  9.00∙10-4 -1.01∙10-2 4.75∙10-2 
H2O -2.79∙10-2 2.54∙10-2 2.50∙10-3  -4.00∙10-4 9.10∙10-3 9.43∙10-3  -1.10∙10-3 1.11∙10-2 9.47∙10-1 




8.3.3 Solute Partition Coefficients 
Estimation of API and impurities partitioning between organic and aqueous phases is required for 
the modelling of CPM-LLE of atropine. Partition coefficients of each solute in different 
combinations of LLE solvent + H2O systems at pH = 7 and TLLE = 25 °C based upon extensive 
SPARC simulations, details of which can be found in the literature.177 For all CPM-LLE solvent 
systems, operation at pH = 7 is chosen, for which published partition coefficients for each solute 
are provided in Table 26. It is assumed that polar components NaOH and NaCl (byproduct from 
neutralisation of tropine ester by NaOH) remain in the aqueous phase, whereas phenylacetyl 
chloride and formaldehyde are assumed to partition completely into the organic phase. Provision 
of partition coefficient data for those species not listed in Table 26 will allow more accurate 
estimation of solute component content of LLE phases required for process development of 
subsequent downstream unit operations. 
Table 26: Partition coefficients of atropine and impurities in different solvent systems (S) at pH 
= 7 based upon published SPARC-derived values.177 
Component S = Et2O S = BuOAc S = PhMe 
API 0.326 0.359 0.273 
Tropine 0.028 0.027 0.021 
Tropine Ester 2.054 2.312 2.598 
Apoatropine 2.054 3.043 3.486 
Component partitioning of API and impurities are based upon partition coefficient data assuming 
pure organic (LLE solvent) and aqueous (water) phases.177 Real LLE phases are not pure 
components, but multicomponent solvent mixtures, including DMF carrier solvent, and various 
solutes (API, impurities, other reagents). The presence of DMF and other components are not 
considered to affect the partition coefficient data used to estimate solute partitioning; 
consideration of these effects require partition coefficient data in multicomponent mixtures, which 
is not available. Investigation into the effect of additional component presence on solute 
partitioning will further elucidate the performance of different LLE designs.  
8.4 Continuous Liquid-Liquid Extraction Cascade Superstructure 
Mass transfer correlations for prediction of extraction efficiencies are as per Chapter 5.3, using the 
Skelland-Moeti correlation. The MINLP superstructure is illustrated in Fig. 57. The flow synthesis 
effluent, which is the feed to the LLE cascade, F, enters from the left in Fig. 57. The superstructure 
considers a cascade of tanks with counter-current flow of LLE solvent and the possibility for co-
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current flow of fresh LLE solvent to tank k in the cascade. The continuous decision variables are 
the tank volume, VLLE, and the LLE solvent to feed ratio, rk; the binary decision variable, yk (for 
tank k = 1,…,N–1), determines whether fresh LLE solvent is added to tank k (note that yk is only 
applicable when N ≥ 2, as co- and counter-current flow configurations are identical when N = 1). 
Fresh solvent addition is implemented for tank k if yk = 1, otherwise yk = 0. Note that no additional 
solvent is added to tank N other than that added via counter-current flow, as adding two separate 
streams of solvent to tank N is equivalent to adding a single counter-current fresh solvent stream. 
If all yk = 0, a purely counter-current LLE configuration is implemented. 
 
Figure 57: Continuous LLE MINLP superstructure for atropine CPM. 
8.4.1 Solvent Allocation 
The total amount of LLE solvent fed to the cascade and the amount in each tank must be such 
that the process mixture remains fully immiscible as per the UNIFAC-modelled ternary phase 
diagrams; this is ensured by maintaining rk in each tank, as well as the sum of rk ≥ 0.20 (the lower 
bound of LLE solvent-to-feed ratio). The total LLE solvent present in tank k, Sk, is the amount 
entering via counter-current flow from subsequent tank k+1 and the fresh amount added if 
applicable (Eq. 98). Of the terms in brackets in Eq. 98, the first represents the fresh LLE solvent 
added to tanks k to N–1 and the second is the amount added to tank N entering stage k via 
counter-current flow. 
Sk =    ykrk
N–1
k
+ rN  F 
(98) 
8.4.2 Optimisation Problem Formulation and Constraints 
The objective of the MINLP optimisation problem is to minimise the total plant cost (estimated 
as per Chapter 3.6). The integer variable, yk, must be binary, the summation of which is constrained 
to state that only tanks 1 to N–1 may have fresh LLE solvent added in co-current flow. The LLE 
solvent-to-feed ratios to tank k are constrained to ensure fully immiscible mixtures in each tank; a 
maximum r ≤ 5 is chosen so that excessive amounts of LLE solvent are not used. The volumes of 
each LLE tank (VLLE) are also constrained to have a minimum feasible volume of 1 L. 
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min Total Cost (99)
s.t.  
yk ∈ {0,1} ∀k ∈ 1,…, N–1, for N ≥ 2 (100)
  y
k




for N ≥ 2 (101)
0.20 ≤ rk ≤ 5 ∀k ∈ 1,…,N (102)
0.20 ≤   rk
N
k = 1
 ≤ 5 
 (103)
1 ≤ VLLE,k ∀k ∈ 1,…,N (104)
The MINLP superstructure describes the attribution of fresh LLE solvent in co-current mode to 
intermediate tanks in addition to counter- current solvent flow entering tank N (as per Fig. 
57). The superstructure does not consider N or the LLE solvent choice as decision variables, with 
these design parameters being considered as separate optimisation problem instances, i.e., 12 
problem instances in total. For each problem instance, there are 2N continuous decision variables 
(VLLE,k, rk) and N–1 integer decision variables (yk), i.e., a total of 3N–1 decision variables. There are 
also varying numbers of linear equality constraints for different problem instances, of which there 
are N for VLLE, 2N+1 for rk and the sum of rk and one for yk for N ≥ 2.  
Separate MINLP problem instances of LLE solvent = {Et2O, BuOAc, PhMe} and number of 
LLE tanks, N = {1, 2, 3, 4} are solved. For a given combination of decision variables, process 
mass balances and PFR volume calculations accounting for reaction and continuous LLE 
inefficiencies are scaled to meet the desired plant capacity, QAPI = 103 kg API yr-1. As in the NLP 
cases presented in Part 2, the plant capacity is met by specifying it as a NLP constraint. The MINLP 
optimisation problem is solved using the Basic Open Source Nonlinear Mixed Integer 
Programming (BONMIN) solver via MATLAB’s OPTI Toolbox.237 The solver uses a coin or 
branch and cut method for the mixed integer problem and the Interior Point Nonlinear Optimiser 
(IPOPT) solver for the relaxed NLP problem. A multistart routine using multiple initial guesses 





8.5 Optimal Plantwide Designs 
8.5.1 Liquid-Liquid Extraction Cascade Design 
The MINLP optimisation results show the same continuous LLE configuration to be optimal for 
all LLE solvent choices and N considered, operating in mode with fresh solvent added to the first 
tank, as shown in Fig. 58. Purely counter-current LLE (i.e., all yk = 0) is typically more economical 
in terms of solvent usage whereas cross-current LLE is more flexible and allows for faster 
dynamics; the LLE superstructure considered in this work is a combination of the two flow 
arrangements, allowing fresh solvent to be added to tanks in addition to the counter-current extract 
entering the tank. The superstructure considered here is relatively simple, but can be expanded to 
consider various combinations of feed splitting and solvent reflux by the consideration of 
additional binary variables.238 For all cases, counter-current LLE solvent flow with fresh solvent 
addition co-current to the first tank in the cascade is established as optimal. The same optimal 
behaviour for N > 4 is also observed. The presented range of tank values considered (N = 1–4) is 
appropriate for the chosen plant capacity (QAPI = 103 kg API yr-1) and can be readily expanded for 
consideration in the described modelling and optimisation framework. 
 
Figure 58: Optimal continuous LLE design configurations for atropine CPM (y2, y3 = 0). 
Optimal LLE solvent-to-feed ratios (rk) for each LLE solvent choice are also shown in Fig. 58. 
Using BuOAc as the LLE solvent choice results in the highest rk, followed by PhMe and then 
Et2O at the resulting cost minima. However, the absolute values of LLE solvent flowrates do not 





flowrates required depend on values of rk determined by the MINLP solution as well as the 
resulting API recoveries of the design (tank number and sizes, LLE solvent choice, flowrates etc.).  
Vessel volumes of LLE units corresponding to optimal designs for each LLE solvent choice are 
shown in Fig. 59. The total cascade volume is the largest when BuOAc is selected as the LLE 
solvent, followed by PhMe and then Et2O, which have significantly smaller cascade volumes. The 
same trend in LLE volumes is observed as for optimal r values; this is likely due to the observed 
trends in value of total volumetric throughputs of the cascades, i.e., greater flowrates result in 
larger required tank volumes. Resulting r and VLLE values affect API recoveries from the plant due 
to their effect on LLE efficiency and are thus important to consider in this analysis. Although 
individual vessel volumes decrease with increasing N, the total cascade volumes increase with this 
trend. Implementing multiple smaller vessels is more beneficial than a single larger tank, despite 
the total cascade volume being higher; the effect this trend has on CapEx components will be 
discussed in Chapter 8.5.3. 
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Figure 60: Atropine recoveries and E-factors corresponding to optimum plant designs. 
Fig. 59 also shows the mean tank diameter for each tank for different LLE solvent choice and 
implemented N; mean values are shown for N ≥ 2 as individual tank volumes are approximately 
the same when multiple tanks are implemented. Mean tank diameters decrease as N increases due 
to the decreasing individual tank volumes. The tank aspect ratio, as well as the ratio of tank-to-
impeller diameter affects the overall mass transfer coefficient and thus the overall LLE efficiency; 
variation of the assumed tank design ratios can be easily varied as a form of sensitivity analysis.51 
8.5.2 Plantwide Recoveries and Material Efficiencies 
The attained recoveries (Fig. 60) at cost optimal points are similar for each N between LLE solvent 
choices. This result does not imply that all solvents perform similarly in general, only that the 
























































































































recoveries attained at cost minima are approximately the same. This result is an indication that 
beyond a certain API recovery, the benefits of enhanced recovery do not outweigh the associated 
additional costs by, e.g., increasing LLE cascade volumes (resulting in higher CapEx) and/or 
greater LLE solvent usage. As N increases, the recovery in each individual tank decreases due to 
the decreasing volumes (Fig. 59), but the final API recovery increases. It is also important to note 
that all LLE processes are considered implemented at TLLE = 25 °C, without consideration of other 
temperatures due to the lack of solute partition coefficient data between product phases as a 
function of temperature. 
The attained E-factors (see Chapter 3.5.4) are quite high for all LLE solvent choices; however, 
such values are not uncommon in pharmaceutical manufacturing processes, which are typically 
very materially-intensive compared to other manufacturing sectors such as oil and gas processes, 
which can have E-factors as low as 0.1. Consideration of solvent reflux/recycle and/or recovery 
to improve the material efficiencies of these processes will likely results in lower E-factors for 
different LLE designs, but will inevitably increase MINLP problem complexity. Consideration of 
subsequent crystallisation process requirements on product streams should also be implemented 
for system solvent harmonisation, which aids process intensification and CPM process 
development. Incorporation of downstream crystallisation impurity limits could be included in the 
problem formulation to give additional complexity to the MINLP problem. 
8.5.3 Economic Analysis 
8.5.3.1 Total Cost Components 
Total cost components corresponding to optimal process designs for different LLE solvent 
choices are shown in Fig. 61. For CapEx components, BLIC dominates over WCC for all process 
designs due to expensive equipment (particularly PFRs). For OpEx components, materials costs 
are the most significant contributor, followed by utilities and waste costs. As the number of 
implemented LLE tanks increases, overall OpEx contributions decrease due to the corresponding 
enhanced API recoveries with increasing N. Waste costs are modelled via an assumed cost per 
unit volume of waste produced from different process designs without explicit consideration of 
the mode of waste treatment. Consideration of specific operations and material requirements for 
waste treatment will increase both CapEx and OpEx components presented here, which should 
be considered when interpreting the results. 
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Figure 61: Total cost components and contributions of different LLE design configurations for 
atropine CPM. 
8.5.3.2 Reactor vs. Separator Component Distribution 
It was shown earlier (Fig. 59) that increasing the number of implemented tanks (N) results in 
decreased individual tank volumes but increased total cascade volumes. Despite this, the total 
CapEx, a significant portion of which is BLIC (containing equipment costs), still decreases with 
increasing N. The reason for this trend is related to the effect of increasing N on plant API 
recoveries and resulting PFR volumes at MINLP cost minima. Increasing N increases the plant 

























































































































































target plant capacity (QAPI) and thus PFR volumes. The reactors are significantly more expensive 
than LLE equipment in this work and thus the benefit of decreasing CapEx contributions of the 
PFRs is more significant than the increasing CapEx contributions associated with increasing N. 
This is illustrated in Fig. 62, which compares the FOB contributions of PFRs and LLE equipment 
for varying N for different LLE solvent choices. The FOB contributions of PFRs are much more 
significant than LLE contributions in all cases and with increasing N, PFR FOB costs decrease 
while LLE FOB costs increase. Increasing N also lowers OpEx due to the reduction of material 
throughput, utilities and waste (both of which are a function of material throughput in the 
implemented costing methodology) associated with enhanced recoveries + plantwide efficiencies. 
 
Figure 62: Free on Board (FOB) PFR and LLE equipment contributions for atropine CPM. 
The MINLP optimisation results show PhMe is the best LLE solvent choice (Fig. 61), attaining 
the lowest total costs of 3.944×106 GBP. Further corroboration of optimisation results with 
experimental validation as well as solvent harmonisation with crystallisation and other downstream 
processes is essential for atropine CPM development. Although PhMe is shown to be more 
economically viable, it has less favourable EHS characteristics compared to BuOAc.223 The current 
MINLP problem formulation is for minimisation of total costs; the problem may be reformulated 
for maximising profits or Net Present Value (NPV), which may yield different process design and 
total cost component results to those presented here for total cost minimisation. It is noted that 
the total cost components continue decreasing for the considered number of LLE vessels (N = 
1–4); cases of N > 4 were not considered due to the lengthy MINLP computational times taken. 





















































8.6 Chapter Conclusions 
This work solves a novel MINLP problem for the total cost minimisation of the CPM of atropine, 
establishing plant designs corresponding to optimal LLE design configurations and operating 
parameters. The implemented process model incorporates kinetic parameter estimation from 
experimental data for PFR design, as well as an evaluation of dimensionless numbers (Re, Pe, Da) 
to compute maximum allowable PFR diameters to ensure homogeneous reaction mixtures (with 
respect to concentration, velocity and temperature gradients) to maximise the benefits of 
continuous processes for atropine flow synthesis. Continuous LLE modelling used ternary phase 
composition estimation via UNIFAC and appropriate mass transfer correlations. For all LLE 
solvent choices, implementing four tanks in counter-current mode with additional solvent flow to 
the first tank is the optimal design configuration from the considered superstructure. Toluene 
(PhMe) emerges as the most economically favourable LLE solvent choice with a total cost of 
3.944×106 GBP at API recovery = 81.0% and E-factor = 62.9 for a plant capacity of QAPI = 103 
kg API yr-1. This work demonstrates the value of conducting technoeconomic optimisation studies 
towards the development of continuous processes in pursuit of economically viable end-to-end 





















This chapter describes the steady-state process modelling and MINLP optimisation for process 
synthesis for the MSMPR continuous cooling crystallisation of melitracen.  
9.1 Continuous MSMPR Cascade Superstructure 
Capellades et al. (2019) demonstrated continuous crystallisation of melitracen from ethanol via 
cooling in a MSMPR cascade without recycle.181 Solids recycling in MSMPR cascades has been 
demonstrated in the literature, allowing for enhanced crystallisation yields.99,230 In this work, a 
MSMPR cascade with solids recycle is considered; the conceptual flowsheet is shown in Fig. 63.  
 
Figure 63: MSMPR cascade for continuous cooling crystallisation of melitracen with solids 
recycle. 
A clear mother liquor feed stream enters MSMPR 1, with dissolved API solute concentration C0 
and volumetric flowrate F0. The product stream exiting one MSMPR (Fi) is then the feed stream 
to the subsequent MSMPR in the cascade, consisting of N crystallisers in total. The product stream 
of crystalliser N (FN) then enters a solid-liquid separator, in which clear mother liquor is removed 
in order to concentrate the stream suspension, which exits from the bottom of the separator, 
producing recycle streams Ri. The concentrated stream is the product, with some being recycled 
back to select crystallisers. Design and operating parameters for the process are the MSMPR 
temperatures (T) and volumes (V), the total recycle ratio (RRTOT), the mother liquor removal ratio 
(x = FN / F2N+2) and binary variable, yi, deciding whether to send recycle to stage i. Each MSMPR 
i has a holdup of crystallised API, HDi. For each crystalliser, Fi, Ci and Mi are the volumetric 
flowrate of the stream leaving the stage, the equilibrium API concentration in the mother liquor 
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and the suspension density, respectively. All flowsheets and process designs are for plant API 
capacities of QAPI = {103, 104} kg API yr-1. The steady-state process models for all flowsheet 
configurations describe crystallisation kinetics, population balance equations and mass balances. 
Simultaneous solution of these equations describes continuous crystallisation in the MSMPR 
crystalliser cascade. 
It is assumed that the total stream of recycled material (F2N+1) is equally distributed between those 
crystallisers to which it will be fed (i.e., those with binary variable yi = 1). A mass balance equation 
around the gravity-driven separator gives the following, 








FN ∀i = 1,…,N  (105)
where x is the clear liquor removal ratio (controlling the suspension density of the stream leaving 
the bottom of the solid-liquid separator, MN+1), defined as FN / F2N+2 and RRTOT is the total recycle 
ratio (controlling how much material is sent back to the MSMPR cascade vs. that withdrawn as 
product). 
The solubility concentration of API in ethanol, Csat, as a function of temperature during cooling 
crystallisation is described by Eq. 106, taken from the literature, with R2 > 0.99 vs. experimental 
data.181 The published experimental data and the regressed correlation (Eq. 106) of Csat vs. T are 
shown in Fig. 64. 
Cisat = 15.282 exp(0.041Ti) ∀i = 1,…,N (106) 
 
Figure 64: Melitracen solubility concentration (Csat) as a function of temperature (T) (Eq. 106) in 






























Model Fit (eq. 1)
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Crystal nucleation, B, and growth, G, rates are calculated as in Chapter 7.1.2, respectively. No 
polymorphism was described in the experimental study on MSMPR crystallisation of melitracen 
and so polymorphic effects are not considered in this work either. All required crystallisation 
kinetic parameters for melitracen are listed in Table 27. 
Table 27: Kinetic parameters for MSMPR crystallisation of melitracen from ethanol.181 
Model Equations Parameter Value Units 
Nucleation rate, B kb0 4.79×1022 m-3 s-1 
 Eb 7.30×104 J mol-1 
 bMSMPR 2.60 – 
 mMSMPR 0.56 – 
Growth rate, G kg0 13.1 m s-1 
 Eg 5.25×104 J mol-1 
 gMSMPR 0.87 – 
Population balances kv 3.74 – 
 ρAPI 1,280 kg m
-3 
 
9.2 Optimisation for Maximisation of Net Present Value 
The objective of the MINLP optimisation problem is to maximise the attained Net Present Value 
(NPV) of the crystallisation process (Eq. 107), calculated as the sum of inflation-adjusted profit 
from API sales minus OpEx over the plant lifetime minus total CapEx. Annual profit is calculated 
from sales of API produced. The wholesale price of melitracen is taken as pAPI = 50 GBP kg API-
1. The problem has 2N+2 continuous decision variables (Vi, Ti, x, RRTOT) and N binary variables 
(yi). Various constraints are also imposed on the problem. Crystalliser volumes must be finite. 
Temperatures are bounded such that the solubility estimation is consistent with experimental 
results in the literature.181 For cooling crystallisation, each MSMPR temperature must be equal to 
or lower than the previous and the fresh feed mother liquor is at T0 = 60 °C, as per the experimental 
demonstrations.181 The total recycle ratio (RRTOT) and clear solvent removal ratio (x) are 
constrained to values observed in the literature.99 Binary decision variables must be 0 or 1. 
 NPV = –CapEx +  





Profit = pAPIQAPI (108) 
max NPV  (109)
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s.t.  
0 < Vi ∀i = 1,…,N  (110)
0 ≤ Ti ≤ 40 °C ∀i = 1,…,N  (111)
TN ≤ … ≤ T1 ∀i = 1,…,N (112)
T0 = 60 °C  (113)
0.0 ≤ RRTOT ≤ 0.9  (114)
0.0 ≤ x ≤ 0.5  (115)
yi = {0,1} ∀i = 1,…,N  (116)
The MINLP optimisation problem is solved using the Basic Open Source Nonlinear Mixed Integer 
Programming (BONMIN) solver via MATLAB’s OPTI Toolbox.237 As in the previous NLP + 
MINLP cases presented, the plant capacity is met by specifying it as a NLP constraint. 
9.3 Continuous Crystallisation Cascade Design 
9.3.1 Crystallisation Kinetics 
Crystallisation kinetics (nucleation and growth rates, B and G, respectively) for different plant 
capacities (QAPI) and number of crystallisers (N) are shown in Fig. 65. The system of model 
equations for crystallisation kinetics, mass balances and population balances are solved 
simultaneously to describe the MSMPR cascade behaviour (see Chapter 7.1.5). Growth rates 
increase along the cascade until N = 3 and then decrease, while nucleation rates generally 
continually increase and then plateau. The balance of growth and nucleation rates in a 
crystallisation system is important in controlling the crystallisation yield (affecting process 
efficiency and cost components) and product quality attributes such as Mean Crystal Size (MCS) 
and size distribution width (affecting downstream operations and drug product bioavailability). 
9.3.2 Supersaturations and Mean Crystal Sizes 
Resulting supersaturations and suspension densities (M) for different considered plant capacities 
(QAPI) and number of crystallisers (N) are shown in Fig. 66. The supersaturation increases gradually 
increases along the MSMPR cascade in all design cases with decreasing temperature. Suspension 
densities increase continually along the cascade in all cases as the crystallisation yield, and hence 
amount of solid product in suspension, increases. The chosen upper bound of the clear mother 
liquor removal ratio (x) in the MINLP optimisation problem definition is such that suspension 
densities are not so high that streams cannot be handled by peristaltic pumps.99,181 
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Figure 65: Optimal melitracen crystal nucleation and growth rates at both considered plant 
capacities (QAPI) at each stage (i) for different assumed numbers of crystallisers (N). 
 
Figure 66: Optimal melitracen MSMPR suspension densities (M) and supersaturations at both 
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The attained final MCS values for different cascade designs (implemented N) at different 
considered plant capacities (QAPI) are shown in Fig. 67. Values of MCS are slightly lower for the 
higher considered QAPI; the desired MCS depends on the implemented downstream unit operations 
and drug product formulation. The attained MCS values here are very low and will likely lead to 
difficulties in solid-liquid separation unit operation and solid flowability during downstream 
processes. This highlights a need to incorporate crystal quality (size properties as well as purity and 
polymorph constraints) into the optimisation problem formulation. The published nucleation and 
growth kinetic parameters from the literature that are used in this work did not account for 
agglomeration and breakage either, which will affect the computed crystal sizes. Harmonisation of 
downstream operation with the considered crystallisation process, as well as upstream API 
synthesis as part of plantwide design problems give significant insight into process development 
where sufficient information for up- and downstream unit operation design is available. 
 
Figure 67: Final Mean Crystal Size (MCS) at both considered plant capacities (QAPI) for different 
assumed numbers of crystallisers (N). 
9.3.3 Optimal Cascade Configuration Design and Operation 
The optimal flowsheet configurations corresponding to MINLP optima (i.e., NPV maxima) are 
shown in Fig. 68. The optimal flowsheet configurations (for both capacities) varies for different 
numbers of implemented crystallisers (N). For N = {1, 2}, recycle streams are allocated to all 
crystallisers in the MSMPR cascade. However, for N ≥ 3, not all crystallisers have recycle streams 
fed to them, i.e., not all yi = 1 (binary decision variable in the MINLP optimisation problem). 
Lower capacities and effects of alternative numbers of crystallisers out with the range considered 
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Figure 68: Optimal melitracen MSMPR cascade configurations for different numbers of 
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The cost-optimal number of crystallisers is the same for both considered plant capacities (QAPI), N 
= 3, as is the allocation of recycle streams, i.e., to the first and final (third) crystallisers with the 
second vessel receiving no recycle; this corresponds to MINLP binary decision variables y = [1 0 
1]. Varying the extent of recycle to different crystallisers has been shown to be an important 
decision variable in controlling the crystallisation yield in MSMPR cascades with solids recycle,99,230 
which in turn affects the productivity and costs to attain a specific desired plant capacity. Allocating 
solids recycle to multiple stages, as opposed to just one crystalliser, increases the extent of 
nucleation throughout the cascade which increases the final crystallisation yield. Were the final 
MCS or size distribution considered as objective functions or constraints in the optimisation 
problem, allocation and extent of solids recycle may vary, as crystal growth would be more 
important. Implementing multi-objective optimisation on both crystallisation yields and product 
quality attributes such as MCS and size distribution width is often implemented for dynamic 
optimisation of batch and continuous processes.239 
The optimal recycle ratios (RRTOT, extent of recycle) and clear mother liquor removal ratios (x, 
controlling concentration of recycle streams) for different considered plant capacities (QAPI) and 
numbers of crystallisers (N) are shown in Fig. 69. For both considered capacities, the optimal 
recycle ratios decrease from N = 1–3 and then increase, whereas the optimal clear mother liquor 
removal ratios decrease. Increasing RRTOT and x increase the available surface area for 
crystallisation in each vessel, however ultimately incur greater recycle flowrates which require larger 
vessels (i.e., sufficient crystalliser residence time) to attain suitable yields and the desired 
productivity to meet the set plant capacity (QAPI). The decrease in the clear mother liquor removal 
ratio (x) with N = 1–3 indicates that the recycle streams do not need to be as concentrated (i.e., 
less mother liquor removed in waste stream F2N+2) for N = 3 in order to be cost optimal; this also 
leads to less waste and enhanced material efficiency.  
 
Figure 69: Optimal melitracen MSMPR cascade recycle ratios and clear mother liquor removal 








































































































The current MINLP problem formulation assumes the solids recycle stream is distributed equally 
between those crystallisers for which y = 1. Formulation of problems with unequal stream 
distribution between crystalliser cascade elements can allow for tighter control of crystal product 
quality attributes. The current MINLP problem is formulated for economic optimisation does not 
consider product quality attribute constraints; however, if such constraints were implemented, 
unequal recycle allocation may be beneficial. 
Optimal crystalliser volumes (V) for different plant capacities (QAPI) and number of crystallisers 
(N) are shown in Fig. 70. As the number of implemented crystallisers increases from N = 1–3, 
total cascade volumes decrease and then increase for N > 3. As N increases, individual vessel 
volumes decrease; implementing multiple smaller volume stages is beneficial in terms of attained 
crystallisation yield (see Chapter 5.3, Fig. 71). Crystalliser volumes are larger for designs at the 
higher considered capacity, reflecting the larger volumetric throughputs to meet the higher API 
production requirements.  
 
Figure 70: Optimal tank volumes (V) and melitracen MSMPR operating temperatures (T) at both 
considered plant capacities (QAPI) at each stage (i) for different numbers of crystallisers (N). 
Optimal crystalliser operating temperatures (T) for different plant capacities (QAPI) and numbers 
of crystallisers (N) are also shown in Fig. 70. As N increases, individual stage temperatures are 
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Temperatures always decrease along the cascade to ensure supersaturation is generated in each 
crystalliser to cause more product API to crystallise from solution from the previous vessel, as 
imposed as one of the MINLP problem constraints. An assumption of the considered MSMPR 
model is that perfect mixing of the crystalliser contents is attained, such that the outlet solution 
concentration is the same as that throughout the MSMPR vessel. The model also assumes that 
heat transfer from crystalliser to cooling jacket is instant; the validity of this assumption weakens 
with increasing plant capacity and volumes. Consideration of heat transfer dynamics should be 
considered as part of further non-steady-state studies. 
9.4 Attained Unit Operation Material Efficiencies 
Attained crystallisation yields at each MSMPR stage for different considered plant capacities (QAPI) 
and varying total numbers of crystallisers (N) are shown in Fig. 71. Yields progressively increase 
along the cascade as more API is crystallised from solution. Individual stage yields are lower as N 
increases, but ultimately the final yield increases when N is higher; eventually the final yield plateaus 
for N ≥ 4. This result indicates that beyond a certain number of crystallisers, the benefit of 
increasing yield associated with increasing N is no longer beneficial with respect to the NPV. 
 
Figure 71: Optimal melitracen crystallisation yields (Ycryst) at both considered plant capacities (QAPI) 
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Figure 72: Optimal plantwide and MSMPR crystalliser mass holdups and flowrates of crystallised melitracen in key flowsheet streams. 
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Fig. 72 shows the API mass flowrates of key flowsheet streams (see Fig. 63) corresponding to 
NPV maxima found by solution of the described MINLP optimisation problem for different 
considered plant capacities (QAPI) and numbers of crystallisers (N). This analysis serves as a 
comparative evaluation of the amount of crystallised API withdrawn as product vs. that leaving 
the MSMPR cascade as waste and that within recycle streams (Ri), crystalliser holdups (HDi) and 
total waste (WS). Fig. 72 shows the total material amounts for different design considerations in 
streams and MSMPR vessel holdups on an hourly basis as well as individual component 
contributions as fractions of the total amounts. 
The amount of crystallised API product (PR in Fig. 72) for different numbers of crystallisers (N) 
is the same for different plant capacities is the same, as each design must produce its target amount 
of crystalline API product. Total mass quantities differ between each considered plant capacity, 
reflecting the different total material throughputs required. For each considered plant capacity, 
there are similar trends observed. As the number of crystallisers (N) increases, the values of 
individual mass holdups and recycle streams decrease as the crystallisation yields increase and the 
units become more efficient. However, the total material quantities decrease to a point (N = 3), 
i.e., the plant becomes more materially efficient, beyond which the total material quantities increase 
and the benefits of increasing N are no longer observed, reflecting results presented in previous 
sections. The benefits of improving material efficiency with increasing N = 1–3 is also shown by 
the decreasing quantities of waste; for N > 3, the benefits of reduced waste decreases with respect 
to N = 3 vs. N = {1, 2}. 
For both considered plant capacities, for N ≥ 3, there are recycle streams which equal zero, i.e., 
the MINLP optimisation has determined that no recycle be allocated to certain crystallisers (i.e., yi 
= 0 for certain stages i). For the higher considered plant capacity (QAPI = 104 kg API yr-1), relative 
quantities of product vs. that withheld in recycle streams and vessel holdups is higher than at the 
lower considered capacity (QAPI = 103 kg API yr-1); relative quantities of waste also increase.  
The current study considers only a stream of pure melitracen in solution which is to be crystallised 
in the MSMPR cascade. Recent studies considering the effects of impurity compounds on 
component solubilities and crystallisation kinetics highlight the importance of such 
considerations.240 While thermal degradation of melitracen was not reported within the considered 
temperature range in the experimental study from which crystallisation kinetic parameters were 
taken,181 expansion of this modelling framework to other APIs should take such phenomena and 
effects into consideration, as investigated in recent MSMPR studies.241 Lower capacities and effects 
of alternative numbers of crystallisers out with the range considered here (i.e., N > 5) can be easily 
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investigated in the described MINLP optimisation framework; however, the number of variables, 
constraints and computational time will increase substantially. 
9.5 Comparative Economic Evaluation of MSMPR Cascades 
9.5.1 Optimal Net Present Value and Total Cost Components 
Optimal Capital (CapEx) and Operating (OpEx) Expenditure components for different considered 
plant capacities (QAPI) and number of implemented crystallisers (N) at the end of the plant lifetime 
are shown in Fig. 73 (calculated as per Chapter 3.6). Total cost components are higher for QAPI = 
104 kg API yr-1 than for QAPI = 103 kg API yr-1 in correspondence with the required larger 
equipment capacities and material throughputs associated with higher plant capacities. Total 
CapEx and OpEx components both decrease from N = 1–3 and then increase for N ≥ 3, following 
the trend observed for cascade volumes (Fig. 70). This result is observed for CapEx components 
because BLIC is a function of equipment capacities (from FOB components), of which MSMPR 
vessels are a significant component; the WCC is a function of material throughput, which also 
follows the same decreasing then increasing trend. 
 
Figure 73: Optimal Capital (CapEx) and Operating (OpEx) Expenditure components and Net 
Present Values (NPV) at both considered plant capacities (QAPI) for different numbers of 
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Total CapEx is dominated by BLIC due to the costs of equipment being much greater than WCC 
costs which are a function of material throughputs. Total OpEx is dominated by utilities 
components, which are associated with material handling and MSMPR cooling duties. Solvent (i.e., 
ethanol from the mother liquor solution) recovery from product and waste streams (i.e., F2N+3 and 
F2N+2 in Fig. 63, respectively) but can easily be incorporated into the existing MINLP framework. 
Resulting NPV maxima for different plant capacities (QAPI) and numbers of implemented 
crystallisers (N) are also shown in Fig. 73. For both considered plant capacities, NPV maxima are 
attained for N = 3, where total cost components are their lowest due to the previously discussed 
trends. The optimal flowsheet configuration and crystalliser vessel design and operating 
parameters depend on the kinetic and thermodynamic (i.e., solubility) behaviour of the API being 
crystallised, the solvent in which the API is dissolved and the method of supersaturation 
generation; a recent study showed the importance of the solvent effect considerations on 
crystallisation kinetics.242 Nevertheless, given crystallisation kinetic parameters and solubility 
behaviour, the current modelling framework may be expanded to other APIs amenable to cooling 
crystallisation in MSMPR cascades. 
9.5.2 Cost Component Breakdown by Process Stream and Vessel 
Fig. 74 compares a CapEx component breakdown per crystallisation unit vs. annualised OpEx 
components (calculated as the sum of time discounted OpEx over the plant lifetime and averaged 
per year) and annualised profits from API sales (averaged in the same way). Profits are relatively 
substantially higher vs. expenditures (negative cash flows) for the higher plant capacity (QAPI); this 
supports the previous discussion of the benefits of operating this MSMPR cascade at higher 
production capacities. The BLIC breakdown per unit crystalliser are approximately the same for 
each capacity and number of crystallisers; this is due to each of the individual vessel volumes being 
approximately equal in each design case (choice of LLE solvent and N for each considered QAPI). 
9.5.3 Economic Sensitivity Analysis 
Sensitivity analysis on the considered value of interest rate (t) is implemented to investigate the 
effect of varying economic parameters on designs. Here, we vary the interest rate for the MINLP 
optimised designs (which used a base case value of t = 5%) for different considered plant capacities 




Figure 74: Annualised cost breakdown of cash flows for different considered plant capacities (QAPI) and numbers of crystallisers (N) for melitracen 
crystallisation. 
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Fig. 75 shows the effect of varying interest rates, t = {2, 5, 8, 10}%, on the calculated NPV for 
fixed, optimal designs established by solution of the MINLP optimisation problems for both 
considered plant capacities (QAPI). At both capacities, the assumed value of t affects the final NPV 
at the end of the plant lifetime significantly; as t increases, the NPV decreases due to the greater 
effect of inflation and thus decreasing time value of profits. The percentage difference in NPV by 
varying t at QAPI = 104 kg API yr-1 is less than for QAPI = 103 kg API yr-1, i.e., operating at higher 
production capacities is more economically stable. It is important to note that this sensitivity 
analysis has been performed by varying t for fixed optimal plant designs from the MINLP 
optimisation problem solution in which t = 5% is the assumed value; it is possible that solving the 
MINLP optimisation problem for different values of t may result in different optimal plant 
configurations and crystalliser designs for the considered values of QAPI and N. Nevertheless, 
variation of the assumed interest rate t is of value to investigate the effect of economic parameters. 
 
Figure 75: Net Present Value (NPV) vs. plant operation time for varying assumptions of interest 
rates for both considered plant capacities at optimal designs (N = 3) for melitracen crystallisation. 
The Payback Period (PBP) is defined as the plant operation time taken for the total CapEx 
investment to be paid off, i.e., the time taken until NPV = 0. Calculated PBP for different plant 
capacities (QAPI), number of implemented crystallisers (N) and assumed interest rate (t) for optimal 
designs presented in previous sections are shown in Fig. 76. The calculated PBP values for QAPI = 
104 kg API yr-1 are significantly less than for QAPI = 103 kg API yr-1; while profits increase 
significantly at a higher production capacity, total cost (i.e., CapEx and OpEx components) do not 
increase as significantly to have such a detrimental effect on the economic performance. This result 
supports the idea mentioned in the previous paragraph that higher production capacities are 
beneficial for continuous crystallisation. However, this does not account for the negative effects 
of scale on mixing and heat and mass transfer efficiencies, upon which the considered MSMPR 
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model is based. Investigating the effect of API sales price on the presented MINLP optimisation 
results will also provide further insight into the sensitivity of the MSMPR cascade design to 
different economic parameters. 
 
Figure 76: Payback Period (PBP) for varying assumptions of interest rates (base case is t = 5%) 
for both considered plant capacities (QAPI) for different numbers of implemented crystallisers (N) 
for melitracen crystallisation. 
9.6 Chapter Conclusions 
This study has constructed and solved a MINLP optimisation problem for the maximisation of 
the Net Present Value (NPV) of a cascade of continuous cooling MSMPR crystallisers for the 
production of melitracen, an antidepressant API. The MINLP optimisation problem considered 
varying numbers of crystallisers (N = 1–5) and different plant API capacities (QAPI = {103, 104} kg 
API yr-1), with crystalliser vessel volumes, operating temperatures and recycle options as decision 
variables. Plantwide material efficiencies (i.e., crystallised API product vs. API withheld in the 
MSMPR cascade and lost in waste streams) increase until N = 3, beyond which the benefits of 
increasing the number of crystalliser vessels decreases. The cost optimal number of vessels N = 3 
for both considered capacities with recycle streams allocated to the first and third crystallisers in 
the MSMPR cascade. The final NPV values were shown to be sensitive to the considered interest 
rate, which will fluctuate throughout the plant lifetime in practice. This study presents the first 
implementation of MINLP optimisation for the design of a cascade of MSMPR crystallisers and 
its novelty and utility lies in the rapid screening of flowsheet configurations for pharmaceutical 
crystallisation processes; the modelling and optimisation framework can be extended to any API 
or solute amenable to cooling crystallisation given the availability of growth and nucleation kinetic 




























This thesis makes several novel research contributions, summarised herein. The most significant 
contributions include reaction kinetic parameter estimations for several API continuous flow 
syntheses, CPM process design for several APIs, the first instance of NLP optimisation for 
MSMPR crystallisation cascade design and the first instances of MINLP optimisation for 
pharmaceutical separation process synthesis, namely LLE and MSMPR cascades. 
10.1 API Continuous Flow Synthesis Reaction Kinetic Analysis 
This work performs reaction rate law elucidation and kinetic parameter estimation for several 
societally important APIs: diphenhydramine, rufinamide, nevirapine and atropine. Understanding 
reaction kinetics allows insight into synthesis performance under different design and operating 
conditions to inform reaction optimisation and plant vessel sizing. Reaction rate law elucidation 
via comparative evaluation of candidate rate laws and kinetic parameter estimation from analysis 
of published conversion/yield data for different flow reactions is used to facilitate flow reactor 
design as part of upstream CPM steady-state plant models. Comparison of different candidate rate 
laws are made where sufficient kinetic data is available and reasonable assumptions on plausible 
rate laws and/or attainable conversions are made where necessary. A summary of the relevant 
kinetic parameter estimations for each API performed are provided here.  
10.1.1 Diphenhydramine 
This work presents original reaction kinetic analysis, rate law elucidation and kinetic parameter 
estimation for the demonstrated continuous flow synthesis of diphenhydramine by Snead and 
Jamison (2013).32 Diphenhydramine is a potent antihistamine and hypnotic with high global sales 
volumes, being used as part of several popular brand formulations. The cost-effective production 
of diphenhydramine via CPM has the potential for significant economic impact. The original flow 
synthesis of diphenhydramine features a single reaction between CDPM and DMAE with carrier 
solvent (NMP) and without (as a neat mixture). The availability of time-dependent conversion data 
allowed comparison of candidate rate law expressions to describe the kinetic behaviour of the API 
synthesis. Comparison of zero-, first-, and overall second-order (first order in both CDPM and 
DMAE) rate laws show first-order kinetics (in CDPM) for the synthesis in NMP but second-order 
behaviour (first-order in both reagents) in a neat mixture. Corroboration of the estimated kinetic 
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parameter values with larger reaction performance data sets will further clarify this hypothesis and 
rate law elucidation. 
10.1.2 Rufinamide 
This work performs reaction kinetic analysis and comparative evaluation of rate law assumption 
on upstream CPM plant design and technoeconomic performance for the demonstrated 
continuous flow synthesis of rufinamide by Zhang et al. (2014).40 Rufinamide is an important API 
for the treatment of childhood epilepsy. The considered continuous flow synthesis of rufinamide 
features three reactions in flow towards the desired API. The first two reactions assume first-order 
kinetics due to them involving a large organic molecule reacting with a much smaller reagent in 
excess. For the third reaction, comparative evaluation of candidate rate laws for their effect on the 
upstream plant designs are considered. Corroboration of the estimated kinetic parameter values 
with larger reaction data sets will further clarify rate laws. 
10.1.3 Nevirapine 
This work performs the first-ever Arrhenius parameter regression for modelling the temperature-
dependence for nevirapine production from published data of the considered API continuous flow 
synthesis by Verghese et al. (2017),170 which considers a three step synthesis from advanced starting 
materials. The first two reactions in the synthesis are assumed to perform as per the demonstrated 
lab-scale synthesis. For the third reaction (between CYCLOR and NaH to form nevirapine), first-
order kinetics in CYCLOR are assumed due to it reacting with a significant excess of NaH. 
Temperature-dependent reaction performance data available in the literature for this step is used 
for the regression of Arrhenius law parameters in order to be able to simulate reaction performance 
as a function of temperature in the nevirapine upstream CPM plant model.  
10.1.4 Atropine 
This work elucidates the plausible rate law and kinetic parameters for the continuous flow synthesis 
of atropine demonstrated by Bédard et al. (2016),177 featuring two steps in series. The first reaction 
is very fast (99% conversion in 3.5 min residence time) and the reported lab-scale performances is 
assumed to apply to the study presented in this work. Kinetic parameter estimation for the second 
reaction is performed, comparing zero-, first- and overall second- order (first-order in both 
reagents) as candidate rate law expressions. An overall second-order rate law expression is shown 
as the most plausible. The literature does not contain sufficient data to model the effect of an 
undesired side reaction of API to apoatropine; however, it is assumed that a fixed portion of 
formed API converts to apoatropine, as described in the literature.177 Corroboration of the 
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estimated kinetic parameter values with larger reaction performance datasets will clarify reaction 
kinetic rate law elucidation. 
10.2 Upstream CPM Plant Design and Economic Evaluation 
Original steady-state process simulation for comparative economic evaluation and design of 
different separation process alternatives for the upstream CPM of diphenhydramine (synthesis + 
LLE) and rufinamide (synthesis + antisolvent crystallisation) is performed. This work is also the 
first instance of rigorous process design screening for the greatest cost savings vs. demonstrated 
batch processes for both diphenhydramine and rufinamide. 
10.2.1 Diphenhydramine: Continuous Synthesis + Liquid-Liquid Extraction 
This study uses regressed reaction kinetics for PFR design and UNIFAC/NRTL modelling for the 
design and technoeconomic comparative evaluation of LLE process options for diphenhydramine. 
Regressed reaction kinetics are used in order to conduct reactor sizing. Comparison of the effect 
of assumed reactor diameter on the resulting tube length shows that reasonable volumes and 
lengths result from the computed reaction kinetics, mass balances and assumed API plant capacity 
(QAPI = 100 kg API yr-1). The potential for significant unit operation vessel size/dimension 
reductions is one of the many benefits attainable via CPM implementation. Reactor heating duty 
estimation shows sensible heating duties for the reactor sizes computed; group contribution 
methods are used to estimate standard enthalpies of formation and component specific heat 
capacities where values are not available in the literature. 
The design of the continuous LLE process uses the UNIFAC and NRTL models for consideration 
of non-ideal multicomponent mixture behaviour for the prediction of liquid-liquid equilibria phase 
compositions and API solubilities and partitioning between resulting mixture phases. Candidate 
separation solvents are chosen on the basis of availability of phase compositions (either from 
available experimental data or the ability to model them via UNIFAC or NRTL). Comparison of 
the effect of LLE operating temperature (TLLE = {20, 40, 60} °C) and the LLE solvent-to-feed 
ratio for different candidate LLE solvents are conducted for technoeconomic evaluation of the 
best continuous LLE design option. 
It is shown that chloroform allows for the greatest CPM cost savings with respect to the plant with 
a batch separation, however its usage is undesirable due to the inherent toxicity issues with 
chlorinated solvent usage. Methylcyclohexane emerges as the next most promising LLE solvent 
with more suitable EHS characteristics while still attaining high API recoveries, good material 
efficiencies (quantified by green chemistry metrics) and significant cost savings. This study 
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illustrates the trade-off that often occurs between LLE solvent performance vs. EHS criteria, e.g., 
although chlorinated solvents are harmful, they often allow for the most rapid phase splitting, API 
recovery and material efficiency.  
10.2.2 Rufinamide: Continuous Synthesis + Antisolvent Crystallisation 
This study demonstrates the use of regressed reaction kinetics for PFR design and the design and 
technoeconomic comparative evaluation of antisolvent crystallisation process options for 
rufinamide CPM. 
Regressed reaction kinetics for each synthetic step are used for the purposes of reactor design. 
Comparison of the effect of reaction rate law assumption and regressed kinetic parameter values 
shows that the assumed rate law does not significantly affect the technoeconomic performance of 
the upstream CPM plant. Due to the large fraction of water in the incoming mixture to the 
antisolvent (using water) crystallisation process, it is assumed that the mixture is mostly aqueous. 
The aqueous solubility of rufinamide is estimated via a published correlation using the API’s 
octanol-water partition coefficient. This solubility is then used to estimate the crystallisation yield 
as a function of antisolvent (i.e., water) usage on the technoeconomic performance of the 
rufinamide CPM plant.  
Examination of crystallisation performance as a function of antisolvent usage shows that beyond 
an antisolvent-to-feed ratio of 2 there are only incremental benefits to the attained crystallisation 
yield and resulting plant costs. All CPM processes show significant cost savings and material 
efficiency improvements over the published continuous flow synthesis with batch crystallisation.  
10.3 Economic NLP Optimisation of Upstream CPM Plants 
This work is the first demonstration of economic optimisation via NLP for warfarin (synthesis + 
LLE) and nevirapine (synthesis + pH crystallisation) upstream CPM and for MSMPR 
crystallisation for cyclosporine, paracetamol and aliskiren; in particular, it is the first utilisation of 
economic optimisation for MSMPR cascade design for any compound. The quantification of 
economic benefits of CPM processes is essential for elucidating the best designs to maximise its 
impact on pharmaceutical production.  
10.3.1 Warfarin: Continuous Synthesis + Liquid-Liquid Extraction 
This work illustrates the first NLP formulation for technoeconomic optimisation of the upstream 
CPM of warfarin, based on the published continuous flow synthesis,166 as well as using UNIFAC 
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modelling to screen candidate continuous LLE process designs with explicit detailed mass transfer 
correlations to estimate continuous LLE efficiency.  
Reactor design assumes the same conversion/API yield as per the published lab-scale 
demonstration. Candidate LLE solvents are shortlisted as per the same criteria as for 
diphenhydramine, i.e., formed a biphasic mixture between whose phases warfarin can partition 
favourably into the organic phase and presented no significant EHS concerns.  
The formulated NLP optimisation problem is to minimise the upstream CPM plant total cost 
objective function subject to suitable constraints on LLE solvent usage and vessel residence time, 
both of which are considered as NLP decision variables. Separate problem instances of LLE 
operating temperature (TLLE = {20, 40, 60} °C) and candidate LLE solvent are solved. The optimal 
operating temperature varies between different solvent choices due to the varying thermodynamic 
and mass transfer behaviours of solutes in different ternary solvent mixtures. It is also observed 
that solvents with similar properties and molecular structures (e.g., esters, alcohols) result in similar 
plantwide performances due to the similar phase splitting behaviour and API partitioning between 
phases. The optimal temperature choice varies across different LLE solvent choices due to 
differing thermodynamic behaviours between ternary solvent systems. The optimal LLE solvent 
(attaining the lowest total costs and having suitable EHS characteristics) is isobutyl acetate 
operating at 60 °C.  
10.3.2 Nevirapine: Continuous Synthesis + pH Crystallisation 
This study is the first use regressed reaction kinetics for reactor and pH crystallisation modelling 
and optimisation for the design and technoeconomic comparative evaluation of process options 
for nevirapine CPM. The study also demonstrates the first comparative evaluation of different 
CPM designs vs. published batch processes from both a plantwide total costs + API cost of goods 
perspective for nevirapine. 
The regressed Arrhenius kinetic parameters for the final step in the continuous flow synthesis of 
nevirapine allow temperature-dependent reaction modelling. For the pH crystallisation, a 
published pH-dependent aqueous solubility model for nevirapine is used to predict the 
crystallisation yield as a function of pH. The NLP optimisation problem is formulated for plant 
total cost minimisation subject to constraints on the final reactor operating temperature and 
crystallisation pH, both of which are used as NLP decision variables in the optimisation problem. 
Separate problem instances of assumed plant API production capacity and attainable solvent 
recovery are considered.  
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The reactor operating temperature is driven to its upper bound whereas crystallisation pH is always 
lower than that of the batch process (pH = 7) to minimise material consumption associated with 
the pH change to crystallise the API and thus operating expenditure contributions which constitute 
a major component of plantwide total costs in all cases. Furthermore, CPM operation allows for 
significant reduction in the API cost of goods compared to the demonstrated continuous flow 
synthesis with a batch crystallisation.  
10.3.3 Cyclosporine, Paracetamol + Aliskiren: MSMPR Cascades 
This work demonstrates the first-ever economic optimisation via NLP for MSMPR cascade design. 
The published demonstration of the continuous MSMPR cooling crystallisation of cyclosporine, 
paracetamol and aliskiren with solubility behaviour as a function of temperature, nucleation and 
growth kinetic and population balance equation parameters are used to formulate a NLP 
optimisation problem for the total cost minimisation of a MSMPR cascade for API production, 
subject to constraints on crystalliser residence times and operating temperatures, which are used 
as decision variables for the NLP problem. Separate problem instances of assumed plant capacity 
and number of crystallisers are considered.  
It is shown that for lower capacities that only one crystalliser is cost optimal whereas at higher 
capacities more vessels are optimal. Implementing multiple crystallisers also allows for higher 
operating temperatures (i.e., less crystalliser cooling and associated lower duties). The modelling 
and optimisation framework can easily consider different plant capacities, more crystallisers and 
can be expanded to other APIs given the availability of crystallisation kinetics and their amenability 
to cooling crystallisation.  
10.4 MINLP Optimisation of Continuous Separation Cascades 
This work presents the first-ever instance of MINLP optimisation for process synthesis of 
separation cascades for pharmaceutical applications. While MINLP optimisation for process 
synthesis has been implemented in literature for separation design in many different applications 
(see Table 2), the contributions towards LLE and MSMPR cascade syntheses made in this work 
are the first instances of MINLP for pharmaceutical separation process design. The contributions 
made towards atropine and melitracen production are described here. 
10.4.1 Atropine: Optimal Process Synthesis of LLE Cascades 
Dimensionless number analysis is conducted to ensure reaction mixture homogeneity as part of 
upstream CPM plant design. Following the kinetic parameter estimation implemented for the 
atropine synthesis, the analysis is performed to ensure the validity of the assumption of 
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homogeneous reaction mixtures (with respect to concentration, temperature and velocity 
gradients) holds true for all reactor designs. Quantification of Reynolds, Péclet and Damköhler 
numbers as a function of assumed reactor diameter is performed to ensure they are not out with 
critical value ranges that would contradict the assumption of homogenous reaction mixture 
behaviour. It is found that the Damköhler numbers dictated the maximum allowable PFR 
diameters for both reactions. 
This study showcases the first demonstration of MINLP for LLE process synthesis for 
pharmaceutical applications in the literature. Candidate LLE solvents are screened as per 
diphenhydramine and warfarin CPM design methodologies. Liquid-liquid equilibria phase 
compositions are estimated using the UNIFAC model and the Skelland-Moeti correlation is used 
for the estimation of LLE efficiency for different options. The MINLP optimisation problem 
formulation for plant total cost minimisation considers LLE solvent feed rate and vessel volumes 
as continuous decision variables with LLE solvent allocation to vessels as binary decision variables. 
Separate problem instances of LLE solvent choice and number of vessels are considered.  
It is demonstrated that synthesis equipment (reactors) is of significantly higher cost compared to 
the LLE vessels and thus implementing more LLE stages in the cascade does not have a 
detrimental effect on total costs within the range considered. It is shown that using toluene with 
four LLE vessels is cost optimal for the considered plant capacities. The MINLP optimisation 
framework presented for continuous flow synthesis + LLE can be used for other APIs given the 
availability of reaction kinetics and ternary phase equilibria acquired via experimental data or a 
group contribution method (e.g., UNIFAC, NRTL etc.) as implemented here.  
10.4.2 Melitracen: Optimal Process Synthesis of MSMPR Cascades 
This study is the first-ever instance of MINLP optimisation for optimal MSMPR cascade process 
synthesis. The demonstrated continuous MSMPR cooling crystallisation from the literature 
describes API solubility as a function of temperature and crystal nucleation and growth kinetic 
parameters and population balances to allow steady-state process modelling of MSMPR cascades 
for this API.181 This work expands the process model to consider a solids recycling configuration 
previously examined in the literature, wherein the product magma of the final crystalliser in the 
cascade is fed to a gravitational separation column, removing mother liquor in order to produce a 
concentrated slurry from the bottom, part of which is recycled to the cascade and the remainder 
of which is withdrawn as product. This work formulates a MINLP optimisation problem for Net 
Present Value (NPV) maximisation of the MSMPR cascade with recycle, with crystalliser operating 
temperatures, vessel volumes, recycle stream flowrates and mother liquor removal extent as 
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continuous decision variables with recycle stream allocation as binary decision variables. Separate 
problem instances of number of vessels and plant capacity are solved.  
It is found for both assumed plant capacities that the optimum cascade configuration is three 
crystallisers, beyond which the benefits of increasing number of units on crystallisation yield are 
incremental at best, with recycle allocation to the first and last crystalliser. The MINLP 
optimisation framework presented for continuous MSMPR crystallisation with solids recycle can 
be used for other APIs given the availability of crystallisation kinetics, solubility description as a 
function of temperature (either from experimental data or estimated via group contribution 
methods such as the activity coefficient models UNIFAC, NRTL or others) and the amenability 





This PhD thesis presents a framework for steady-state modelling, simulation and optimisation of 
Continuous Pharmaceutical Manufacturing (CPM) upstream plants, focussing on reaction and 
separation processes, the latter of which presents a technically challenging obstacle with respect to 
end-to-end CPM process implementation. This work has been conducted with the aim to elucidate 
optimal technoeconomic benefits of CPM processes to maximise their potential for industrial 
adoption. Continuous process case studies on several Active Pharmaceutical Ingredients (APIs) 
have been conducted for the first time, including upstream CPM flowsheets (reaction + separation) 
for diphenhydramine (antihistamine), rufinamide (antiepileptic), warfarin (anticoagulant), 
nevirapine (HIV-1 treatment) and atropine (nerve agent effects) and continuous cooling 
crystallisation cascades in Mixed Suspension, Mixed Product Removal (MSMPR) vessels for 
cyclosporine (immunosuppressant), paracetamol (analgaesic), aliskiren (antihypertensive) and 
melitracen (antidepressant). Process simulation and NLP/MINLP optimisation have been 
implemented to various extents for different APIs for the best design and operation of CPM plants 
with respect to economic performance and environmental impact. 
Reaction kinetic parameter estimation from published data for diphenhydramine, rufinamide, 
nevirapine and atropine have been conducted for flow reactor design. Separation process design 
predicts ternary phase compositions and API solubilities using popular activity coefficient models 
such as UNIFAC and NRTL and mass transfer correlations for biphasic mixtures in agitated tanks 
to estimate continuous separation efficiency (for Liquid-Liquid Extraction (LLE) design) and 
crystal nucleation and growth kinetics, population and mass balances for MSMPR cascade design. 
Continuous flowsheet simulation for process design has been implemented for diphenhydramine 
and rufinamide, performing comparative evaluation of separation options on the respective merits 
of plant total costs, material efficiency and EHS criteria of solvents. Economic optimisation via 
Nonlinear Programming (NLP) has been conducted for upstream CPM plants (reaction + 
separation) for warfarin and nevirapine and for MSMPR cascades for cyclosporine, paracetamol 
and aliskiren; the latter presents the first instance of economic optimisation of MSMPR cascades. 
Process synthesis for optimal separation design for pharmaceutical applications has been 
conducted for the first time in the literature. The case studies considered are the design of LLE 
cascades for upstream CPM (reaction + separation) of atropine and MSMPR cascades with solids 
recycle for the continuous cooling crystallisation of melitracen. Continuous decision variables 
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involve vessel volumes, operating temperatures and stream flowrates, while binary decision 
variables describe whether stream allocation to certain vessels occurs. 
The results presented in this thesis are subject to various assumptions and limitations.  
 Reaction kinetic parameter estimations for the continuous syntheses of diphenhydramine, 
rufinamide, nevirapine and atropine are subject to limited datasets (i.e., yields as a function of 
concentration and temperature). Parameter estimations from larger datasets (concentrations 
for many time, temperature, initial concentration, base and catalyst equivalents combinations 
etc.) will allow more robust regressions and consideration of more complex rate laws. These 
datasets should include details of side reactions towards undesired by-products whose presence 
in pharmaceuticals can drastically affect downstream processing and efficacy in patients. 
 Phase equilibria involved in pharmaceutical separation processes involve non-ideal 
multicomponent mixtures for which experimental data (phase compositions, API solubilities, 
solute partitioning) is often not available, necessitating theoretical methods (e.g., UNIFAC + 
NRTL models) for prediction of the phase behaviour of these mixtures for separation process 
design. These models are best used as guides/indicators of promising process options, but not 
for accurate design; thus, the design options highlighted as best via the case studies presented 
in this thesis should be investigated further via experimental campaigns and pilot plant studies. 
 The modelling of MSMPR cascades for continuous cooling crystallisation of cyclosporine, 
paracetamol, aliskiren (NLP studies) and melitracen (MINLP study) use nucleation and growth 
kinetics available in the literature; however, these do not consider agglomeration and breakage 
of crystallisation, nor do they decouple primary and secondary nucleation phenomena in their 
nucleation model equations. The optimisation cases in the MSMPR studies (Chapters 7 and 9) 
consider technoeconomic objective functions in comparison to other research groups that 
address optimisation from a product quality perspective (see Chapter 2). Product quality 
constraints (regarding size properties, purity and polymorph) can easily be incorporated into 
the modelling and optimisation methodologies presented here. 
 The aims of the optimisation cases are from technoeconomic perspectives with comparison 
of material efficiencies of different process designs. Material efficiency can also be explicitly 
considered in the optimisation objective functions by formulation of multi-objective problems. 
 The case studies presented highlight the immense value in systematic and rigorous model-
based simulation and optimisation campaigns for CPM process systems, and the applicability 
of the methodologies outlined in this PhD thesis. The frameworks presented within can be 
























Nomenclature and Acronyms 
A.1 Acronyms 
API Active Pharmaceutical Ingredient 
BONMIN Basic Open Source Nonlinear Mixed Integer Programming 
BX Batch 
CEPCI Chemical Engineering Plant Cost Index 
COBC Continuous Oscillatory Baffled Crystalliser 
CPM Continuous Pharmaceutical Manufacturing 
CSTR Continuous Stirred Tank Reactor 
DWC Dividing Wall Column 
EHS Environment, Health and Safety 
HEN Heat Exchange Network 
HX Heat Exchanger 
HIV Human Immunodeficiency Virus 
IPOPT Interior-Point Nonlinear Optimiser 
LCA Life Cycle Assessment 
LLE Liquid-Liquid Extraction 
MINLP Mixed Integer Nonlinear Programming 
MSMPR Mixed Suspension, Mixed Product Removal 
NLP Nonlinear Programming 
NRTL Non-Random Two Liquid 
ODE Ordinary Differential Equation 
OSN Organic Solvent Nanofiltration 
PAT Process Analytical Technology 
PDE Partial Differential Equation 
PFC Plug Flow Crystalliser 
PFR Plug Flow Reactor 
PR Product 
PSA Pressure Swing Adsorption 
PSE Process Systems Engineering 
R&D Research and Development 
SMB Simulated Moving Bed 
UNIFAC UNIQUAC Functional group Activity Coefficient 
UNIQUAC Universal Quasichemical 
WHO World Health Organisation 
WS Waste 
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2-CAN 2-(Cyclopropylamino)nicotinic acid 
AC Activated carbon 
Ac2O Acetic anhydride 
AcOH Acetic acid 
Al2O3 Aluminium oxide 
BuOAc Butyl acetate 
BuOH 1-Butanol 
CAPIC 2-Chloro-3-amino-4-picoline 











DMF-DMS Dimethyl formamide-dimethyl sulphate 
DMK Dimethyl ketone 
DMSO Dimethyl sulfoxide 
Et2O Diethyl ether 
EtOAc Ethyl acetate 
H2O Water 
H2SO4 Sulphuric acid 
HepOH Heptanol 
HCl Hydrogen chloride 
iBuOH Isobutanol 
iPrOAc Isopropyl acetate 
iPrOH/IPA Isopropanol 
KOH Potassium hydroxide 
MeCAN 2-(Cyclopropylamino)nicotinate 
MeCyHex Methylcyclohexane 
MEK Methyl ethyl ketone 
MeOH Methanol 
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Mg2SO4 Magnesium sulphate 
N2 Nitrogen 
NaBr Sodium bromide 
NaCH3O Sodium methoxide 
NaCl Sodium chloride 
NaH Sodium hydride 
NaN3 Sodium azide 
NaOBr Sodium hypobromite 







SOCl2 Thionyl chloride 
TCM Chloroform / Trichloromethane 
TEA Triethylamine 
TFA Trifluoroacetic acid 
A.3 Variables 
A.3.1 Latin Letters and Symbols 
A Arrhenius pre-exponential factor (–) 
a Interfacial area between LLE phases (m2 m-3) 
ais Solid component activity 
aij Interaction energy between components i and j in the NRTL model (J mol-1) 
ak Parameter in eq. 12 
b Right hand side of NLP/MINLP inequality constraint vector 
Bi Nucleation rate in MSMPR crystalliser i (# crystals m-3 suspension s-1) 
bk Parameter in eq. 12 
bMSMPR Nucleation rate exponent (–) 
BLIC Battery Limits Installed Costs (GBP) 
c Right hand side of NLP/MINLP equality constraint vector 
Ci Concentration of species i (M or kg m-3) 
Cisat Saturation concentration of i (M or kg m-3) 
Cj Cost of equipment purchase at capacity j (GBP) 
Ck Group additivity coefficient for group k in estimation of total phase change 
entropy 
ck Parameter in eq. 12 
C0 Initial / Feed concentration (M or kg m-3) 
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Cp,m Mixture specific heat capacity at constant pressure (J kg-1 K-1) 
CapEx Capital Expenditure (GBP) 
CoG Cost of goods (GBP kg API-1) 
D Diffusivity (m2 s-1) 
d32 Sauter mean droplet diameter (m) 
dimp LLE tank impeller diameter (m) 
dk Parameter in eq. 12 
dPFR Inner diameter of PFR (m) 
dPFR,MAX Maximum PFR diameter (m) 
dt LLE tank inner diameter (m) 
Da Damköhler number (–) 
E Environmental (E)-factor 
Ea Activation energy (J mol-1) 
Eb Energy barriers to crystal nucleation (J mol-1) 
Ef Solute extraction factor 
Eg Energy barrier to crystal growth (J mol-1) 
ELLE LLE efficiency (%) 
Eo Eotvos number (–) 
f Correction factor in costing correlation (–) 
Fi  Flowrate of stream leaving vessel i (varying units) 
F0 Flowrate of fresh feed entering process (varying units) 
FOB Free-on-Board Costs (GBP) 
Fr Froude number (–) 
g NLP/MINLP inequality constraint function vector 
g Acceleration due to gravity (= 9.81 m s-2) 
Gi Crystal growth rate in MSMPR i (m API s-1) 
Gij Coefficient of NRTL equation between components i and j in the NRTL model
Gk Contribution of functional group k to total phase change entropy 
gMSMPR Crystal growth rate exponent (–) 
h NLP/MINLP equality constraint function vector 
h1i, h2j Group contribution of first-order group i, second-order group j in estimation 
of standard enthalpy of formation 
hf0 Constant in estimating the standard enthalpy of formation (= 10 kJ mol-1) 
Δ0Hf Standard enthalpy of formation (J mol
-1) 
ΔHfus Enthalpy of fusion (J mol
-1) 
Δ0Hrxn Standard enthalpy of reaction (J mol
-1) 
ΔHrxn Enthalpy of reaction (J mol
-1) 
HDi Crystalliser API holdup in MSMPR i (kg API) 
K Overall mass transfer coefficient (m s-1) 
kb Boltzmann constant (= 1.38064852×10-23 m2 kg s-2 K-1) 
kb0 Pre-exponential factor for nucleation (# crystals m-3 suspension s-1) 
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kg0 Pre-exponential factor for growth (m API s-1) 
ki,j ith order reaction rate constant in PFR j (varying units) 
KOW API octanol-water partition coefficient (–) 
kp Specific mass transfer coefficient of phase p (m s-1) 
kv API volume shape factor (–) 
L Crystal length (m API) 
Li UNIFAC compound parameter of r, q and z for molecule i 
LPFR PFR length (m) 
m Solute partition coefficient 
mAPI Mass of recovered API (kg yr-1) 
Mi Suspension density in MSMPR i (kg API m-3 suspension) 
Mj Number of  second-order functional groups 
mMSMPR MSMPR suspension density exponent (–) 
mprocess Plant material throughput (kg yr-1) 
muAPI Mass of unrecovered API (kg yr-1) 
mur Mass of reagents remaining in waste streams (kg yr-1) 
mus Mass of unrecovered solvent (kg yr-1) 
mwaste Mass of waste (kg yr-1) 
MCS Mean Crystal Size (m API) 
MP Mass Productivity (%) 
n Exponent in Eq. 41 (–) 
N Number of vessels (–) 
nCH2 Number of consecutive CH2 groups 
Ni Number of first-order functional groups 
ni Crystal population density function in MSMPR i (# crystals m-3 suspension m-1
API) 
ni0 Nuclei population density function in MSMPR i (# crystals m-3 suspension m-1
API) 
Nimp Tank impeller rotation speed (rps) 
nk Number of functional groups of type k 
NPV Net Present Value (GBP) 
OpEx Operating Expenditure (GBP) 
pAPI API wholesale price (GBP kg API-1) 
Pj Equipment purchase cost at capacity j (GBP) 
PBP Payback Period (yr) 
Pe Péclet number (–) 
pHCRYST Crystallisation pH 
PMI Process Mass Intensity (–) 
QAPI Plant API capacity (kg API yr-1) 
qi UNIFAC parameter of molecule i, representing van der Waals molecular 
surface area 
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Qk UNIFAC surface area parameter for functional group k 
R Universal gas constant (= 8.314 J mol-1 K-1) 
R2 Coefficient of determination (–) 
Ri Volumetric flowrate of recycle stream entering vessel i (m3 s-1) 
ri Molecular radius of component i (m) 
Rk UNIFAC volume parameter for functional group k 
rMIN Minimum LLE solvent-to-feed ratio (mass basis) 
r0 Initial value for LLE solvent-to-feed ratio (mass basis) 
rTOT LLE solvent-to-feed ratio (mass basis) to LLE process (mass basis) 
Reimp LLE tank impeller Reynolds’ number (–) 
RePFR PFR Reynolds’ number (–) 
RRTOT Total solids recycle ratio (–) 
S LLE solvent feed rate (m3 s-1) 
Saq Aqueous API solubility (g L-1) 
Sj Capacity of equipment j (varying units) 
S0 Non-ionised aqueous API solubility (g L-1) 
ΔS Entropy of fusion (J mol-1 K-1) 
Δ0
TfusSpc Total phase change entropy (J mol
-1K-1) 
Sc Schmidt number (–) 
Sh Sherwood number (–) 
t Interest rate (%) 
T Temperature (°C) 
Tfus Melting point (K) 
Umn UNIFAC energy of interaction between groups m and n 
U&W Utilities and Waste (GBP or GBP yr-1) 
uPFR Average fluid mixture velocity in PFR (m s-1) 
Vi Volume of vessel i (m3) 
Vm API molar volume (cm3 mol-1) 
WCC Working Capital and Contingency costs (GBP) 
We Weber number 
WS Waste (kg API hr-1) 
x Clear mother liquor removal ratio in solid-liquid separation column (–) 
x Decision variable vector 
XA Conversion of limiting reagent A (%) 
xi,pS Mole fraction of component i in phase p in solvent system S 
xisat Component i saturation mole fraction 
xLB, xUB Lower, Upper bound on decision variable vector 
xm UNIFAC mole fraction of group m 
yi Binary decision variable deciding whether to allocate stream to vessel i (–) 
Yi Yield in stage i (%) 
z UNIFAC coordination number (= 10) 
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A.3.2 Greek Letters and Symbols 
αij Non-randomness parameter between components i and j in the NRTL model 
αi,pS, βi,pS, γi,pS Quadratic, linear and constant coefficients in Eq. 97, respectively 
β Coefficient of thermal expansion (K-1) 
γ
i





R  Combinatorial, Residual UNIFAC activity coefficient component of molecule i
γ
i
sat UNIFAC activity coefficient of molecule i at saturation 
η Fugacity ratio 
Θ Molar ratio of excess reagent to limiting reagent 
θi UNIFAC molecular-weighted area fraction component for molecule i 
θm UNIFAC summation of area fraction of group m over all groups 
λm Mixture thermal conductivity (W m-1 K-1) 
μ Viscosity (kg m-1 s-1) 
ν Component stoichiometric coefficient (–) 
νk
i  Number of occurrences of group k on molecule i 
ρ Density (kg m-3) 
σ Interphase surface tension (N m-1) 
τ Residence time (s) 
τij Dimensionless interaction parameter between components i and j in the NRTL 
ϕ Dispersed phase volume fraction (–) 
Γk  UNIFAC residual group activity coefficient for group k 
Γk
i  UNIFAC residual group activity coefficient for group k in a solution of pure i 
ϕ
i
 UNIFAC molecular-weighted segment fractional component of molecule i 
χ Parameter in Eq. 46 
ψ
mn
 Interaction parameter between groups m and n in the UNIFAC model 
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